atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,DDD_O,DDD_P,DDD_R,DDD_SL,DDD_TD,note,unit_O,unit_P,unit_R,unit_SL,unit_TD,atc_level_05_note,DDD_inhalesolution,DDD_N,unit_inhalesolution,unit_N,DDD_oral_aerosol,unit_oral_aerosol,DDD_sc_implant,DDD_urethral,DDD_V,unit_sc_implant,unit_urethral,unit_V,DDD_inhalepowder,unit_inhalepowder,DDD_implant,DDD_intravesical,unit_implant,unit_intravesical,DDD_chewing_gum,DDD_inhale,DDD_inhaleaerosol,unit_chewing_gum,unit_inhale,unit_inhaleaerosol,DDD_instillsolution,unit_instillsolution,DDD_lamella,DDD_ointment,unit_lamella,unit_ointment
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AA,Caries prophylactic agents,"For caries prophylactic agents in A01AA, the DDDs are based on use in children.  DDDs are only established for tablets.",A01AA01,sodium fluoride,1.1,NA,NA,NA,NA,0.5 mg fluoride,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AA,Caries prophylactic agents,"For caries prophylactic agents in A01AA, the DDDs are based on use in children.  DDDs are only established for tablets.",A01AA02,sodium monofluorophosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AA,Caries prophylactic agents,"For caries prophylactic agents in A01AA, the DDDs are based on use in children.  DDDs are only established for tablets.",A01AA03,olaflur,1.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AA,Caries prophylactic agents,"For caries prophylactic agents in A01AA, the DDDs are based on use in children.  DDDs are only established for tablets.",A01AA04,stannous fluoride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AA,Caries prophylactic agents,"For caries prophylactic agents in A01AA, the DDDs are based on use in children.  DDDs are only established for tablets.",A01AA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AA,Caries prophylactic agents,"For caries prophylactic agents in A01AA, the DDDs are based on use in children.  DDDs are only established for tablets.",A01AA51,"sodium fluoride, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB02,hydrogen peroxide,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB03,chlorhexidine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB04,amphotericin B,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB05,polynoxylin,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB06,domiphen,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB07,oxyquinoline,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB08,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB09,miconazole,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB10,natamycin,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB11,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB12,hexetidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB13,tetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB14,benzoxonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB15,tibezonium iodide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB16,mepartricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB17,metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB18,clotrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB19,sodium perborate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB21,chlortetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB22,doxycycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB23,minocycline,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB24,octenidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB25,oxytetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AB,Antiinfectives and antiseptics for local oral treatment,The DDD for amphotericin in this group refers to lozenges.The DDD for minocycline is based on the amount of active substance used in one periodontal pocket in local treatment of periodontitis.,A01AB53,chlorhexidine and cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AC,Corticosteroids for local oral treatment,No DDDs have been established in this group.  The dosage forms are mainly ointments and pastes.,A01AC01,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AC,Corticosteroids for local oral treatment,No DDDs have been established in this group.  The dosage forms are mainly ointments and pastes.,A01AC02,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AC,Corticosteroids for local oral treatment,No DDDs have been established in this group.  The dosage forms are mainly ointments and pastes.,A01AC03,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AC,Corticosteroids for local oral treatment,No DDDs have been established in this group.  The dosage forms are mainly ointments and pastes.,A01AC04,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AC,Corticosteroids for local oral treatment,No DDDs have been established in this group.  The dosage forms are mainly ointments and pastes.,A01AC54,"prednisolone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD01,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD02,benzydamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD05,acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD06,adrenalone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD07,amlexanox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD08,becaplermin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A01,STOMATOLOGICAL PREPARATIONS,A01A,STOMATOLOGICAL PREPARATIONS,A01AD,Other agents for local oral treatment,NA,A01AD11,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AA,Magnesium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AA01,magnesium carbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AA,Magnesium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AA02,magnesium oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AA,Magnesium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AA03,magnesium peroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AA,Magnesium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AA04,magnesium hydroxide,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AA,Magnesium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AA05,magnesium silicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AA,Magnesium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB01,aluminium hydroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB02,algeldrate,5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB03,aluminium phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB04,dihydroxialumini sodium carbonate,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB05,aluminium acetoacetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB06,aloglutamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB07,aluminium glycinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AB,Aluminium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AB10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AC,Calcium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AC01,calcium carbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AC,Calcium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AC02,calcium silicate,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AC,Calcium compounds,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AC10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AD,"Combinations and complexes of aluminium, calcium and magnesium compounds","The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AD01,ordinary salt combinations,NA,NA,NA,NA,NA,Standard dose: 10 tablets or 50 ml mixt,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AD,"Combinations and complexes of aluminium, calcium and magnesium compounds","The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AD02,magaldrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AD,"Combinations and complexes of aluminium, calcium and magnesium compounds","The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AD03,almagate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AD,"Combinations and complexes of aluminium, calcium and magnesium compounds","The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AD04,hydrotalcite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AD,"Combinations and complexes of aluminium, calcium and magnesium compounds","The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AD05,almasilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AF,Antacids with antiflatulents,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AF01,magaldrate and antiflatulents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AF,Antacids with antiflatulents,"The DDDs for antacids are based on treatment of hyperacidity and dyspepsia, not ulcus.  One exception, however, is antacids in combination with antispasmodics in A02AG, where the DDDs are based on treatment of ulcus.For ordinary salt combinations in A02AD, fixed doses are used instead of individual doses for every single preparation (10 tablets = 10 UD; 50 ml mixture = 10 UD).",A02AF02,ordinary salt combinations and antiflatulents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AG,Antacids with antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AH,Antacids with sodium bicarbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02A,ANTACIDS,A02AX,"Antacids, other combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA01,cimetidine,0.8,0.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA02,ranitidine,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA03,famotidine,40,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA04,nizatidine,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA05,niperotidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA06,roxatidine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA07,ranitidine bismuth citrate,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA08,lafutidine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA51,"cimetidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BA,H2-receptor antagonists,The DDDs are based on treatment of peptic ulcers.,A02BA53,"famotidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BB,Prostaglandins,NA,A02BB01,misoprostol,0.8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BB,Prostaglandins,NA,A02BB02,enprostil,70,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC01,omeprazole,20,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC02,pantoprazole,40,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC03,lansoprazole,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC04,rabeprazole,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC05,esomeprazole,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC06,dexlansoprazole,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC07,dexrabeprazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC08,vonoprazan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC09,tegoprazan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC51,"omeprazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC53,"lansoprazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BC,Proton pump inhibitors,The DDDs are based on treatment of gastro-oesophageal reflux disease.,A02BC54,"rabeprazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD01,"omeprazole, amoxicillin and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD02,"lansoprazole, tetracycline and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD03,"lansoprazole, amoxicillin and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD04,"pantoprazole, amoxicillin and clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD05,"omeprazole, amoxicillin and clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD06,"esomeprazole, amoxicillin and clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD07,"lansoprazole, amoxicillin and clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD08,"bismuth subcitrate, tetracycline and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD09,"lansoprazole, clarithromycin and tinidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD10,"lansoprazole, amoxicillin and levofloxacin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD11,"pantoprazole, amoxicillin, clarithromycin and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD12,"rabeprazole, amoxicillin and clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD13,"rabeprazole, amoxicillin and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD14,"vonoprazan, amoxicillin and clarithromycin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD15,"vonoprazan, amoxicillin and metronidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD16,"omeprazole, amoxicillin and rifabutin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BD,Combinations for eradication of Helicobacter pylori,"The DDDs for combination packages in this group are given a fixed dose DDD, e.g. 6 tablets per day gives a DDD = 6 UD.",A02BD17,vonoprazan and amoxicillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX01,carbenoxolone,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX02,sucralfate,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX03,pirenzepine,0.1,20,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX04,methiosulfonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX05,bismuth subcitrate,0.48,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX06,proglumide,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX07,gefarnate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX08,sulglicotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX09,acetoxolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX10,zolimidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX11,troxipide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX12,bismuth subnitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX13,alginic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX14,rebamipide,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX15,teprenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX16,irsogladine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX51,"carbenoxolone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX71,"carbenoxolone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02B,DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD),A02BX,Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD),The DDD for alginic acid in combination with antacids (A02BX13) is given in a fixed doses (10 tablets = 10 UD; 50 ml mixture = 10 UD).,A02BX77,"gefarnate, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A02,DRUGS FOR ACID RELATED DISORDERS,A02X,OTHER DRUGS FOR ACID RELATED DISORDERS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA01,oxyphencyclimine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA03,camylofin,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA04,mebeverine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA05,trimebutine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA06,rociverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA07,dicycloverine,80,80,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA08,dihexyverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA09,difemerine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AA,"Synthetic anticholinergics, esters with tertiary amino group","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AA30,piperidolate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB01,benzilone,70,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB02,glycopyrronium bromide,3,0.3,3,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB03,oxyphenonium,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB04,penthienate,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB05,propantheline,60,60,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB06,otilonium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB07,methantheline,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB08,tridihexethyl,0.125,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB09,isopropamide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB10,hexocyclium,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB11,poldine,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB12,mepenzolate,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB13,bevonium,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB14,pipenzolate,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB15,diphemanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB16,(2-benzhydryloxyethyl)diethyl-methylammonium iodide,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB17,tiemonium iodide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB18,prifinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB19,timepidium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB21,fenpiverinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose. The parenteral DDD for glycopyrronium bromide is based on the use as premedication for anesthetic procedures.",A03AB53,"oxyphenonium, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AC,"Synthetic antispasmodics, amides with tertiary amines","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AC02,dimethylaminopropionylphenothiazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AC,"Synthetic antispasmodics, amides with tertiary amines","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AC04,nicofetamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AC,"Synthetic antispasmodics, amides with tertiary amines","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AC05,tiropramide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AD,Papaverine and derivatives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AD01,papaverine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AD,Papaverine and derivatives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AD02,drotaverine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AD,Papaverine and derivatives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AD30,moxaverine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AE,Serotonin receptor antagonists,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AE01,alosetron,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AE,Serotonin receptor antagonists,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AE03,cilansetron,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX01,fenpiprane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX02,diisopromine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX03,chlorbenzoxamine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX04,pinaverium,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX05,fenoverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX06,idanpramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX07,proxazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX08,alverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX09,trepibutone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX10,isometheptene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX11,caroverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX12,phloroglucinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX13,silicones,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX14,valethamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX15,menthae piperitae aetheroleum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX30,trimethyldiphenylpropylamine,50,50,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03A,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03AX,Other drugs for functional gastrointestinal disorders,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03AX58,"alverine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BA,"Belladonna alkaloids, tertiary amines","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BA01,atropine,1.5,1.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BA,"Belladonna alkaloids, tertiary amines","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BA03,hyoscyamine,1.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BA,"Belladonna alkaloids, tertiary amines","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BA04,belladonna total alkaloids,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BB01,butylscopolamine,60,60,60,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BB02,methylatropine,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BB03,methylscopolamine,12,12,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BB04,fentonium,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BB05,cimetropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03B,"BELLADONNA AND DERIVATIVES, PLAIN",A03BB,"Belladonna alkaloids, semisynthetic, quaternary ammonium compounds","The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03BB06,homatropine methylbromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA01,isopropamide and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA02,clidinium and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA03,oxyphencyclimine and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA04,otilonium bromide and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA05,glycopyrronium bromide and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA06,bevonium and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA07,ambutonium and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA08,diphemanil and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA09,pipenzolate and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA30,emepronium and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CA,Synthetic anticholinergic agents in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CA34,propantheline and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CB,Belladonna and derivatives in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CB01,methylscopolamine and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CB,Belladonna and derivatives in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CB02,belladonna total alkaloids and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CB,Belladonna and derivatives in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CB03,atropine and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CB,Belladonna and derivatives in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CB04,homatropine methylbromide and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CB,Belladonna and derivatives in combination with psycholeptics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03CB31,hyoscyamine and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03C,ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS,A03CC,Other antispasmodics in combination with psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA01,tropenzilone and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA02,pitofenone and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA03,bevonium and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA04,ciclonium and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA05,camylofin and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA06,trospium and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DA,Synthetic anticholinergic agents in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DA07,tiemonium iodide and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DB,Belladonna and derivatives in combination with analgesics,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03DB04,butylscopolamine and analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03D,ANTISPASMODICS IN COMBINATION WITH ANALGESICS,A03DC,Other antispasmodics in combination with analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03E,ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS,A03EA,"Antispasmodics, psycholeptics and analgesics in combination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03E,ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS,A03ED,Antispasmodics in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA01,metoclopramide,30,30,30,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA02,cisapride,30,NA,30,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA03,domperidone,30,30,0.12,NA,NA,NA,mg,mg,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA04,bromopride,20,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA05,alizapride,0.15,0.15,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA06,clebopride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA07,itopride,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA08,cinitapride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA09,mosapride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A03,DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS,A03F,PROPULSIVES,A03FA,Propulsives,"The DDD for the substances is usually equal for different routes of administration (oral, parenteral or rectal) of the same compound and is based on the oral dose.",A03FA10,acotiamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AA,Serotonin (5HT3) antagonists,The DDDs are based on antiemetic treatment. The DDD for palonosetron is based on single dose treatment.,A04AA01,ondansetron,16,16,16,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AA,Serotonin (5HT3) antagonists,The DDDs are based on antiemetic treatment. The DDD for palonosetron is based on single dose treatment.,A04AA02,granisetron,2,3,NA,NA,3.1,NA,mg,mg,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AA,Serotonin (5HT3) antagonists,The DDDs are based on antiemetic treatment. The DDD for palonosetron is based on single dose treatment.,A04AA03,tropisetron,5,5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AA,Serotonin (5HT3) antagonists,The DDDs are based on antiemetic treatment. The DDD for palonosetron is based on single dose treatment.,A04AA04,dolasetron,0.2,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AA,Serotonin (5HT3) antagonists,The DDDs are based on antiemetic treatment. The DDD for palonosetron is based on single dose treatment.,A04AA05,palonosetron,0.5,0.25,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AA,Serotonin (5HT3) antagonists,The DDDs are based on antiemetic treatment. The DDD for palonosetron is based on single dose treatment.,A04AA55,"palonosetron, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD01,scopolamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD02,cerium oxalate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD04,chlorobutanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD05,metopimazine,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD10,dronabinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD11,nabilone,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD12,aprepitant,NA,150,NA,NA,NA,Refers to fosaprepitant,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD12,aprepitant,165,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD13,casopitant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD14,rolapitant,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD51,"scopolamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A04,ANTIEMETICS AND ANTINAUSEANTS,A04A,ANTIEMETICS AND ANTINAUSEANTS,A04AD,Other antiemetics,The DDD for scopolamine plaster is one plaster (i.e. 1 UD).  This DDD is based on prophylaxis of motion sickness.DDDs for other substances classified in this group are based on antiemetic treatment.The DDDs for aprepitant/fosaprepitant (A04AD12) are based on treatment with 165 mg tablets/150 mg injection given as a single dose on day one of the treatment regimen. The DDD for rolapitant is also based on the single dose treatment on day one of the treatment regimen.,A04AD54,"chlorobutanol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AA,Bile acids and derivatives,NA,A05AA01,chenodeoxycholic acid,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AA,Bile acids and derivatives,NA,A05AA02,ursodeoxycholic acid,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AA,Bile acids and derivatives,NA,A05AA03,cholic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AA,Bile acids and derivatives,NA,A05AA04,obeticholic acid,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AA,Bile acids and derivatives,NA,A05AA05,ursodoxicoltaurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AB,Preparations for biliary tract therapy,NA,A05AB01,nicotinyl methylamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AX,Other drugs for bile therapy,NA,A05AX01,piprozolin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AX,Other drugs for bile therapy,NA,A05AX02,hymecromone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AX,Other drugs for bile therapy,NA,A05AX03,cyclobutyrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AX,Other drugs for bile therapy,NA,A05AX04,maralixibat chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AX,Other drugs for bile therapy,NA,A05AX05,odevixibat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05A,BILE THERAPY,A05AX,Other drugs for bile therapy,NA,A05AX06,elafibranor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA01,arginine glutamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA03,silymarin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA04,citiolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA05,epomediol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA06,ornithine oxoglurate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA07,tidiacic arginine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA08,glycyrrhizic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA09,metadoxine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05B,"LIVER THERAPY, LIPOTROPICS",A05BA,Liver therapy,NA,A05BA10,phospholipids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A05,BILE AND LIVER THERAPY,A05C,DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AA,"Softeners, emollients","DDDs for e.g. liquid paraffin and castor oil are given using the following unit: g (gram), (1 g = 1 ml for all practical purposes). Preparations classified in A06AA51 - liquid paraffin, combinations, are all given the same DDD = 3 UD (15 ml), independent of liquid paraffin concentration.",A06AA01,liquid paraffin,15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AA,"Softeners, emollients","DDDs for e.g. liquid paraffin and castor oil are given using the following unit: g (gram), (1 g = 1 ml for all practical purposes). Preparations classified in A06AA51 - liquid paraffin, combinations, are all given the same DDD = 3 UD (15 ml), independent of liquid paraffin concentration.",A06AA02,docusate sodium,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AA,"Softeners, emollients","DDDs for e.g. liquid paraffin and castor oil are given using the following unit: g (gram), (1 g = 1 ml for all practical purposes). Preparations classified in A06AA51 - liquid paraffin, combinations, are all given the same DDD = 3 UD (15 ml), independent of liquid paraffin concentration.",A06AA51,"liquid paraffin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB01,oxyphenisatine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB02,bisacodyl,10,NA,10,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB03,dantron,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB04,phenolphthalein,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB05,castor oil,20,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB06,senna glycosides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB07,cascara,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB08,sodium picosulfate,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB09,bisoxatin,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB20,contact laxatives in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB30,contact laxatives in combination with belladonna alkaloids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB52,"bisacodyl, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB53,"dantron, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB56,"senna glycosides, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB57,"cascara, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AB,Contact laxatives,NA,A06AB58,"sodium picosulfate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC01,ispaghula (psylla seeds),7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC02,ethulose,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC03,sterculia,8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC05,linseed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC06,methylcellulose,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC07,triticum (wheat fibre),10,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC08,polycarbophil calcium,2.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC51,"ispaghula, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC53,"sterculia, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AC,Bulk-forming laxatives,NA,A06AC55,"linseed, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD01,magnesium carbonate,7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD02,magnesium oxide,7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD03,magnesium peroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD04,magnesium sulfate,7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD10,mineral salts in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD11,lactulose,6.7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD12,lactitol,10,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD13,sodium sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD14,pentaerithrityl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD15,macrogol,10,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD16,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD17,sodium phosphate,50,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD18,sorbitol,10,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD19,magnesium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD21,sodium tartrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD61,"lactulose, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AD,Osmotically acting laxatives,The DDD for macrogol refers to macrogol 4000.,A06AD65,"macrogol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG01,sodium phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG02,bisacodyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG03,"dantron, incl. combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG04,glycerol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG06,oil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG07,sorbitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG10,"docusate sodium, incl. combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG11,"sodium lauryl sulfoacetate, incl. combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AG,Enemas,The DDDs for enemas classified in this group are 1 enema.,A06AG20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AH,Peripheral opioid receptor antagonists,NA,A06AH01,methylnaltrexone bromide,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AH,Peripheral opioid receptor antagonists,NA,A06AH02,alvimopan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AH,Peripheral opioid receptor antagonists,NA,A06AH03,naloxegol,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AH,Peripheral opioid receptor antagonists,NA,A06AH04,naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AH,Peripheral opioid receptor antagonists,NA,A06AH05,naldemedine,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX01,glycerol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX02,carbon dioxide producing drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX03,lubiprostone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX04,linaclotide,0.29,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX05,prucalopride,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX06,tegaserod,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX07,plecanatide,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX08,tenapanor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A06,DRUGS FOR CONSTIPATION,A06A,DRUGS FOR CONSTIPATION,A06AX,Other drugs for constipation,The DDD for linaclotide is based on treatment of irritable bowel syndrome with constipation.,A06AX09,elobixibat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA01,neomycin,5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA02,nystatin,1.5,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA03,natamycin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA04,streptomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA05,polymyxin B,3,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA06,paromomycin,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA07,amphotericin B,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA08,kanamycin,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA09,vancomycin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA10,colistin,9,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA11,rifaximin,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA12,fidaxomicin,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA13,rifamycin,0.8,NA,NA,NA,NA,as sodium salt,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA51,"neomycin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AA,Antibiotics,The DDDs are based on treatment of intestinal infections.,A07AA54,"streptomycin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AB,Sulfonamides,The DDDs are based on preoperative prophylaxis of intestinal infections.,A07AB02,phthalylsulfathiazole,9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AB,Sulfonamides,The DDDs are based on preoperative prophylaxis of intestinal infections.,A07AB03,sulfaguanidine,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AB,Sulfonamides,The DDDs are based on preoperative prophylaxis of intestinal infections.,A07AB04,succinylsulfathiazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AC,Imidazole derivatives,The DDDs are based on treatment of gastrointestinal mycosis.,A07AC01,miconazole,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AX,Other intestinal antiinfectives,NA,A07AX01,broxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AX,Other intestinal antiinfectives,NA,A07AX02,acetarsol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AX,Other intestinal antiinfectives,NA,A07AX03,nifuroxazide,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07A,INTESTINAL ANTIINFECTIVES,A07AX,Other intestinal antiinfectives,NA,A07AX04,nifurzide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BA,Charcoal preparations,The DDD for charcoal preparations is based on treatment of common diarrhea.,A07BA01,medicinal charcoal,5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BA,Charcoal preparations,The DDD for charcoal preparations is based on treatment of common diarrhea.,A07BA51,"medicinal charcoal, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BB,Bismuth preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC01,pectin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC02,kaolin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC03,crospovidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC04,attapulgite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC05,diosmectite,9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07B,INTESTINAL ADSORBENTS,A07BC,Other intestinal adsorbents,NA,A07BC54,"attapulgite, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07C,ELECTROLYTES WITH CARBOHYDRATES,A07CA,Oral rehydration salt formulations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA01,diphenoxylate,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA02,opium,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA03,loperamide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA04,difenoxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA05,loperamide oxide,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA06,eluxadoline,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA52,"morphine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07D,ANTIPROPULSIVES,A07DA,Antipropulsives,The DDDs are based on treatment of acute diarrhea.,A07DA53,"loperamide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA01,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA02,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA03,prednisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA04,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA05,tixocortol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA06,budesonide,9,NA,NA,1.5,NA,NA,mg,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EA,Corticosteroids acting locally,The DDDs are given as 1 enema.  The DDD for hydrocortisone rectal foam is given in amount of active substance.The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.,A07EA07,beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EB,"Antiallergic agents, excl. corticosteroids",The DDD is based on treatment of food allergy.,A07EB01,cromoglicic acid,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EC,Aminosalicylic acid and similar agents,The DDDs are based on treatment of colitis ulcerosa and morbus Crohn.,A07EC01,sulfasalazine,2,NA,2,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EC,Aminosalicylic acid and similar agents,The DDDs are based on treatment of colitis ulcerosa and morbus Crohn.,A07EC02,mesalazine,1.5,NA,1.5,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EC,Aminosalicylic acid and similar agents,The DDDs are based on treatment of colitis ulcerosa and morbus Crohn.,A07EC03,olsalazine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07E,INTESTINAL ANTIINFLAMMATORY AGENTS,A07EC,Aminosalicylic acid and similar agents,The DDDs are based on treatment of colitis ulcerosa and morbus Crohn.,A07EC04,balsalazide,6.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07F,ANTIDIARRHEAL MICROORGANISMS,A07FA,Antidiarrheal microorganisms,The DDDs are given in UDs (e.g. numbers of tablets).,A07FA01,lactic acid producing organisms,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07F,ANTIDIARRHEAL MICROORGANISMS,A07FA,Antidiarrheal microorganisms,The DDDs are given in UDs (e.g. numbers of tablets).,A07FA02,saccharomyces boulardii,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07F,ANTIDIARRHEAL MICROORGANISMS,A07FA,Antidiarrheal microorganisms,The DDDs are given in UDs (e.g. numbers of tablets).,A07FA03,escherichia coli,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07F,ANTIDIARRHEAL MICROORGANISMS,A07FA,Antidiarrheal microorganisms,The DDDs are given in UDs (e.g. numbers of tablets).,A07FA51,"lactic acid producing organisms, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07X,OTHER ANTIDIARRHEALS,A07XA,Other antidiarrheals,NA,A07XA01,albumin tannate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07X,OTHER ANTIDIARRHEALS,A07XA,Other antidiarrheals,NA,A07XA02,ceratonia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07X,OTHER ANTIDIARRHEALS,A07XA,Other antidiarrheals,NA,A07XA03,calcium compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07X,OTHER ANTIDIARRHEALS,A07XA,Other antidiarrheals,NA,A07XA04,racecadotril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07X,OTHER ANTIDIARRHEALS,A07XA,Other antidiarrheals,NA,A07XA06,crofelemer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A07,"ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS",A07X,OTHER ANTIDIARRHEALS,A07XA,Other antidiarrheals,NA,A07XA51,"albumin tannate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA01,phentermine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA02,fenfluramine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA03,amfepramone,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA04,dexfenfluramine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA05,mazindol,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA06,etilamfetamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA07,cathine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA08,clobenzorex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA09,mefenorex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA10,sibutramine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA11,lorcaserin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA12,setmelanotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA51,phentermine and topiramate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA56,"ephedrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AA,Centrally acting antiobesity products,NA,A08AA62,bupropion and naltrexone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AB,Peripherally acting antiobesity products,NA,A08AB01,orlistat,0.36,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A08,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08A,"ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS",A08AX,Other antiobesity drugs,NA,A08AX01,rimonabant,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AA,Enzyme preparations,"DDDs can be difficult to establish because of great variations in enzyme content.  The DDDs are based on average recommended doses given in different drug catalogues.  Most of the preparations are combinations of different enzymes, and the DDDs are therefore given in UDs.  Some specific products have been given a DDD, see list of DDDs for combination products, www.whocc.no.",A09AA01,diastase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AA,Enzyme preparations,"DDDs can be difficult to establish because of great variations in enzyme content.  The DDDs are based on average recommended doses given in different drug catalogues.  Most of the preparations are combinations of different enzymes, and the DDDs are therefore given in UDs.  Some specific products have been given a DDD, see list of DDDs for combination products, www.whocc.no.",A09AA02,"multienzymes (lipase, protease etc.)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AA,Enzyme preparations,"DDDs can be difficult to establish because of great variations in enzyme content.  The DDDs are based on average recommended doses given in different drug catalogues.  Most of the preparations are combinations of different enzymes, and the DDDs are therefore given in UDs.  Some specific products have been given a DDD, see list of DDDs for combination products, www.whocc.no.",A09AA03,pepsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AA,Enzyme preparations,"DDDs can be difficult to establish because of great variations in enzyme content.  The DDDs are based on average recommended doses given in different drug catalogues.  Most of the preparations are combinations of different enzymes, and the DDDs are therefore given in UDs.  Some specific products have been given a DDD, see list of DDDs for combination products, www.whocc.no.",A09AA04,tilactase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AB,Acid preparations,NA,A09AB01,glutamic acid hydrochloride,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AB,Acid preparations,NA,A09AB02,betaine hydrochloride,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AB,Acid preparations,NA,A09AB03,hydrochloric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AB,Acid preparations,NA,A09AB04,citric acid,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AC,"Enzyme and acid preparations, combinations",NA,A09AC01,pepsin and acid preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A09,"DIGESTIVES, INCL. ENZYMES",A09A,"DIGESTIVES, INCL. ENZYMES",A09AC,"Enzyme and acid preparations, combinations",NA,A09AC02,multienzymes and acid preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB01,insulin (human),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB02,insulin (beef),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB03,insulin (pork),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB04,insulin lispro,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB05,insulin aspart,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB06,insulin glulisine,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AB,"Insulins and analogues for injection, fast-acting",The DDD for insulins is 40 units.,A10AB30,combinations,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AC,"Insulins and analogues for injection, intermediate-acting",The DDD for insulins is 40 units.,A10AC01,insulin (human),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AC,"Insulins and analogues for injection, intermediate-acting",The DDD for insulins is 40 units.,A10AC02,insulin (beef),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AC,"Insulins and analogues for injection, intermediate-acting",The DDD for insulins is 40 units.,A10AC03,insulin (pork),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AC,"Insulins and analogues for injection, intermediate-acting",The DDD for insulins is 40 units.,A10AC04,insulin lispro,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AC,"Insulins and analogues for injection, intermediate-acting",The DDD for insulins is 40 units.,A10AC30,combinations,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD01,insulin (human),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD02,insulin (beef),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD03,insulin (pork),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD04,insulin lispro,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD05,insulin aspart,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD06,insulin degludec and insulin aspart,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",The DDD for insulins is 40 units.,A10AD30,combinations,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE01,insulin (human),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE02,insulin (beef),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE03,insulin (pork),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE04,insulin glargine,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE05,insulin detemir,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE06,insulin degludec,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE07,insulin icodec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE30,combinations,NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE54,insulin glargine and lixisenatide,NA,40,NA,NA,NA,Refers to insulin glargine,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AE,"Insulins and analogues for injection, long-acting",The DDD for insulins is 40 units.,A10AE56,insulin degludec and liraglutide,NA,40,NA,NA,NA,Refers to insulin degludec,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10A,INSULINS AND ANALOGUES,A10AF,Insulins and analogues for inhalation,The DDD for insulins is 40 units.,A10AF01,insulin (human),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BA,Biguanides,NA,A10BA01,phenformin,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BA,Biguanides,NA,A10BA02,metformin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BA,Biguanides,NA,A10BA03,buformin,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB01,glibenclamide,7,NA,NA,NA,NA,microcryst.substance,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB01,glibenclamide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB02,chlorpropamide,0.375,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB03,tolbutamide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB04,glibornuride,38,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB05,tolazamide,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB06,carbutamide,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB07,glipizide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB08,gliquidone,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB09,gliclazide,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB10,metahexamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB11,glisoxepide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB12,glimepiride,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BB,Sulfonylureas,"The DDD for micronized glibenclamide is lower compared to non-micronized formulations, due to higher bioavailability.The DDD for gliclazide is based on the modified release formulation.",A10BB31,acetohexamide,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BC,Sulfonamides (heterocyclic),NA,A10BC01,glymidine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD01,phenformin and sulfonylureas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD02,metformin and sulfonylureas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD03,metformin and rosiglitazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD04,glimepiride and rosiglitazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD05,metformin and pioglitazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD06,glimepiride and pioglitazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD07,metformin and sitagliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD08,metformin and vildagliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD09,pioglitazone and alogliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD10,metformin and saxagliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD11,metformin and linagliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD12,pioglitazone and sitagliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD13,metformin and alogliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD14,metformin and repaglinide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD15,metformin and dapagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD16,metformin and canagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD17,metformin and acarbose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD18,metformin and gemigliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD19,linagliptin and empagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD20,metformin and empagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD21,saxagliptin and dapagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD22,metformin and evogliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD23,metformin and ertugliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD24,sitagliptin and ertugliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD25,"metformin, saxagliptin and dapagliflozin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD26,metformin and lobeglitazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD27,"metformin, linagliptin and empagliflozin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD28,metformin and teneligliptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BD,Combinations of oral blood glucose lowering drugs,"It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  One UD is the fixed DDD for products dosed as 1 tablet daily whereas two UD is the fixed DDD for products dosed as 2 tablets daily.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.See list of DDDs for combined products, www.whocc.no.",A10BD29,sitagliptin and dapagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BF,Alpha glucosidase inhibitors,NA,A10BF01,acarbose,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BF,Alpha glucosidase inhibitors,NA,A10BF02,miglitol,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BF,Alpha glucosidase inhibitors,NA,A10BF03,voglibose,0.6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BG,Thiazolidinediones,The DDD for troglitazone is based on combination therapy.  The DDDs for rosiglitazone and pioglitazone are based on monotherapy.,A10BG01,troglitazone,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BG,Thiazolidinediones,The DDD for troglitazone is based on combination therapy.  The DDDs for rosiglitazone and pioglitazone are based on monotherapy.,A10BG02,rosiglitazone,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BG,Thiazolidinediones,The DDD for troglitazone is based on combination therapy.  The DDDs for rosiglitazone and pioglitazone are based on monotherapy.,A10BG03,pioglitazone,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BG,Thiazolidinediones,The DDD for troglitazone is based on combination therapy.  The DDDs for rosiglitazone and pioglitazone are based on monotherapy.,A10BG04,lobeglitazone,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH01,sitagliptin,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH02,vildagliptin,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH03,saxagliptin,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH04,alogliptin,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH05,linagliptin,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH06,gemigliptin,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH07,evogliptin,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH08,teneligliptin,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH51,sitagliptin and simvastatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BH,Dipeptidyl peptidase 4 (DPP-4) inhibitors,NA,A10BH52,gemigliptin and rosuvastatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ01,exenatide,NA,0.286,NA,NA,NA,depot inj,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ01,exenatide,NA,15,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ02,liraglutide,NA,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ03,lixisenatide,NA,20,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ04,albiglutide,NA,5.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ05,dulaglutide,NA,0.16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ06,semaglutide,10.5,0.11,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,NA,A10BJ07,beinaglutide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK01,dapagliflozin,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK02,canagliflozin,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK03,empagliflozin,17.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK04,ertugliflozin,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK05,ipragliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK06,sotagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK07,luseogliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BK,Sodium-glucose co-transporter 2 (SGLT2) inhibitors,NA,A10BK08,bexagliflozin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX01,guar gum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX02,repaglinide,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX03,nateglinide,0.36,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX05,pramlintide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX06,benfluorex,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX08,mitiglinide,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX15,imeglimin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX16,tirzepatide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX17,carfloglitazar,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10B,"BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS",A10BX,"Other blood glucose lowering drugs, excl. insulins",NA,A10BX18,dorzagliatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10X,OTHER DRUGS USED IN DIABETES,A10XA,Aldose reductase inhibitors,NA,A10XA01,tolrestat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A10,DRUGS USED IN DIABETES,A10X,OTHER DRUGS USED IN DIABETES,A10XX,Other drugs used in diabetes,NA,A10XX01,teplizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11A,"MULTIVITAMINS, COMBINATIONS",A11AA,Multivitamins with minerals,"The DDDs are based on prophylaxis.  For simplicity, the DDDs for oral formulations are given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 6 UD).",A11AA01,multivitamins and iron,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11A,"MULTIVITAMINS, COMBINATIONS",A11AA,Multivitamins with minerals,"The DDDs are based on prophylaxis.  For simplicity, the DDDs for oral formulations are given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 6 UD).",A11AA02,multivitamins and calcium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11A,"MULTIVITAMINS, COMBINATIONS",A11AA,Multivitamins with minerals,"The DDDs are based on prophylaxis.  For simplicity, the DDDs for oral formulations are given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 6 UD).",A11AA03,"multivitamins and other minerals, incl. combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11A,"MULTIVITAMINS, COMBINATIONS",A11AA,Multivitamins with minerals,"The DDDs are based on prophylaxis.  For simplicity, the DDDs for oral formulations are given as fixed doses (1 tablet = 1 UD; 30 ml mixture = 6 UD).",A11AA04,multivitamins and trace elements,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11A,"MULTIVITAMINS, COMBINATIONS",A11AB,"Multivitamins, other combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11B,"MULTIVITAMINS, PLAIN",A11BA,"Multivitamins, plain",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CA,"Vitamin A, plain",The DDD is based on treatment of vitamin A deficiency.,A11CA01,retinol (vit A),50,50,NA,NA,NA,NA,TU,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CA,"Vitamin A, plain",The DDD is based on treatment of vitamin A deficiency.,A11CA02,betacarotene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CB,Vitamin A and D in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC01,ergocalciferol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC02,dihydrotachysterol,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC03,alfacalcidol,1,1,NA,NA,NA,NA,mcg,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC04,calcitriol,1,1,NA,NA,NA,NA,mcg,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC05,colecalciferol,20,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC06,calcifediol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11C,"VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO",A11CC,Vitamin D and analogues,The DDDs are based on therapeutic use.  No DDD is established for ergocalciferol due to great differences between doses used for various indications. The DDD of 20 mcg colecalciferol corresponds to 800 IU.,A11CC55,"colecalciferol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11D,"VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12",A11DA,"Vitamin B1, plain",The DDDs are based on treatment of vitamin B1 deficiency.,A11DA01,thiamine (vit B1),50,50,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11D,"VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12",A11DA,"Vitamin B1, plain",The DDDs are based on treatment of vitamin B1 deficiency.,A11DA02,sulbutiamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11D,"VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12",A11DA,"Vitamin B1, plain",The DDDs are based on treatment of vitamin B1 deficiency.,A11DA03,benfotiamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11D,"VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12",A11DB,Vitamin B1 in combination with vitamin B6 and/or vitamin B12,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11E,"VITAMIN B-COMPLEX, INCL. COMBINATIONS",A11EA,"Vitamin B-complex, plain",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11E,"VITAMIN B-COMPLEX, INCL. COMBINATIONS",A11EB,Vitamin B-complex with vitamin C,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11E,"VITAMIN B-COMPLEX, INCL. COMBINATIONS",A11EC,Vitamin B-complex with minerals,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11E,"VITAMIN B-COMPLEX, INCL. COMBINATIONS",A11ED,Vitamin B-complex with anabolic steroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11E,"VITAMIN B-COMPLEX, INCL. COMBINATIONS",A11EX,"Vitamin B-complex, other combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11G,"ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",A11GA,"Ascorbic acid (vitamin C), plain","The DDD refers to the assumed daily requirement.For combination products, the DDDs are given as fixed doses for all tablets (1 tablet = 1 UD).",A11GA01,ascorbic acid (vit C),0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11G,"ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS",A11GB,"Ascorbic acid (vitamin C), combinations","The DDD refers to the assumed daily requirement.For combination products, the DDDs are given as fixed doses for all tablets (1 tablet = 1 UD).",A11GB01,ascorbic acid (vit C) and calcium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA01,nicotinamide,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA02,pyridoxine (vit B6),0.16,0.16,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA03,tocopherol (vit E),0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA04,riboflavin (vit B2),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA05,biotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA06,pyridoxal phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA07,inositol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA08,tocofersolan,0.2,NA,NA,NA,NA,Expressed as tocopherol,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA30,dexpanthenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA31,calcium pantothenate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11H,OTHER PLAIN VITAMIN PREPARATIONS,A11HA,Other plain vitamin preparations,"DDDs are established only for tocopherol, pyridoxine and nicotinamide, and refer to assumed daily requirement in vitamin deficiency.",A11HA32,pantethine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11J,"OTHER VITAMIN PRODUCTS, COMBINATIONS",A11JA,Combinations of vitamins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11J,"OTHER VITAMIN PRODUCTS, COMBINATIONS",A11JB,Vitamins with minerals,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A11,VITAMINS,A11J,"OTHER VITAMIN PRODUCTS, COMBINATIONS",A11JC,"Vitamins, other combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA01,calcium phosphate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA02,calcium glubionate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA03,calcium gluconate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA04,calcium carbonate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA05,calcium lactate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA06,calcium lactate gluconate,3,NA,NA,NA,NA,equivalent to 0.5 g Ca2+,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA07,calcium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA08,calcium glycerylphosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA09,calcium citrate lysine complex,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA10,calcium glucoheptonate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA11,calcium pangamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA13,calcium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA20,calcium (different salts in combination),0.5,NA,NA,NA,NA,Ca2+,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AA,Calcium,The DDDs are based on treatment of calcium deficiency and osteoporosis.,A12AA30,calcium laevulate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12A,CALCIUM,A12AX,"Calcium, combinations with vitamin D and/or other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA01,potassium chloride,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA02,potassium citrate,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA03,potassium hydrogentartrate,7.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA04,potassium hydrogencarbonate,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA05,potassium gluconate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA30,potassium (different salts in combination),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12B,POTASSIUM,A12BA,Potassium,The DDDs are based on treatment of potassium deficiency and correspond to a potassium content of about 40 mmol potassium.,A12BA51,"potassium chloride, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CA,Sodium,The DDD has been set to 1 g NaCl.,A12CA01,sodium chloride,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CA,Sodium,The DDD has been set to 1 g NaCl.,A12CA02,sodium sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CB,Zinc,The DDD is based on treatment of zinc deficiency.,A12CB01,zinc sulfate,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CB,Zinc,The DDD is based on treatment of zinc deficiency.,A12CB02,zinc gluconate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CB,Zinc,The DDD is based on treatment of zinc deficiency.,A12CB03,zinc protein complex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC01,magnesium chloride,2.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC02,magnesium sulfate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC03,magnesium gluconate,5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC04,magnesium citrate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC05,magnesium aspartate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC06,magnesium lactate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC07,magnesium levulinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC08,magnesium pidolate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC09,magnesium orotate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC10,magnesium oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CC,Magnesium,The DDDs for the various magnesium salts are equivalent to an assumed daily requirement of 300 mg magnesium (oral dose).  -,A12CC30,magnesium (different salts in combination),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CD,Fluoride,The DDD is based on treatment of osteoporosis.,A12CD01,sodium fluoride,88,NA,NA,NA,NA,40 mg fluoride,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CD,Fluoride,The DDD is based on treatment of osteoporosis.,A12CD02,sodium monofluorophosphate,0.152,NA,NA,NA,NA,20 mg fluoride,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CD,Fluoride,The DDD is based on treatment of osteoporosis.,A12CD51,"fluoride, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CE,Selenium,The DDDs are based on treatment of selenium deficiency and is expressed as amount of selenium (Se).,A12CE01,sodium selenate,0.2,NA,NA,NA,NA,Se,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CE,Selenium,The DDDs are based on treatment of selenium deficiency and is expressed as amount of selenium (Se).,A12CE02,sodium selenite,0.2,NA,NA,NA,NA,Se,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A12,MINERAL SUPPLEMENTS,A12C,OTHER MINERAL SUPPLEMENTS,A12CX,Other mineral products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A13,TONICS,A13A,TONICS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA01,androstanolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA02,stanozolol,5,3.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA03,metandienone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA04,metenolone,10,7,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA05,oxymetholone,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA06,quinbolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA07,prasterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA08,oxandrolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AA,Androstan derivatives,The DDDs are based on e.g. treatment of anemia.,A14AA09,norethandrolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AB,Estren derivatives,The DDDs are based on e.g. treatment of anemia.,A14AB01,nandrolone,NA,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AB,Estren derivatives,The DDDs are based on e.g. treatment of anemia.,A14AB02,ethylestrenol,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14A,ANABOLIC STEROIDS,A14AB,Estren derivatives,The DDDs are based on e.g. treatment of anemia.,A14AB03,oxabolone cipionate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A14,ANABOLIC AGENTS FOR SYSTEMIC USE,A14B,OTHER ANABOLIC AGENTS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA01,levocarnitine,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA02,ademetionine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA03,glutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA04,mercaptamine,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA05,carglumic acid,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA06,betaine,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AA,Amino acids and derivatives,The DDD of levocarnitine is based on treatment of primary carnitine deficiency.,A16AA07,metreleptin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB01,alglucerase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB02,imiglucerase,NA,300,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB03,agalsidase alfa,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB04,agalsidase beta,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB05,laronidase,NA,1,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB06,sacrosidase,68,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB07,alglucosidase alfa,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB08,galsulfase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB09,idursulfase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB10,velaglucerase alfa,NA,300,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB11,taliglucerase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB12,elosulfase alfa,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB13,asfotase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB14,sebelipase alfa,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB15,velmanase alfa,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB16,idursulfase beta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB17,cerliponase alfa,NA,21,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB18,vestronidase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB19,pegvaliase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB20,pegunigalsidase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB21,atidarsagene autotemcel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB22,avalglucosidase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB23,cipaglucosidase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB24,pegzilarginase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB25,olipudase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB26,eladocagene exuparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AB,Enzymes,NA,A16AB27,pabinafusp alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX01,thioctic acid,0.6,0.6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX02,anethole trithione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX03,sodium phenylbutyrate,20,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX04,nitisinone,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX05,zinc acetate,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX06,miglustat,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX07,sapropterin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX08,teduglutide,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX09,glycerol phenylbutyrate,15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX10,eliglustat,0.168,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX11,sodium benzoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX12,trientine,0.45,NA,NA,NA,NA,Expressed as trientine,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX13,uridine triacetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX14,migalastat,61.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX15,telotristat,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX16,givosiran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX17,triheptanoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX18,lumasiran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX19,fosdenopterin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX20,lonafarnib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX21,elivaldogene autotemcel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX22,tiomolibdic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX23,leriglitazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A,ALIMENTARY TRACT AND METABOLISM,A16,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16A,OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS,A16AX,Various alimentary tract and metabolism products,The DDD for zinc acetate is expressed as the amount of zinc (Zn).The DDD for nitisinone is based on the treatment of children with a bodyweight of 20 kg.The DDD for thioctic acid is based on the treatment of patients with peripheral diabetic polyneuropathy.The DDD for miglustat is based on the treatment of Gauchers disease.,A16AX30,sodium benzoate and sodium phenylacetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA01,dicoumarol,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA02,phenindione,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA03,warfarin,7.5,7.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA04,phenprocoumon,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA07,acenocoumarol,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA08,ethyl biscoumacetate,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA09,clorindione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA10,diphenadione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA11,tioclomarol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA12,fluindione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB01,heparin,NA,10,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB02,antithrombin III,NA,2.1,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB04,dalteparin,NA,2.5,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB05,enoxaparin,NA,2,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB06,nadroparin,NA,2.85,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB07,parnaparin,NA,3.2,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB08,reviparin,NA,1.43,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB09,danaparoid,NA,1.5,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB10,tinzaparin,NA,3.5,NA,NA,NA,NA,NA,TU,NA,NA,NA,anti Xa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB11,sulodexide,500,500,NA,NA,NA,NA,LSU,LSU,NA,NA,NA,LSU = lipoprotein lipase releasing units,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB12,bemiparin,NA,2.5,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB51,"heparin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC01,ditazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC02,cloricromen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC03,picotamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC04,clopidogrel,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC05,ticlopidine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC06,acetylsalicylic acid,1,NA,NA,NA,NA,NA,tablet,NA,NA,NA,NA,Independent of strength,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC07,dipyridamole,0.4,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC08,carbasalate calcium,1,NA,NA,NA,NA,NA,tablet,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC09,epoprostenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC10,indobufen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC11,iloprost,NA,50,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,0.15,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC13,abciximab,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC15,aloxiprin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC16,eptifibatide,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC17,tirofiban,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC18,triflusal,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC19,beraprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC21,treprostinil,NA,4.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC22,prasugrel,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC23,cilostazol,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC24,ticagrelor,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC25,cangrelor,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC26,vorapaxar,2.08,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC27,selexipag,1.8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC28,limaprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC56,"acetylsalicylic acid, combinations with proton pump inhibitors",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD01,streptokinase,NA,1.5,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD02,alteplase,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD03,anistreplase,NA,30,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD04,urokinase,NA,3,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD05,fibrinolysin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD06,brinase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD07,reteplase,NA,20,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD08,saruplase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD09,ancrod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD10,drotrecogin alfa (activated),NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD11,tenecteplase,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD12,protein C,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD13,apadamtase alfa and cinaxadamtase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE01,desirudin,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE02,lepirudin,NA,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE03,argatroban,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE04,melagatran,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE05,ximelagatran,48,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE06,bivalirudin,NA,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE07,dabigatran etexilate,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF01,rivaroxaban,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF02,apixaban,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF03,edoxaban,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF04,betrixaban,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF51,rivaroxaban and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX01,defibrotide,NA,1.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX04,dermatan sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX05,fondaparinux,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX07,caplacizumab,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AA,Amino acids,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AA01,aminocaproic acid,16,16,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AA,Amino acids,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AA02,tranexamic acid,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AA,Amino acids,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AA03,aminomethylbenzoic acid,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB01,aprotinin,NA,500,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB02,alfa1 antitrypsin,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB04,camostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB05,ulinastatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BA,Vitamin K,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).",B02BA01,phytomenadione,20,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BA,Vitamin K,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).",B02BA02,menadione,10,2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BB,Fibrinogen,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).",B02BB01,"fibrinogen, human",NA,5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC01,absorbable gelatin sponge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC02,oxidized cellulose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC03,tetragalacturonic acid hydroxymethylester,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC05,adrenalone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC06,thrombin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC07,collagen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC08,calcium alginate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC09,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD01,"coagulation factor IX, II, VII and X in combination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD02,coagulation factor VIII,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD03,factor VIII inhibitor bypassing activity,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD04,coagulation factor IX,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD05,coagulation factor VII,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD06,von Willebrand factor and coagulation factor VIII in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD07,coagulation factor XIII,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD08,coagulation factor VIIa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD10,von Willebrand factor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD11,catridecacog,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD13,coagulation factor X,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD14,susoctocog alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD15,valoctocogene roxaparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD16,etranacogene dezaparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD30,thrombin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX01,etamsylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX02,carbazochrome,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX03,batroxobin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX04,romiplostim,NA,30,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX05,eltrombopag,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX06,emicizumab,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX07,lusutrombopag,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX08,avatrombopag,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX09,fostamatinib,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX10,concizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA01,ferrous glycine sulfate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA02,ferrous fumarate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA03,ferrous gluconate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA04,ferrous carbonate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA05,ferrous chloride,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA06,ferrous succinate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA07,ferrous sulfate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA08,ferrous tartrate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA09,ferrous aspartate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA10,ferrous ascorbate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA11,ferrous iodine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe2+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA12,ferrous sodium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB01,ferric sodium citrate,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe3+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB02,saccharated iron oxide,0.11,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe3+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB03,sodium feredetate,0.17,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Fe3+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB04,ferric hydroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB05,ferric oxide polymaltose complexes,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Fe3+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB07,chondroitin sulfate-iron complex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB08,ferric acetyl transferrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB09,ferric proteinsuccinylate,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Fe3+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB10,ferric maltol,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Fe3+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AC,"Iron, parenteral preparations",NA,B03AC,"Iron, parenteral preparations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD01,ferrous amino acid complex and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD02,ferrous fumarate and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD03,ferrous sulfate and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD04,ferric oxide polymaltose complexes and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD05,ferrous gluconate and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE01,"iron, vitamin B12 and folic acid",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE02,"iron, multivitamins and folic acid",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE03,iron and multivitamins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE04,"iron, multivitamins and minerals",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE10,various combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA01,cyanocobalamin,1,20,NA,NA,NA,NA,mg,mcg,NA,NA,NA,NA,NA,70,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA02,cyanocobalamin tannin complex,NA,20,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA03,hydroxocobalamin,NA,20,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA04,cobamamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA05,mecobalamin,1.5,0.2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA51,"cyanocobalamin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA53,"hydroxocobalamin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BB,Folic acid and derivatives,The DDD for oral folic acid is based on prophylactic use and the parenteral DDD is based on treatment.,B03BB01,folic acid,0.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,prophylactic dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BB,Folic acid and derivatives,The DDD for oral folic acid is based on prophylactic use and the parenteral DDD is based on treatment.,B03BB01,folic acid,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,therapeutic dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BB,Folic acid and derivatives,The DDD for oral folic acid is based on prophylactic use and the parenteral DDD is based on treatment.,B03BB51,"folic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA01,erythropoietin,NA,1,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA02,darbepoetin alfa,NA,4.5,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA03,methoxy polyethylene glycol-epoetin beta,NA,4,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA04,peginesatide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA05,roxadustat,43,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA06,luspatercept,NA,3.33,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA07,daprodustat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA08,vadadustat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA01,albumin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA02,other plasma protein fractions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA03,fluorocarbon blood substitutes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA05,dextran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA06,gelatin agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA07,hydroxyethylstarch,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA08,hemoglobin crosfumaril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA09,hemoglobin raffimer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA10,hemoglobin glutamer (bovine),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX01,erythrocytes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX02,thrombocytes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX03,blood plasma,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX04,stem cells from umbilical cord blood,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA01,amino acids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA02,fat emulsions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA03,carbohydrates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA04,protein hydrolysates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB01,electrolytes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB02,electrolytes with carbohydrates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB03,trometamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB04,electrolytes in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BC,Solutions producing osmotic diuresis,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BC01,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BC,Solutions producing osmotic diuresis,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BC02,carbamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA01,cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA02,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA03,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA04,sulfamethizole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA05,taurolidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA06,mandelic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA07,noxytiolin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA08,ethacridine lactate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA09,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB01,sodium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB02,sodium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB03,magnesium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB04,sodium bicarbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX01,glucose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX02,sorbitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX03,glycine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX04,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05D,PERITONEAL DIALYTICS,B05DA,Isotonic solutions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05D,PERITONEAL DIALYTICS,B05DB,Hypertonic solutions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA01,potassium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA02,sodium bicarbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA03,sodium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA04,ammonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA05,magnesium sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA06,"potassium phosphate, incl. combinations with other potassium salts",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA07,calcium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA08,sodium acetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA09,sodium phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA10,magnesium phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA11,magnesium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA12,zinc chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA13,hydrochloric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA14,sodium glycerophosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA15,potassium lactate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA16,cardioplegia solutions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA17,potassium acetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA18,zinc sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA19,calcium gluconate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA20,sodium selenite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA30,combinations of electrolytes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA31,electrolytes in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XB,Amino acids,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XB01,arginine hydrochloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XB,Amino acids,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XB02,alanyl glutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XB,Amino acids,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XB03,lysine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XC,Vitamins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XX,Other i.v. solution additives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XX02,trometamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05Z,HEMODIALYTICS AND HEMOFILTRATES,B05ZA,"Hemodialytics, concentrates",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05Z,HEMODIALYTICS AND HEMOFILTRATES,B05ZB,Hemofiltrates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA02,fibrinolysin and desoxyribonuclease,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA03,hyaluronidase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA04,chymotrypsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA07,trypsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA10,desoxyribonuclease,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA55,"streptokinase, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AB,Heme products,NA,B06AB01,hemin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC01,"c1-inhibitor, plasma derived",NA,1.4,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC02,icatibant,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC03,ecallantide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC04,conestat alfa,NA,3.5,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC05,lanadelumab,NA,21.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC06,berotralstat,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX01,crizanlizumab,NA,12.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX02,betibeglogene autotemcel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX03,voxelotor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX04,mitapivat,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX05,exagamglogene autotemcel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA01,acetyldigitoxin,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA02,acetyldigoxin,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA03,digitalis leaves,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA04,digitoxin,0.1,0.1,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA05,digoxin,0.25,0.25,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA06,lanatoside C,1,NA,1,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA07,deslanoside,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,Acute treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA08,metildigoxin,0.2,0.2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA09,gitoformate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AA,Digitalis glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AA52,"acetyldigoxin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AB,Scilla glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AB01,proscillaridin,0.75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AB,Scilla glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AB51,"proscillaridin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AC,Strophanthus glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AC01,g-strophanthin,NA,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AC,Strophanthus glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AC03,cymarin,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01A,CARDIAC GLYCOSIDES,C01AX,Other cardiac glycosides,The DDDs are based on the average maintenance dose for the treatment of cardiac failure.  Exception: the DDD for deslanoside is for acute treatment.,C01AX02,peruvoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA01,quinidine,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA02,procainamide,3,3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA03,disopyramide,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA04,sparteine,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA05,ajmaline,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA08,prajmaline,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA12,lorajmine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA13,hydroquinidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA51,"quinidine, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BA,"Antiarrhythmics, class Ia",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BA71,"quinidine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB01,lidocaine,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB02,mexiletine,0.8,0.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB03,tocainide,1.2,1.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BB,"Antiarrhythmics, class Ib",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BB04,aprindine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC03,propafenone,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC04,flecainide,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC07,lorcainide,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC08,encainide,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BC,"Antiarrhythmics, class Ic",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BC09,ethacizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD01,amiodarone,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD02,bretylium tosilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD03,bunaftine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD04,dofetilide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD05,ibutilide,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD06,tedisamil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BD,"Antiarrhythmics, class III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations. The DDD for ibutilide refer to ibutilide fumarate.,C01BD07,dronedarone,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BG,"Other antiarrhythmics, class I and III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BG01,moracizine,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BG,"Other antiarrhythmics, class I and III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BG07,cibenzoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01B,"ANTIARRHYTHMICS, CLASS I AND III",C01BG,"Other antiarrhythmics, class I and III",The DDDs are based on the prophylaxis and treatment of supraventricular and ventricular arrhythmias.  The DDDs are based on the maintenance dose.  Preparations for parenteral administration are only used initially and are therefore given the same DDD as oral preparations.,C01BG11,vernakalant,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA01,etilefrine,50,50,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA02,isoprenaline,90,90,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA03,norepinephrine,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA04,dopamine,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA05,norfenefrine,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA06,phenylephrine,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA07,dobutamine,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA08,oxedrine,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA09,metaraminol,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA10,methoxamine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA11,mephentermine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA12,dimetofrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA13,prenalterol,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA14,dopexamine,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA15,gepefrine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA16,ibopamine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA17,midodrine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA18,octopamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA19,fenoldopam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA21,cafedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA22,arbutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA23,theodrenaline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA24,epinephrine,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA25,amezinium metilsulfate,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA26,ephedrine,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA27,droxidopa,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA28,centhaquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CA,Adrenergic and dopaminergic agents,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CA51,"etilefrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE01,amrinone,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE02,milrinone,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE03,enoximone,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CE,Phosphodiesterase inhibitors,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CE04,bucladesine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX06,angiotensinamide,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX07,xamoterol,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX08,levosimendan,NA,11,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX09,angiotensin II,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01C,CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES,C01CX,Other cardiac stimulants,This group includes various drugs used on different indications.  The DDDs are therefore established individually for each substance (i.e. each ATC 5th level).,C01CX10,omecamtiv mecarbil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA02,glyceryl trinitrate,5,NA,NA,2.5,5,NA,mg,NA,NA,mg,mg,NA,NA,NA,NA,NA,2.5,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA04,methylpropylpropanediol dinitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA05,pentaerithrityl tetranitrate,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA07,propatylnitrate,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA08,isosorbide dinitrate,60,NA,NA,20,0.1,NA,mg,NA,NA,mg,g,NA,NA,NA,NA,NA,20,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA09,trolnitrate,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA13,eritrityl tetranitrate,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA14,isosorbide mononitrate,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA20,organic nitrates in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA38,tenitramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA52,"glyceryl trinitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA54,"methylpropylpropanediol dinitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA55,"pentaerithrityl tetranitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA57,"propatylnitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA58,"isosorbide dinitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA59,"trolnitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA63,"eritrityl tetranitrate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DA,Organic nitrates,"The DDDs for the nitrates are mainly based on the treatment of angina pectoris attacks (3-4 times daily).  The DDDs of preparations for oral and transdermal administration are higher than the DDDs for other routes of administration (e.g. sublingual) due to a lower bioavailability.The DDDs for some preparations are mainly based on prophylaxis, for instance the DDDs of isosorbide dinitrate and glyceryl trinitrate plaster.No DDDs are established for parenteral preparations due to great differences in the dosages used.",C01DA70,organic nitrates in combination with psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DB,Quinolone vasodilators,NA,C01DB01,flosequinan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX01,itramin tosilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX02,prenylamine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX03,oxyfedrine,40,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX04,benziodarone,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX05,carbocromen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX06,hexobendine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX07,etafenone,0.225,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX08,heptaminol,0.45,0.45,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX09,imolamine,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX10,dilazep,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX11,trapidil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX12,molsidomine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX13,efloxate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX14,cinepazet,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX15,cloridarol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX16,nicorandil,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX18,linsidomine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX19,nesiritide,NA,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX21,serelaxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX22,vericiguat,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX51,"itramin tosilate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX52,"prenylamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX53,"oxyfedrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01D,VASODILATORS USED IN CARDIAC DISEASES,C01DX,Other vasodilators used in cardiac diseases,NA,C01DX54,"benziodarone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EA,Prostaglandins,The DDD for alprostadil equals the content of active substance in one ampoule.,C01EA01,alprostadil,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB02,camphora,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB03,indometacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB04,crataegus glycosides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB05,creatinolfosfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB06,fosfocreatine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB07,"fructose 1,6-diphosphate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB09,ubidecarenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB10,adenosine,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB11,tiracizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB13,acadesine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB15,trimetazidine,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB16,ibuprofen,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB17,ivabradine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB18,ranolazine,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB21,regadenoson,NA,0.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB22,meldonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB23,tiazotic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EB,Other cardiac preparations,The DDD for ibuprofen is based on the course dose.,C01EB24,mavacamten,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C01,CARDIAC THERAPY,C01E,OTHER CARDIAC PREPARATIONS,C01EX,Other cardiac combination products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA01,rescinnamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA02,reserpine,0.5,0.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA03,combinations of rauwolfia alkaloids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA04,"rauwolfia alkaloids, whole root",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA05,deserpidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA06,methoserpidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA07,bietaserpine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA52,"reserpine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA53,"combinations of rauwolfia alkoloids, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AA,Rauwolfia alkaloids,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AA57,"bietaserpine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AB,Methyldopa,"The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). Different DDDs have been established for the various stereoiso-meric forms of methyldopa, because of different potency.",C02AB01,methyldopa (levorotatory),1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AB,Methyldopa,"The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). Different DDDs have been established for the various stereoiso-meric forms of methyldopa, because of different potency.",C02AB02,methyldopa (racemic),2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC01,clonidine,0.45,0.45,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC02,guanfacine,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC04,tolonidine,0.75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC05,moxonidine,0.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02A,"ANTIADRENERGIC AGENTS, CENTRALLY ACTING",C02AC,Imidazoline receptor agonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02AC06,rilmenidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02B,"ANTIADRENERGIC AGENTS, GANGLION-BLOCKING",C02BA,Sulfonium derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02BA01,trimetaphan,NA,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02B,"ANTIADRENERGIC AGENTS, GANGLION-BLOCKING",C02BB,Secondary and tertiary amines,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02BB01,mecamylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02B,"ANTIADRENERGIC AGENTS, GANGLION-BLOCKING",C02BC,Bisquaternary ammonium compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA01,prazosin,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA02,indoramin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA03,trimazosin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA04,doxazosin,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CA,Alpha-adrenoreceptor antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CA06,urapidil,0.12,50,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC01,betanidine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC02,guanethidine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC03,guanoxan,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC04,debrisoquine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC05,guanoclor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC06,guanazodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02C,"ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING",C02CC,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02CC07,guanoxabenz,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DA,Thiazide derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DA01,diazoxide,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB01,dihydralazine,75,25,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB02,hydralazine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB03,endralazine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DB,Hydrazinophthalazine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The oral DDD of dihydralazine is higher than the parenteral DDD. The parenteral DDD is given as the chloride salt while the oral DDD is given as the mesylate salt.,C02DB04,cadralazine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DC,Pyrimidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DC01,minoxidil,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DD,Nitroferricyanide derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DD01,nitroprusside,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02D,"ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON",C02DG,Guanidine derivatives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02DG01,pinacidil,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KA,"Alkaloids, excl. rauwolfia",The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KA01,veratrum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KB,Tyrosine hydroxylase inhibitors,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KB01,metirosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KC,MAO inhibitors,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KC01,pargyline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KD,Serotonin antagonists,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KD01,ketanserin,40,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KN,Other antihypertensives,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule).,C02KN01,aprocitentan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX01,bosentan,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX02,ambrisentan,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX03,sitaxentan,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX04,macitentan,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX05,riociguat,4.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX52,ambrisentan and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02K,OTHER ANTIHYPERTENSIVES,C02KX,Antihypertensives for pulmonary arterial hypertension,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). The DDDs are based on treatment of pulmonary arterial hypertension.,C02KX54,macitentan and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA01,reserpine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA02,rescinnamine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA03,deserpidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA04,methoserpidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA07,bietaserpine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA08,"rauwolfia alkaloids, whole root and diuretics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA09,syrosingopine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA50,combination of rauwolfia alkaloids and diuretics incl. other combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA51,"reserpine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA52,"rescinnamine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LA,Rauwolfia alkaloids and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LA71,"reserpine and diuretics, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LB,Methyldopa and diuretics in combination,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LB01,methyldopa (levorotatory) and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LC,Imidazoline receptor agonists in combination with diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LC01,clonidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LC,Imidazoline receptor agonists in combination with diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LC05,moxonidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LC,Imidazoline receptor agonists in combination with diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LC51,"clonidine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LE,Alpha-adrenoreceptor antagonists and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LE01,prazosin and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LF,Guanidine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LF01,guanethidine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG01,dihydralazine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG02,hydralazine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG03,picodralazine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG51,"dihydralazine and diuretics, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LG,Hydrazinophthalazine derivatives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LG73,"picodralazine and diuretics, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LK,"Alkaloids, excl. rauwolfia, in combination with diuretics",The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LK01,veratrum and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LL,MAO inhibitors and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LL01,pargyline and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LN,Serotonin antagonists and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02L,ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION,C02LX,Other antihypertensives and diuretics,The oral DDDs are based on the average doses needed to reduce the blood pressure to a normal level in patients with mild-moderate hypertension.Parenteral DDDs are based on dosages used for the treatment of hypertensive crises and are based on the content of the active ingredient pr. vial (ampoule). It has been considered most appropriate to assign fixed DDDs based on the average use of the different combinations without considering and comparing the strengths of the various components.  1 tablet is the fixed DDD for products given once daily whereas the fixed DDD for products given twice daily and three times daily is respectively2 tablets and 3 tablets.  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.,C02LX01,pinacidil and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C02,ANTIHYPERTENSIVES,C02N,COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA01,bendroflumethiazide,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA02,hydroflumethiazide,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA03,hydrochlorothiazide,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA04,chlorothiazide,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA05,polythiazide,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA06,trichlormethiazide,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA07,cyclopenthiazide,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA08,methyclothiazide,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA09,cyclothiazide,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AA,"Thiazides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AA13,mebutizide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB01,bendroflumethiazide and potassium,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to bendroflumethiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB02,hydroflumethiazide and potassium,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to hydroflumethiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB03,hydrochlorothiazide and potassium,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to hydrochlorothiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB04,chlorothiazide and potassium,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to chlorothiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB05,polythiazide and potassium,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to polythiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB06,trichlormethiazide and potassium,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to trichlormethiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB07,cyclopenthiazide and potassium,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to cyclopenthiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB08,methyclothiazide and potassium,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to methyclothiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AB,Thiazides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AB09,cyclothiazide and potassium,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to cyclothiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AH,"Thiazides, combinations with psycholeptics and/or analgesics","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AH01,"chlorothiazide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AH,"Thiazides, combinations with psycholeptics and/or analgesics","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AH02,"hydroflumethiazide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03A,"LOW-CEILING DIURETICS, THIAZIDES",C03AX,"Thiazides, combinations with other drugs","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The different lipid solubility of the thiazides should be considered when assigning DDDs.",C03AX01,"hydrochlorothiazide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA02,quinethazone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA03,clopamide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA04,chlortalidone,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA05,mefruside,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA07,clofenamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA08,metolazone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA09,meticrane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA10,xipamide,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA11,indapamide,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA12,clorexolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA13,fenquizone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BA82,"clorexolone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB02,quinethazone and potassium,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to quinethazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB03,clopamide and potassium,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to clopamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB04,chlortalidone and potassium,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to chlortalidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB05,mefruside and potassium,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to mefruside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BB07,clofenamide and potassium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BC,Mercurial diuretics,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BC01,mersalyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BD,Xanthine derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BD01,theobromine,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BK,"Sulfonamides, combinations with other drugs",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03B,"LOW-CEILING DIURETICS, EXCL. THIAZIDES",C03BX,Other low-ceiling diuretics,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03BX03,cicletanine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA01,furosemide,40,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA02,bumetanide,1,1,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA03,piretanide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CA,"Sulfonamides, plain","The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CA04,torasemide,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CB01,furosemide and potassium,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to furosemide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CB,Sulfonamides and potassium in combination,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CB02,bumetanide and potassium,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to bumetanide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CC,Aryloxyacetic acid derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CC01,etacrynic acid,50,50,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CC,Aryloxyacetic acid derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CC02,tienilic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CD,Pyrazolone derivatives,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CD01,muzolimine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03C,HIGH-CEILING DIURETICS,C03CX,Other high-ceiling diuretics,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03CX01,etozolin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA01,spironolactone,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA02,potassium canrenoate,NA,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA03,canrenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA04,eplerenone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DA,Aldosterone antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. The DDD for finerenone is based on the treatment of chronic kidney disease associated with type 2 diabetes.",C03DA05,finerenone,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DB,Other potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03DB01,amiloride,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03D,ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS,C03DB,Other potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03DB02,triamterene,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA01,hydrochlorothiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA02,trichlormethiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA03,epitizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA04,altizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA05,mebutizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA06,chlortalidone and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA07,cyclopenthiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA12,metolazone and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA13,bendroflumethiazide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EA,Low-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EA14,butizide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EB,High-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EB01,furosemide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03E,DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION,C03EB,High-ceiling diuretics and potassium-sparing agents,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level. Fixed DDDs are assigned for combinations in this group.E.g. 1 tablet regardless of strengths is the DDD assigned for hydrochlorothiazide and amiloride in combinations.  See comments to C02L also.",C03EB02,bumetanide and potassium-sparing agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03X,OTHER DIURETICS,C03XA,Vasopressin antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03XA01,tolvaptan,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C03,DIURETICS,C03X,OTHER DIURETICS,C03XA,Vasopressin antagonists,"The DDDs for diuretics are based on monotherapy.  Most diuretics are used both for the treatment of edema and hypertension in similar doses and the DDDs are therefore based on both indications.The DDDs for combinations correspond to the DDD for the diuretic component, except for ATC group C03E, see comments under this level.",C03XA02,conivaptan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AA,2-amino-1-phenylethanol derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AA01,isoxsuprine,60,60,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AA,2-amino-1-phenylethanol derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AA02,buphenine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AA,2-amino-1-phenylethanol derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AA31,bamethan,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AB,Imidazoline derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AB01,phentolamine,10,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AB,Imidazoline derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AB02,tolazoline,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC01,nicotinic acid,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC02,nicotinyl alcohol (pyridylcarbinol),0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC03,inositol nicotinate,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AC,Nicotinic acid and derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AC07,ciclonicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD01,pentifylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD02,xantinol nicotinate,0.9,0.9,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD03,pentoxifylline,1,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AD,Purine derivatives,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AD04,etofylline nicotinate,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE01,ergoloid mesylates,3,3,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE02,nicergoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE04,dihydroergocristine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE51,"ergoloid mesylates, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AE,Ergot alkaloids,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AE54,"dihydroergocristine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AF,Enzymes,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AF01,kallidinogenase,30,30,NA,NA,NA,NA,U,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX01,cyclandelate,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX02,phenoxybenzamine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX07,vincamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX10,moxisylyte,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX11,bencyclane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX17,vinburnine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX19,suloctidil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX20,buflomedil,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX21,naftidrofuryl,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX23,butalamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX24,visnadine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX26,cetiedil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX27,cinepazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX28,ifenprodil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX30,azapetine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX32,fasudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C04,PERIPHERAL VASODILATORS,C04A,PERIPHERAL VASODILATORS,C04AX,Other peripheral vasodilators,The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.,C04AX33,clazosentan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA01,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA04,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA05,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA06,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA08,fluocortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA09,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA10,fluocinolone acetonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA11,fluocinonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AA,Corticosteroids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AA12,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AB,Antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD01,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD02,tetracaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD03,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD04,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD05,procaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD06,oxetacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AD,Local anesthetics,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AD07,pramocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AE,Muscle relaxants,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AE01,glyceryl trinitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AE,Muscle relaxants,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AE02,isosorbide dinitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AE,Muscle relaxants,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AE03,diltiazem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX01,aluminium preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX02,"bismuth preparations, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX03,"other preparations, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX04,zinc preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX05,tribenoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05A,AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE,C05AX,Other agents for treatment of hemorrhoids and anal fissures for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05AX06,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA01,organo-heparinoid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA02,sodium apolate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA03,heparin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA04,pentosan polysulfate sodium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA51,"heparinoid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BA,Heparins or heparinoids for topical use,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BA53,"heparin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB01,monoethanolamine oleate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB02,polidocanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB03,invert sugar,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB04,sodium tetradecyl sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB05,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BB,Sclerosing agents for local injection,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BB56,"glucose, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BX,Other sclerosing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BX01,calcium dobesilate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05B,ANTIVARICOSE THERAPY,C05BX,Other sclerosing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05BX51,"calcium dobesilate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA01,rutoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA02,monoxerutin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA03,diosmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA04,troxerutin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA05,hidrosmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA51,"rutoside, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA53,"diosmin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CA,Bioflavonoids,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CA54,"troxerutin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CX,Other capillary stabilizing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CX01,tribenoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CX,Other capillary stabilizing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CX02,naftazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05C,CAPILLARY STABILIZING AGENTS,C05CX,Other capillary stabilizing agents,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05CX03,Hippocastani semen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C05,VASOPROTECTIVES,C05X,OTHER VASOPROTECTIVES,C05XX,Other vasoprotectives,"No DDDs are established in this group, since most of the drugs in this group are for topical use.",C05XX01,beperminogene perplasmid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA01,alprenolol,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA02,oxprenolol,0.16,0.16,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA03,pindolol,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA05,propranolol,0.16,0.16,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA06,timolol,20,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA07,sotalol,0.16,0.16,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA12,nadolol,0.16,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA14,mepindolol,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA15,carteolol,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA16,tertatolol,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA17,bopindolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA19,bupranolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA23,penbutolol,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AA,"Beta blocking agents, non-selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AA27,cloranolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB01,practolol,0.3,20,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB02,metoprolol,0.15,0.15,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB03,atenolol,75,75,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB04,acebutolol,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB05,betaxolol,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB06,bevantolol,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB07,bisoprolol,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB08,celiprolol,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB09,esmolol,NA,2.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB10,epanolol,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB11,s-atenolol,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB12,nebivolol,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB13,talinolol,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AB,"Beta blocking agents, selective","The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol. Different DDDs have been assigned for the two stereoisomeric forms of atenolol due to different potency.",C07AB14,landiolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AG,Alpha and beta blocking agents,"The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AG01,labetalol,0.6,0.6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07A,BETA BLOCKING AGENTS,C07AG,Alpha and beta blocking agents,"The DDDs are based on the treatment of mild-moderate hypertension.The DDDs for oral and parenteral formulations are equal, even if the parenteral preparations are used for the initial treatment of arrhythmias.  Exception: practolol.",C07AG02,carvedilol,37.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA02,oxprenolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA05,propranolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA06,timolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA07,sotalol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA12,nadolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BA,"Beta blocking agents, non-selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BA68,"metipranolol and thiazides, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB02,metoprolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB03,atenolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB04,acebutolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB06,bevantolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB07,bisoprolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB12,nebivolol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BB,"Beta blocking agents, selective, and thiazides",See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BB52,"metoprolol and thiazides, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07B,BETA BLOCKING AGENTS AND THIAZIDES,C07BG,Alpha and beta blocking agents and thiazides,See comments to C02L concerning the principles for assignment of DDDs for the combined preparations.,C07BG01,labetalol and thiazides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA02,oxprenolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA03,pindolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA17,bopindolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CA,"Beta blocking agents, non-selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CA23,penbutolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CB,"Beta blocking agents, selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CB02,metoprolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CB,"Beta blocking agents, selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CB03,atenolol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CB,"Beta blocking agents, selective, and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CB53,"atenolol and other diuretics, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07C,BETA BLOCKING AGENTS AND OTHER DIURETICS,C07CG,Alpha and beta blocking agents and other diuretics,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07CG01,labetalol and other diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07D,"BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS",C07DA,"Beta blocking agents, non-selective, thiazides and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07DA06,"timolol, thiazides and other diuretics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07D,"BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS",C07DB,"Beta blocking agents, selective, thiazides and other diuretics",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07DB01,"atenolol, thiazides and other diuretics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07E,BETA BLOCKING AGENTS AND VASODILATORS,C07EA,"Beta blocking agents, non-selective, and vasodilators",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07E,BETA BLOCKING AGENTS AND VASODILATORS,C07EB,"Beta blocking agents, selective, and vasodilators",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB02,metoprolol and felodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB03,atenolol and nifedipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB07,bisoprolol and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB12,nebivolol and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FB,Beta blocking agents and calcium channel blockers,See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FB13,metoprolol and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX01,propranolol and other combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX02,sotalol and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX03,metoprolol and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX04,bisoprolol and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX05,metoprolol and ivabradine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C07,BETA BLOCKING AGENTS,C07F,"BETA BLOCKING AGENTS, OTHER COMBINATIONS",C07FX,"Beta blocking agents, other combinations",See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C07FX06,carvedilol and ivabradine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA01,amlodipine,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA02,felodipine,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA03,isradipine,5,5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA04,nicardipine,90,90,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA05,nifedipine,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA06,nimodipine,0.3,50,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA07,nisoldipine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA08,nitrendipine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA09,lacidipine,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA10,nilvadipine,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA11,manidipine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA12,barnidipine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA13,lercanidipine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA14,cilnidipine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA15,benidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA16,clevidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA17,levamlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA51,amlodipine and celecoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CA,Dihydropyridine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CA55,"nifedipine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08C,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS,C08CX,Other selective calcium channel blockers with mainly vascular effects,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08CX01,mibefradil,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DA01,verapamil,0.24,0.24,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DA02,gallopamil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DA51,"verapamil, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08D,SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS,C08DB,Benzothiazepine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08DB01,diltiazem,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EA01,fendiline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EA,Phenylalkylamine derivatives,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EA02,bepridil,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EX,Other non-selective calcium channel blockers,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EX01,lidoflazine,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08E,NON-SELECTIVE CALCIUM CHANNEL BLOCKERS,C08EX,Other non-selective calcium channel blockers,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08EX02,perhexiline,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08G,CALCIUM CHANNEL BLOCKERS AND DIURETICS,C08GA,Calcium channel blockers and diuretics,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08GA01,nifedipine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C08,CALCIUM CHANNEL BLOCKERS,C08G,CALCIUM CHANNEL BLOCKERS AND DIURETICS,C08GA,Calcium channel blockers and diuretics,"The DDDs for calcium channel blockers are based on the treatment of mild-moderate hypertension, although some are used for other indications (e.g. angina pectoris).The DDDs for oral and parenteral preparations are equal and are based on the oral dose, since oral preparations represent the major fraction of the total consumption.",C08GA02,amlodipine and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA01,captopril,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA02,enalapril,10,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA03,lisinopril,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA04,perindopril,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA05,ramipril,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA06,quinapril,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA07,benazepril,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA08,cilazapril,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA09,fosinopril,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA10,trandolapril,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA11,spirapril,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA12,delapril,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA13,moexipril,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA14,temocapril,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA15,zofenopril,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09A,"ACE INHIBITORS, PLAIN",C09AA,"ACE inhibitors, plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09AA16,imidapril,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA01,captopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA02,enalapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA03,lisinopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA04,perindopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA05,ramipril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA06,quinapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA07,benazepril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA08,cilazapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA09,fosinopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA12,delapril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA13,moexipril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BA,ACE inhibitors and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BA15,zofenopril and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB02,enalapril and lercanidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB03,lisinopril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB04,perindopril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB05,ramipril and felodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB06,enalapril and nitrendipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB07,ramipril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB10,trandolapril and verapamil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB12,delapril and manidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BB,ACE inhibitors and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BB13,benazepril and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX01,"perindopril, amlodipine and indapamide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX02,perindopril and bisoprolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX03,"ramipril, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX04,"perindopril, bisoprolol and amlodipine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX05,ramipril and bisoprolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX06,"perindopril, bisoprolol, amlodipine and indapamide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09B,"ACE INHIBITORS, COMBINATIONS",C09BX,"ACE inhibitors, other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09BX07,zofenopril and nebivolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA01,losartan,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA02,eprosartan,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA03,valsartan,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA04,irbesartan,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA05,tasosartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA06,candesartan,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA07,telmisartan,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA08,olmesartan medoxomil,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA09,azilsartan medoxomil,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09C,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN",C09CA,"Angiotensin II receptor blockers (ARBs), plain",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09CA10,fimasartan,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA01,losartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA02,eprosartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA03,valsartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA04,irbesartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA06,candesartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA07,telmisartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA08,olmesartan medoxomil and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA09,azilsartan medoxomil and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DA,Angiotensin II receptor blockers (ARBs) and diuretics,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DA10,fimasartan and diuretics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB01,valsartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB02,olmesartan medoxomil and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB04,telmisartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB05,irbesartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB06,losartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB07,candesartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB08,valsartan and lercanidipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DB,Angiotensin II receptor blockers (ARBs) and calcium channel blockers,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DB09,fimasartan and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX01,"valsartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX02,valsartan and aliskiren,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX03,"olmesartan medoxomil, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX04,valsartan and sacubitril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX05,valsartan and nebivolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX06,"candesartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX07,"irbesartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09D,"ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS",C09DX,"Angiotensin II receptor blockers (ARBs), other combinations",The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09DX08,"telmisartan, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA01,remikiren,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA02,aliskiren,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA52,aliskiren and hydrochlorothiazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA53,aliskiren and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C09,AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09X,OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM,C09XA,Renin-inhibitors,The DDDs are based on the treatment of mild-moderate hypertension.See comments to C02L concerning the principles for assignment of DDDs for combined preparations.,C09XA54,"aliskiren, amlodipine and hydrochlorothiazide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA01,simvastatin,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA02,lovastatin,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA03,pravastatin,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA04,fluvastatin,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA05,atorvastatin,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA06,cerivastatin,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA07,rosuvastatin,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AA,HMG CoA reductase inhibitors,The DDDs are based on the treatment of hypercholesterolemia.,C10AA08,pitavastatin,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB01,clofibrate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB02,bezafibrate,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB03,aluminium clofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB04,gemfibrozil,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB05,fenofibrate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,micronised,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB06,simfibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB07,ronifibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB08,ciprofibrate,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB09,etofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB10,clofibride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB11,choline fenofibrate,0.135,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to fenofibric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AB,Fibrates,The DDDs are based on the treatment of hypercholesterolemia. The DDD for fenofibrate is based on the micronised formulation.,C10AB12,pemafibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC01,colestyramine,14,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC02,colestipol,20,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC03,colextran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AC,Bile acid sequestrants,The DDDs are based on the treatment of hypercholesterolemia.,C10AC04,colesevelam,3.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD01,niceritrol,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD02,nicotinic acid,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD03,nicofuranose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD04,aluminium nicotinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD05,nicotinyl alcohol (pyridylcarbinol),0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD06,acipimox,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AD,Nicotinic acid and derivatives,The DDDs are based on the treatment of hypercholesterolemia.,C10AD52,"nicotinic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX01,dextrothyroxine,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX02,probucol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX03,tiadenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX05,meglutol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX06,omega-3-triglycerides incl. other esters and acids,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX07,magnesium pyridoxal 5-phosphate glutamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX08,policosanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX09,ezetimibe,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX10,alipogene tiparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX11,mipomersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX12,lomitapide,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX13,evolocumab,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX14,alirocumab,NA,5.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX15,bempedoic acid,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX16,inclisiran,NA,1.6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX17,evinacumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10A,"LIPID MODIFYING AGENTS, PLAIN",C10AX,Other lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. The DDD for evolocumab is based on dosing every second week.The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.,C10AX18,volanesorsen,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA01,lovastatin and nicotinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA02,simvastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA03,pravastatin and fenofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA04,simvastatin and fenofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA05,atorvastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA06,rosuvastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA07,rosuvastatin and omega-3 fatty acids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA08,atorvastatin and omega-3 fatty acids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA09,rosuvastatin and fenofibrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA10,bempedoic acid and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA11,pravastatin and ezetimibe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BA,Combinations of various lipid modifying agents,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BA12,"pravastatin, ezetimibe and fenofibrate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX01,simvastatin and acetylsalicylic acid,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to simvastatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX02,pravastatin and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX03,atorvastatin and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX04,"simvastatin, acetylsalicylic acid and ramipril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX05,rosuvastatin and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX06,"atorvastatin, acetylsalicylic acid and ramipril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX07,"rosuvastatin, amlodipine and lisinopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX08,atorvastatin and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX09,rosuvastatin and amlodipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX10,rosuvastatin and valsartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX11,"atorvastatin, amlodipine and perindopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX12,"atorvastatin, acetylsalicylic acid and perindopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX13,"rosuvastatin, perindopril and indapamide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX14,"rosuvastatin, amlodipine and perindopril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX15,atorvastatin and perindopril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX16,rosuvastatin and fimasartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX17,rosuvastatin and ramipril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX18,"atorvastatin, amlodipine and ramipril",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX19,"atorvastatin, amlodipine and candesartan",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX20,rosuvastatin and telmisartan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C,CARDIOVASCULAR SYSTEM,C10,LIPID MODIFYING AGENTS,C10B,"LIPID MODIFYING AGENTS, COMBINATIONS",C10BX,Lipid modifying agents in combination with other drugs,The DDDs are based on the treatment of hypercholesterolemia. For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.,C10BX21,rosuvastatin and perindopril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA01,nystatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA02,natamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA03,hachimycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA04,pecilocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA06,mepartricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA07,pyrrolnitrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA08,griseofulvin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AA,Antibiotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AA20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC01,clotrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC02,miconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC03,econazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC04,chlormidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC05,isoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC06,tiabendazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC07,tioconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC08,ketoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC09,sulconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC10,bifonazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC11,oxiconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC12,fenticonazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC13,omoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC14,sertaconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC15,fluconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC16,flutrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC17,eberconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC18,luliconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC19,efinaconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC20,imidazoles/triazoles in combination with corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC21,neticonazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC22,lanoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC52,"miconazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AC,Imidazole and triazole derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AC60,"bifonazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE01,bromochlorosalicylanilide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE02,methylrosaniline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE03,tribromometacresol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE04,undecylenic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE05,polynoxylin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE06,2-(4-chlorphenoxy)-ethanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE07,chlorphenesin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE08,ticlatone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE09,sulbentine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE10,ethyl hydroxybenzoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE11,haloprogin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE12,salicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE13,selenium sulfide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE14,ciclopirox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE15,terbinafine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE16,amorolfine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE17,dimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE18,tolnaftate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE19,tolciclate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE21,flucytosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE22,naftifine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE23,butenafine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE24,tavaborole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE25,liranaftate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01A,ANTIFUNGALS FOR TOPICAL USE,D01AE,Other antifungals for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D01AE54,"undecylenic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01B,ANTIFUNGALS FOR SYSTEMIC USE,D01BA,Antifungals for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs for griseofulvin and terbinafine are based on the treatment of dermatophyte infections in skin, hair or nails.",D01BA01,griseofulvin,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01B,ANTIFUNGALS FOR SYSTEMIC USE,D01BA,Antifungals for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs for griseofulvin and terbinafine are based on the treatment of dermatophyte infections in skin, hair or nails.",D01BA02,terbinafine,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D01,ANTIFUNGALS FOR DERMATOLOGICAL USE,D01B,ANTIFUNGALS FOR SYSTEMIC USE,D01BA,Antifungals for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs for griseofulvin and terbinafine are based on the treatment of dermatophyte infections in skin, hair or nails.",D01BA03,fosravuconazole,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Expressed as ravuconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AA,Silicone products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AB,Zinc products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AC,Soft paraffin and fat products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AD,Liquid plasters,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AE,Carbamide products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D02AE01,carbamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AE,Carbamide products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D02AE51,"carbamide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AF,Salicylic acid preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02A,EMOLLIENTS AND PROTECTIVES,D02AX,Other emollients and protectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02B,PROTECTIVES AGAINST UV-RADIATION,D02BA,Protectives against UV-radiation for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D02BA01,aminobenzoic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02B,PROTECTIVES AGAINST UV-RADIATION,D02BA,Protectives against UV-radiation for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D02BA02,octinoxate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02B,PROTECTIVES AGAINST UV-RADIATION,D02BB,Protectives against UV-radiation for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDD of betacarotene is based on the treatment of patients with erythropoietic protoporphyria.",D02BB01,betacarotene,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D02,EMOLLIENTS AND PROTECTIVES,D02B,PROTECTIVES AGAINST UV-RADIATION,D02BB,Protectives against UV-radiation for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDD of betacarotene is based on the treatment of patients with erythropoietic protoporphyria.",D02BB02,afamelanotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AA,Cod-liver oil ointments,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX01,cadexomer iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX02,dextranomer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX03,dexpanthenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX04,calcium pantothenate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX05,hyaluronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX06,becaplermin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX09,crilanomer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX10,enoxolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX11,sodium chlorite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX12,trolamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX13,Betulae cortex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX14,"Centella asiatica herba, incl. combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX15,trafermin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03A,CICATRIZANTS,D03AX,Other cicatrizants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03AX16,beremagene geperpavec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03B,ENZYMES,D03BA,Proteolytic enzymes,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03BA01,trypsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03B,ENZYMES,D03BA,Proteolytic enzymes,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03BA02,collagenase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03B,ENZYMES,D03BA,Proteolytic enzymes,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03BA03,bromelains,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D03,PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS,D03B,ENZYMES,D03BA,Proteolytic enzymes,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D03BA52,"collagenase, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA01,thonzylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA02,mepyramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA03,thenalidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA04,tripelennamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA09,chloropyramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA10,promethazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA12,tolpropamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA13,dimetindene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA14,clemastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA15,bamipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA16,pheniramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA22,isothipendyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA32,diphenhydramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA33,diphenhydramine methylbromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AA,Antihistamines for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AA34,chlorphenoxamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB01,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB02,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB03,oxybuprocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB04,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB05,quinisocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB06,tetracaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AB,Anesthetics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AB07,pramocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D04,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04A,"ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.",D04AX,Other antipruritics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D04AX01,doxepin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AA,Tars,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AC,Antracen derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AC01,dithranol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AC,Antracen derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AC51,"dithranol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AD,Psoralens for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AD01,trioxysalen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AD,Psoralens for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AD02,methoxsalen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX01,fumaric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX02,calcipotriol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX03,calcitriol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX04,tacalcitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX05,tazarotene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX06,roflumilast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX07,tapinarof,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX52,"calcipotriol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05A,ANTIPSORIATICS FOR TOPICAL USE,D05AX,Other antipsoriatics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05AX55,tazarotene and ulobetasol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05B,ANTIPSORIATICS FOR SYSTEMIC USE,D05BA,Psoralens for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs for psoralens for systemic use are based on the combined treatment with drug and UV-A irradiation.",D05BA01,trioxysalen,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05B,ANTIPSORIATICS FOR SYSTEMIC USE,D05BA,Psoralens for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs for psoralens for systemic use are based on the combined treatment with drug and UV-A irradiation.",D05BA02,methoxsalen,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05B,ANTIPSORIATICS FOR SYSTEMIC USE,D05BA,Psoralens for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs for psoralens for systemic use are based on the combined treatment with drug and UV-A irradiation.",D05BA03,bergapten,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05B,ANTIPSORIATICS FOR SYSTEMIC USE,D05BB,Retinoids for treatment of psoriasis,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05BB01,etretinate,35,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05B,ANTIPSORIATICS FOR SYSTEMIC USE,D05BB,Retinoids for treatment of psoriasis,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05BB02,acitretin,35,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D05,ANTIPSORIATICS,D05B,ANTIPSORIATICS FOR SYSTEMIC USE,D05BX,Other antipsoriatics for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D05BX51,"fumaric acid derivatives, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AA,Tetracycline and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AA01,demeclocycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AA,Tetracycline and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AA02,chlortetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AA,Tetracycline and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AA03,oxytetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AA,Tetracycline and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AA04,tetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX01,fusidic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX02,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX04,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX05,bacitracin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX07,gentamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX08,tyrothricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX09,mupirocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX10,virginiamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX11,rifaximin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX12,amikacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX13,retapamulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX14,ozenoxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06A,ANTIBIOTICS FOR TOPICAL USE,D06AX,Other antibiotics for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06AX15,rifamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA01,silver sulfadiazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA02,sulfathiazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA03,mafenide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA04,sulfamethizole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA05,sulfanilamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA06,sulfamerazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BA,Sulfonamides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BA51,"silver sulfadiazine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB01,idoxuridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB02,tromantadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB03,aciclovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB04,podophyllotoxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB05,inosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB06,penciclovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB07,lysozyme,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB08,ibacitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB09,edoxudine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB10,imiquimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB11,docosanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB12,sinecatechins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BB,Antivirals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BB53,"aciclovir, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BX,Other chemotherapeutics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BX01,metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BX,Other chemotherapeutics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BX02,ingenol mebutate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06B,CHEMOTHERAPEUTICS FOR TOPICAL USE,D06BX,Other chemotherapeutics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D06BX03,tirbanibulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AA,"Corticosteroids, weak (group I)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AA01,methylprednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AA,"Corticosteroids, weak (group I)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AA02,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AA,"Corticosteroids, weak (group I)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AA03,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB01,clobetasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB02,hydrocortisone butyrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB03,flumetasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB04,fluocortin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB05,fluperolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB06,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB07,fluprednidene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB08,desonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB09,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB10,alclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB11,hydrocortisone buteprate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB19,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB21,clocortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AB,"Corticosteroids, moderately potent (group II)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AB30,combinations of corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC01,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC02,fluclorolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC03,desoximetasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC04,fluocinolone acetonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC05,fluocortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC06,diflucortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC07,fludroxycortide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC08,fluocinonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC09,budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC10,diflorasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC11,amcinonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC12,halometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC13,mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC14,methylprednisolone aceponate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC15,beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC16,hydrocortisone aceponate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC17,fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC18,prednicarbate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC19,difluprednate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AC,"Corticosteroids, potent (group III)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AC21,ulobetasol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AD,"Corticosteroids, very potent (group IV)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AD01,clobetasol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07A,"CORTICOSTEROIDS, PLAIN",D07AD,"Corticosteroids, very potent (group IV)","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07AD02,halcinonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BA,"Corticosteroids, weak, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BA01,prednisolone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BA,"Corticosteroids, weak, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BA04,hydrocortisone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BB,"Corticosteroids, moderately potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BB01,flumetasone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BB,"Corticosteroids, moderately potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BB02,desonide and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BB,"Corticosteroids, moderately potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BB03,triamcinolone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BB,"Corticosteroids, moderately potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BB04,hydrocortisone butyrate and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BC,"Corticosteroids, potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BC01,betamethasone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BC,"Corticosteroids, potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BC02,fluocinolone acetonide and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BC,"Corticosteroids, potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BC03,fluocortolone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BC,"Corticosteroids, potent, combinations with antiseptics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07BC04,diflucortolone and antiseptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07B,"CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS",D07BD,"Corticosteroids, very potent, combinations with antiseptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CA,"Corticosteroids, weak, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CA01,hydrocortisone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CA,"Corticosteroids, weak, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CA02,methylprednisolone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CA,"Corticosteroids, weak, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CA03,prednisolone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CB,"Corticosteroids, moderately potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CB01,triamcinolone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CB,"Corticosteroids, moderately potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CB02,fluprednidene and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CB,"Corticosteroids, moderately potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CB03,fluorometholone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CB,"Corticosteroids, moderately potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CB04,dexamethasone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CB,"Corticosteroids, moderately potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CB05,flumetasone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CC,"Corticosteroids, potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CC01,betamethasone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CC,"Corticosteroids, potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CC02,fluocinolone acetonide and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CC,"Corticosteroids, potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CC03,fludroxycortide and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CC,"Corticosteroids, potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CC04,beclometasone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CC,"Corticosteroids, potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CC05,fluocinonide and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CC,"Corticosteroids, potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CC06,fluocortolone and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07C,"CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS",D07CD,"Corticosteroids, very potent, combinations with antibiotics","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07CD01,clobetasol and antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XA,"Corticosteroids, weak, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XA01,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XA,"Corticosteroids, weak, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XA02,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XB,"Corticosteroids, moderately potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XB01,flumetasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XB,"Corticosteroids, moderately potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XB02,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XB,"Corticosteroids, moderately potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XB03,fluprednidene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XB,"Corticosteroids, moderately potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XB04,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XB,"Corticosteroids, moderately potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XB05,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XB,"Corticosteroids, moderately potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XB30,combinations of corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XC,"Corticosteroids, potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XC01,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XC,"Corticosteroids, potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XC02,desoximetasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XC,"Corticosteroids, potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XC03,mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XC,"Corticosteroids, potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XC04,diflucortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XC,"Corticosteroids, potent, other combinations","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D07XC05,fluocortolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D07,"CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS",D07X,"CORTICOSTEROIDS, OTHER COMBINATIONS",D07XD,"Corticosteroids, very potent, other combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AA,Acridine derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AA01,ethacridine lactate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AA,Acridine derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AA02,aminoacridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AA,Acridine derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AA03,euflavine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AB,Aluminium agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AC,Biguanides and amidines,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AC01,dibrompropamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AC,Biguanides and amidines,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AC02,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AC,Biguanides and amidines,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AC03,propamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AC,Biguanides and amidines,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AC04,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AC,Biguanides and amidines,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AC05,polihexanide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AC,Biguanides and amidines,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AC52,"chlorhexidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AD,Boric acid products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AE,Phenol and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AE01,hexachlorophene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AE,Phenol and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AE02,policresulen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AE,Phenol and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AE03,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AE,Phenol and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AE04,triclosan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AE,Phenol and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AE05,chloroxylenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AE,Phenol and derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AE06,biphenylol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AF,Nitrofuran derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AF01,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AG,Iodine products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AG01,iodine/octylphenoxypolyglycolether,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AG,Iodine products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AG02,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AG,Iodine products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AG03,iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AG,Iodine products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AG04,diiodohydroxypropane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AH,Quinoline derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AH01,dequalinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AH,Quinoline derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AH02,chlorquinaldol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AH,Quinoline derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AH03,oxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AH,Quinoline derivatives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AH30,clioquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ01,benzalkonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ02,cetrimonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ03,cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ04,cetrimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ05,benzoxonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ06,didecyldimethylammonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ08,benzethonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ10,decamethoxine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ57,"octenidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ58,"benzethonium chloride, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AJ,Quaternary ammonium compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AJ59,"dodeclonium bromide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK01,mercuric amidochloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK02,phenylmercuric borate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK03,mercuric chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK04,merbromin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK05,"mercury, metallic",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK06,thiomersal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AK,Mercurial products,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AK30,mercuric iodide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AL,Silver compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AL01,silver nitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AL,Silver compounds,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AL30,silver,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX01,hydrogen peroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX02,eosin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX03,propanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX04,tosylchloramide sodium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX05,isopropanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX06,potassium permanganate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX07,sodium hypochlorite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX08,ethanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D08,ANTISEPTICS AND DISINFECTANTS,D08A,ANTISEPTICS AND DISINFECTANTS,D08AX,Other antiseptics and disinfectants,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D08AX53,"propanol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA01,framycetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA02,fusidic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA03,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA04,phenylmercuric nitrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA05,benzododecinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA06,triclosan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA07,cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA08,aluminium chlorohydrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA09,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA10,clioquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA11,benzalkonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA12,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AA,Medicated dressings with antiinfectives,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AA13,iodoform,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AB,Zinc bandages,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AB01,zinc bandage without supplements,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AB,Zinc bandages,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D09AB02,zinc bandage with supplements,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D09,MEDICATED DRESSINGS,D09A,MEDICATED DRESSINGS,D09AX,Soft paraffin dressings,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AA,"Corticosteroids, combinations for treatment of acne","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AA01,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AA,"Corticosteroids, combinations for treatment of acne","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AA02,methylprednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AA,"Corticosteroids, combinations for treatment of acne","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AA03,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AB,Preparations containing sulfur,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AB01,bithionol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AB,Preparations containing sulfur,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AB02,sulfur,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AB,Preparations containing sulfur,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AB03,tioxolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AB,Preparations containing sulfur,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AB05,mesulfen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD01,tretinoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD02,retinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD03,adapalene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD04,isotretinoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD05,motretinide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD06,trifarotene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD51,"tretinoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD53,"adapalene, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AD,Retinoids for topical use in acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AD54,"isotretinoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AE,Peroxides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AE01,benzoyl peroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AE,Peroxides,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AE51,"benzoyl peroxide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF01,clindamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF02,erythromycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF03,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF04,meclocycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF05,nadifloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF06,sulfacetamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF07,minocycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF51,"clindamycin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AF,Antiinfectives for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AF52,"erythromycin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX01,aluminium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX02,resorcinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX03,azelaic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX04,aluminium oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX05,dapsone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX06,clascoterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10A,ANTI-ACNE PREPARATIONS FOR TOPICAL USE,D10AX,Other anti-acne preparations for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10AX30,various combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10B,ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE,D10BA,Retinoids for treatment of acne,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10BA01,isotretinoin,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D10,ANTI-ACNE PREPARATIONS,D10B,ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE,D10BX,Other anti-acne preparations for systemic use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength. The DDDs are based on the treatment of severe acne.",D10BX01,ichtasol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AA,Antihidrotics,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AA01,glycopyrronium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC01,cetrimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC02,cadmium compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC03,selenium compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC06,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC08,sulfur compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC09,xenysalate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AC,Medicated shampoos,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AC30,others,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AE,Androgens for topical use,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AE01,metandienone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AF,Wart and anti-corn preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH01,tacrolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH02,pimecrolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH03,cromoglicic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH04,alitretinoin,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH05,dupilumab,NA,21.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH06,crisaborole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH07,tralokinumab,NA,16.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH08,abrocitinib,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH09,ruxolitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH10,lebrikizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH11,delgocitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AH,"Agents for dermatitis, excluding corticosteroids","Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AH12,nemolizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX01,minoxidil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX02,gamolenic acid,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX03,calcium gluconate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX04,lithium succinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX05,magnesium sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX06,mequinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX08,tiratricol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX09,oxaceprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX10,finasteride,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX11,hydroquinone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX12,pyrithione zinc,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX13,monobenzone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX16,eflornithine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX18,diclofenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX21,brimonidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX22,ivermectin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX23,aminobenzoate potassium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX24,deoxycholic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX25,hydrogen peroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX26,caffeine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX27,oxymetazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX52,"gamolenic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D,DERMATOLOGICALS,D11,OTHER DERMATOLOGICAL PREPARATIONS,D11A,OTHER DERMATOLOGICAL PREPARATIONS,D11AX,Other dermatologicals,"Only oral preparations in ATC group D are given DDDs.  Most products in this group are for topical use, and no DDDs are assigned because the amount given per day can vary very much according to the intensity and distribution of the disease.  Consumption figures for these dermatological preparations can be expressed in grams of preparations regardless of strength.",D11AX57,"collagen, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
D06C,Hide text from Guidelines,D,DERMATOLOGICALS,D06,ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE,D06C,"ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA01,nystatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA02,natamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA03,amphotericin B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA04,candicidin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA05,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA06,hachimycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA07,oxytetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA08,carfecillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA09,mepartricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA10,clindamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA11,pentamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AA,Antibiotics,The DDDs are based on the treatment of vaginal infections.,G01AA51,"nystatin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AB,Arsenic compounds,The DDDs are based on the treatment of vaginal infections.,G01AB01,acetarsol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC01,diiodohydroxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC02,clioquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC03,chlorquinaldol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC05,dequalinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC06,broxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AC,Quinoline derivatives,The DDDs are based on the treatment of vaginal infections.,G01AC30,oxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AD,Organic acids,The DDDs are based on the treatment of vaginal infections.,G01AD01,lactic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AD,Organic acids,The DDDs are based on the treatment of vaginal infections.,G01AD02,acetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AD,Organic acids,The DDDs are based on the treatment of vaginal infections.,G01AD03,ascorbic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AE,Sulfonamides,The DDDs are based on the treatment of vaginal infections.,G01AE01,sulfatolamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AE,Sulfonamides,The DDDs are based on the treatment of vaginal infections.,G01AE10,combinations of sulfonamides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF01,metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF02,clotrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF04,miconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF05,econazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF06,ornidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF07,isoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF08,tioconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Single dose treatment,NA,NA,NA,NA,NA,NA,NA,NA,0.3,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF11,ketoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF12,fenticonazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF13,azanidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF14,propenidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF15,butoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF16,omoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF17,oxiconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF18,flutrimazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF19,sertaconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF20,combinations of imidazole derivatives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF21,tinidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AF,Imidazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AF55,"econazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AG,Triazole derivatives,The DDDs are based on the treatment of vaginal infections.,G01AG02,terconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX01,clodantoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX02,inosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX03,policresulen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX05,nifuratel,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX06,furazolidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX09,methylrosaniline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX11,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX12,ciclopirox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX13,protiofate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX14,lactobacillus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX15,copper usnate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX16,hexetidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX17,dapivirine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01A,"ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS",G01AX,Other antiinfectives and antiseptics,The DDDs are based on the treatment of vaginal infections.,G01AX66,"octenidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BA,Antibiotics and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BC,Quinoline derivatives and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BD,Antiseptics and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BE,Sulfonamides and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G01,GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS,G01B,ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS,G01BF,Imidazole derivatives and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AB,Ergot alkaloids,The DDDs are based on use in delivery.,G02AB01,methylergometrine,0.2,0.2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AB,Ergot alkaloids,The DDDs are based on use in delivery.,G02AB02,ergot alkaloids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AB,Ergot alkaloids,The DDDs are based on use in delivery.,G02AB03,ergometrine,0.2,0.2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AC,"Ergot alkaloids and oxytocin incl. analogues, in combination",NA,G02AC01,methylergometrine and oxytocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD01,dinoprost,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD02,dinoprostone,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.5,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD03,gemeprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Single dose treatment,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD04,carboprost,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,Single dose treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD05,sulprostone,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD06,misoprostol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"vaginal insert, refers to the content of one vaginal insert",NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AD,Prostaglandins,NA,G02AD06,misoprostol,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02A,UTEROTONICS,G02AX,Other uterotonics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BA,Intrauterine contraceptives,NA,G02BA01,plastic IUD,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BA,Intrauterine contraceptives,NA,G02BA02,plastic IUD with copper,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BA,Intrauterine contraceptives,NA,G02BA03,plastic IUD with progestogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BB,Intravaginal contraceptives,The DDDs for combined devices containing estrogen and progestogen are based on use in menstrual cycles of 28 days.  Thus the DDD is 0.0357 UD (1 UD = 1 device).,G02BB01,vaginal ring with progestogen and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02B,CONTRACEPTIVES FOR TOPICAL USE,G02BB,Intravaginal contraceptives,The DDDs for combined devices containing estrogen and progestogen are based on use in menstrual cycles of 28 days.  Thus the DDD is 0.0357 UD (1 UD = 1 device).,G02BB02,vaginal ring with progestogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CA,"Sympathomimetics, labour repressants",The DDDs are based on use as labour repressants.,G02CA01,ritodrine,40,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CA,"Sympathomimetics, labour repressants",The DDDs are based on use as labour repressants.,G02CA02,buphenine,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CA,"Sympathomimetics, labour repressants",The DDDs are based on use as labour repressants.,G02CA03,fenoterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB01,bromocriptine,5,5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB02,lisuride,0.6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB03,cabergoline,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB04,quinagolide,75,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB05,metergoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CB,Prolactine inhibitors,"The DDDs are based on use as lactation inhibitors.  The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.",G02CB06,terguride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC01,ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC02,naproxen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC03,benzydamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CC,Antiinflammatory products for vaginal administration,NA,G02CC04,flunoxaprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX01,atosiban,NA,165,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX02,flibanserin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX03,Agni casti fructus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX04,Cimicifugae rhizoma,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX05,bremelanotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G02,OTHER GYNECOLOGICALS,G02C,OTHER GYNECOLOGICALS,G02CX,Other gynecologicals,NA,G02CX06,fezolinetant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA01,etynodiol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA02,quingestanol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA03,lynestrenol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA04,megestrol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA05,norethisterone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA06,norgestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA07,levonorgestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA08,medroxyprogesterone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA09,desogestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA10,gestodene and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA11,norgestimate and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA12,drospirenone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA13,norelgestromin and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA14,nomegestrol and estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA15,chlormadinone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA16,dienogest and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA17,medroxyprogesterone and estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AA18,drospirenone and estetrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB01,megestrol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB02,lynestrenol and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB03,levonorgestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB04,norethisterone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB05,desogestrel and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB06,gestodene and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB07,chlormadinone and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB08,dienogest and estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AB09,norgestimate and ethinylestradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC01,norethisterone,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC02,lynestrenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC03,levonorgestrel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC04,quingestanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC05,megestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC06,medroxyprogesterone,NA,1.67,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC07,norgestrienone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC08,etonogestrel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,68,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC09,desogestrel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AC,Progestogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AC10,drospirenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AD,Emergency contraceptives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AD01,levonorgestrel,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03A,HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE,G03AD,Emergency contraceptives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use as contraceptives.The DDDs of combined preparations of estrogen and progestogen and plain progestogen products are based on use in menstrual cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle package, respectively. The same principle is used for transdermal patches.For the 24 tablets cycle packages the DDD is based on continuous use for 120 days and a 4-days tablet free interval. Thus, the DDD is 0.967 UD.The DDDs for preparations only used in postcoital contraception are based on the course dose.",G03AD02,ulipristal,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA01,fluoxymesterone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA02,methyltestosterone,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA03,testosterone,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,mg,gel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BA,3-oxoandrosten (4) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered. The DDD for parenteral and oral testosterone is expressed as declared amount of ester. The DDD for TD and SL route of administration is expressed as declared amount of testosterone.,G03BA03,testosterone,0.12,18,0.12,60,3,NA,g,mg,g,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BB,5-androstanon (3) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered.,G03BB01,mesterolone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03B,ANDROGENS,G03BB,5-androstanon (3) derivatives,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on use in substitution therapy in male hypogonadism.  The DDDs for patches (e.g. testosterone) are given in amount delivered.,G03BB02,androstanolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA01,ethinylestradiol,25,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,0.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot long duration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot short duration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,NA,NA,NA,1,NA,NA,NA,NA,NA,mg,gel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,NA,NA,NA,50,NA,NA,NA,NA,NA,mcg,"patch, refer to amount delivered per 24 hours",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,NA,NA,NA,1.53,NA,NA,NA,NA,NA,mg,spray,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"vaginal ring,  refers to amount delivered per 24 hours",NA,NA,NA,NA,NA,NA,NA,NA,7.5,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA03,estradiol,2,NA,5,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,0.3,NA,mg,NA,NA,NA,NA,25,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA04,estriol,2,2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA06,chlorotrianisene,24,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA07,estrone,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA09,promestriene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA53,"estradiol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CA,"Natural and semisynthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used. The DDD for nasal administration of estradiol is based on daily treatment.",G03CA57,conjugated estrogens,0.625,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.625,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB01,dienestrol,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB02,diethylstilbestrol,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB03,methallenestril,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CB,"Synthetic estrogens, plain","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CB04,moxestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC02,dienestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC03,methallenestril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC04,estrone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC05,diethylstilbestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC06,estriol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CC,"Estrogens, combinations with other drugs","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CC07,conjugated estrogens and bazedoxifene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03C,ESTROGENS,G03CX,Other estrogens,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments.  However, for some preparations for vaginal administration the DDDs are based on local treatment.The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.",G03CX01,tibolone,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA01,gestonorone,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA02,medroxyprogesterone,5,7,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA03,hydroxyprogesterone,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DA,Pregnen (4) derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DA04,progesterone,0.3,5,0.2,NA,NA,NA,g,mg,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB01,dydrogesterone,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB02,megestrol,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB03,medrogestone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB04,nomegestrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB05,demegestone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB06,chlormadinone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB07,promegestone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DB,Pregnadien derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DB08,dienogest,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC01,allylestrenol,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC02,norethisterone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC03,lynestrenol,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC04,ethisterone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC06,etynodiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03D,PROGESTOGENS,G03DC,Estren derivatives,"The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on gynecological indications, for instance corpus luteum insufficiency and endometriosis.",G03DC31,methylestrenolone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EA,Androgens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EA01,methyltestosterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EA,Androgens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EA02,testosterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EA,Androgens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EA03,prasterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EB,"Androgen, progestogen and estrogen in combination",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03E,ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION,G03EK,Androgens and female sex hormones in combination with other drugs,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of climacterical ailments.,G03EK01,methyltestosterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA01,norethisterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA02,hydroxyprogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA03,ethisterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA04,progesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA05,methylnortestosterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA06,etynodiol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA07,lynestrenol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA08,megestrol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA09,noretynodrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA10,norgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA11,levonorgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA12,medroxyprogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA13,norgestimate and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA14,dydrogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA15,dienogest and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA16,trimegestone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FA,"Progestogens and estrogens, fixed combinations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FA17,drospirenone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB01,norgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB02,lynestrenol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB03,chlormadinone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB04,megestrol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB05,norethisterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB06,medroxyprogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB07,medrogestone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB08,dydrogesterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB09,levonorgestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB10,desogestrel and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB11,trimegestone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03F,PROGESTOGENS AND ESTROGENS IN COMBINATION,G03FB,"Progestogens and estrogens, sequential preparations","The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days.  Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.",G03FB12,nomegestrol and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA01,chorionic gonadotrophin,NA,250,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA02,human menopausal gonadotrophin,NA,75,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA03,serum gonadotrophin,NA,750,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA04,urofollitropin,NA,75,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA05,follitropin alfa,NA,75,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA06,follitropin beta,NA,75,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA07,lutropin alfa,NA,75,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA08,choriogonadotropin alfa,NA,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA09,corifollitropin alfa,NA,0.15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA10,follitropin delta,NA,12,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GA,Gonadotropins,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GB,"Ovulation stimulants, synthetic",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GB01,cyclofenil,0.14,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GB,"Ovulation stimulants, synthetic",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GB02,clomifene,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03G,GONADOTROPINS AND OTHER OVULATION STIMULANTS,G03GB,"Ovulation stimulants, synthetic",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the initial treatment of anovulation.,G03GB03,epimestrol,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03H,ANTIANDROGENS,G03HA,"Antiandrogens, plain",The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of hypersexualism.,G03HA01,cyproterone,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03H,ANTIANDROGENS,G03HB,Antiandrogens and estrogens,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs are based on the treatment of hirsutism or prophylaxis of postmenopausal osteoporosis.,G03HB01,cyproterone and estrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XA,Antigonadotropins and similar agents,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs of danazol and gestrinone are based on the treatment of endometriosis.,G03XA01,danazol,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XA,Antigonadotropins and similar agents,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDDs of danazol and gestrinone are based on the treatment of endometriosis.,G03XA02,gestrinone,0.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XB,Progesterone receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.The DDD for the combination package is given as amount of mifepristone.,G03XB01,mifepristone,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XB,Progesterone receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.The DDD for the combination package is given as amount of mifepristone.,G03XB02,ulipristal,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XB,Progesterone receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval. The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.The DDD for the combination package is given as amount of mifepristone.,G03XB51,"mifepristone, combinations",0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to mifepristone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC01,raloxifene,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC02,bazedoxifene,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC03,lasofoxifene,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC04,ormeloxifene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XC,Selective estrogen receptor modulators,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XC05,ospemifene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G03,SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03X,OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM,G03XX,Other sex hormones and modulators of the genital system,The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability.  The DDDs of depot preparations are calculated as the dose divided by the dosing interval.,G03XX01,prasterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6.5,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BA,Acidifiers,NA,G04BA01,ammonium chloride,8.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BA,Acidifiers,NA,G04BA03,calcium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BC,Urinary concrement solvents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD01,emepronium,0.5,75,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD02,flavoxate,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD03,meladrazine,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD04,oxybutynin,15,NA,NA,NA,3.9,NA,mg,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD05,terodiline,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD06,propiverine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD07,tolterodine,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD08,solifenacin,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD09,trospium,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD10,darifenacin,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD11,fesoterodine,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD12,mirabegron,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD13,desfesoterodine,3.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD14,imidafenacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BD,Drugs for urinary frequency and incontinence,"The DDD for oral administered emeperonium is higher than the DDD for parenteral administered formulations, due to low oral bioavailability.",G04BD15,vibegron,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE01,alprostadil,NA,20,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.25,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE02,papaverine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE03,sildenafil,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE04,yohimbine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE06,moxisylyte,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE07,apomorphine,NA,NA,NA,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE08,tadalafil,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE09,vardenafil,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE10,avanafil,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE11,udenafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BE,Drugs used in erectile dysfunction,The DDDs are based on single treatment of erectile dysfunction.,G04BE52,"papaverine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX01,magnesium hydroxide,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX03,acetohydroxamic acid,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX06,phenazopyridine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX10,succinimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX11,collagen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX12,phenyl salicylate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX13,dimethyl sulfoxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX14,dapoxetine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX15,pentosan polysulfate sodium,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX16,tiopronin,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04B,UROLOGICALS,G04BX,Other urologicals,"The DDD of phenazopyridine is based on analgesic treatment of conditions such as cystitis, prostatitis and urethritis.  The DDD for phenylsalicylate is based on the prophylaxis of urinary tract infections.  The other DDDs are based on the prophylaxis of urinary concrements.",G04BX17,sodium salicylate and methenamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA01,alfuzosin,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA02,tamsulosin,0.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA03,terazosin,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA04,silodosin,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA51,alfuzosin and finasteride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA52,tamsulosin and dutasteride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA53,tamsulosin and solifenacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA54,tamsulosin and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CA,Alpha-adrenoreceptor antagonists,NA,G04CA55,doxazosin and finasteride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CB,Testosterone-5-alpha reductase inhibitors,NA,G04CB01,finasteride,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CB,Testosterone-5-alpha reductase inhibitors,NA,G04CB02,dutasteride,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CB,Testosterone-5-alpha reductase inhibitors,NA,G04CB51,finasteride and tadalafil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX01,Prunus africanae cortex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX02,Sabalis serrulatae fructus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX03,mepartricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
G,GENITO URINARY SYSTEM AND SEX HORMONES,G04,UROLOGICALS,G04C,DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY,G04CX,Other drugs used in benign prostatic hypertrophy,NA,G04CX04,fexapotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AA,ACTH,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of corticotrophin is based on therapy, whereas that of tetracosactide is based on use as a diagnostic agent.",H01AA01,corticotropin,NA,25,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AA,ACTH,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of corticotrophin is based on therapy, whereas that of tetracosactide is based on use as a diagnostic agent.",H01AA02,tetracosactide,NA,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AB,Thyrotropin,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD for biological thyrotropin classified in H01AB01 is 5 U.,H01AB01,thyrotropin alfa,NA,0.9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC01,somatropin,NA,2,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC02,somatrem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC03,mecasermin,NA,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC04,sermorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC05,mecasermin rinfabate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC06,tesamorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC07,somapacitan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC08,somatrogon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AC,Somatropin and somatropin agonists,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.,H01AC09,lonapegsomatropin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01A,ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES,H01AX,Other anterior pituitary lobe hormones and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01AX01,pegvisomant,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BA,Vasopressin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of diabetes insipidus.The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.,H01BA01,vasopressin (argipressin),NA,40,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BA,Vasopressin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of diabetes insipidus.The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.,H01BA02,desmopressin,NA,NA,NA,0.24,NA,NA,NA,NA,NA,mg,NA,base,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BA,Vasopressin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of diabetes insipidus.The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.,H01BA02,desmopressin,0.4,4,NA,NA,NA,NA,mg,mcg,NA,NA,NA,NA,NA,25,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BA,Vasopressin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of diabetes insipidus.The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.,H01BA03,lypressin,NA,20,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,20,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BA,Vasopressin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of diabetes insipidus.The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.,H01BA04,terlipressin,NA,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BA,Vasopressin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of diabetes insipidus.The DDD for terlipressin (as acetate) is based on treatment of bleeding oesophageal varices.,H01BA05,ornipressin,NA,5,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BB,Oxytocin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on use in delivery.,H01BB01,demoxytocin,100,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BB,Oxytocin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on use in delivery.,H01BB02,oxytocin,200,15,NA,NA,NA,NA,U,U,NA,NA,NA,NA,NA,15,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01B,POSTERIOR PITUITARY LOBE HORMONES,H01BB,Oxytocin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on use in delivery.,H01BB03,carbetocin,NA,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CA,Gonadotropin-releasing hormones,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of nafarelin is based on the treatment of endometriosis.  No other DDDs have been assigned, due to the highly variable dosages used.",H01CA01,gonadorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CA,Gonadotropin-releasing hormones,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of nafarelin is based on the treatment of endometriosis.  No other DDDs have been assigned, due to the highly variable dosages used.",H01CA02,nafarelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CB,Somatostatin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of octreotide and lanreotide are based on the treatment of acromegaly.,H01CB01,somatostatin,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CB,Somatostatin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of octreotide and lanreotide are based on the treatment of acromegaly.,H01CB02,octreotide,NA,0.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CB,Somatostatin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of octreotide and lanreotide are based on the treatment of acromegaly.,H01CB03,lanreotide,NA,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CB,Somatostatin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of octreotide and lanreotide are based on the treatment of acromegaly.,H01CB04,vapreotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CB,Somatostatin and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of octreotide and lanreotide are based on the treatment of acromegaly.,H01CB05,pasireotide,NA,1.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CC,Anti-gonadotropin-releasing hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01CC01,ganirelix,NA,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CC,Anti-gonadotropin-releasing hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01CC02,cetrorelix,NA,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CC,Anti-gonadotropin-releasing hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01CC03,elagolix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CC,Anti-gonadotropin-releasing hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01CC04,linzagolix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CC,Anti-gonadotropin-releasing hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01CC53,"elagolix, estradiol and norethisterone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H01,PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES,H01C,HYPOTHALAMIC HORMONES,H01CC,Anti-gonadotropin-releasing hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H01CC54,"relugolix, estradiol and norethisterone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AA,Mineralocorticoids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on substitution therapy in Addisons disease.,H02AA01,aldosterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AA,Mineralocorticoids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on substitution therapy in Addisons disease.,H02AA02,fludrocortisone,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AA,Mineralocorticoids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on substitution therapy in Addisons disease.,H02AA03,desoxycortone,5,5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB01,betamethasone,NA,0.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB01,betamethasone,1.5,1.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB02,dexamethasone,1.5,1.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB03,fluocortolone,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB04,methylprednisolone,7.5,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB05,paramethasone,4,4,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB06,prednisolone,10,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB07,prednisone,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB08,triamcinolone,7.5,7.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB09,hydrocortisone,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB10,cortisone,37.5,37.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB11,prednylidene,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB12,rimexolone,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,intraarticular,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB13,deflazacort,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB14,cloprednol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB15,meprednisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB17,cortivazol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02A,"CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN",H02AB,Glucocorticoids,"The DDDs are generally based on the treatment or diagnosis of endocrine disorders. Depot preparations may have different DDDs, compared to other formulations, due to different indications.",H02AB18,vamorolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02B,"CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS",H02BX,"Corticosteroids for systemic use, combinations",The DDDs are generally based on the treatment or diagnosis of endocrine disorders. No DDDs have been assigned.,H02BX01,"methylprednisolone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02C,ANTIADRENAL PREPARATIONS,H02CA,Anticorticosteroids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of trilostan is based on the treatment of Cushings syndrome.,H02CA01,trilostane,0.36,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02C,ANTIADRENAL PREPARATIONS,H02CA,Anticorticosteroids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of trilostan is based on the treatment of Cushings syndrome.,H02CA02,osilodrostat,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02C,ANTIADRENAL PREPARATIONS,H02CA,Anticorticosteroids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of trilostan is based on the treatment of Cushings syndrome.,H02CA03,ketoconazole,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H02,CORTICOSTEROIDS FOR SYSTEMIC USE,H02C,ANTIADRENAL PREPARATIONS,H02CA,Anticorticosteroids,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of trilostan is based on the treatment of Cushings syndrome.,H02CA04,levoketoconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03A,THYROID PREPARATIONS,H03AA,Thyroid hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hypothyrosis.,H03AA01,levothyroxine sodium,0.15,0.15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03A,THYROID PREPARATIONS,H03AA,Thyroid hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hypothyrosis.,H03AA02,liothyronine sodium,60,60,NA,NA,NA,NA,mcg,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03A,THYROID PREPARATIONS,H03AA,Thyroid hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hypothyrosis.,H03AA03,combinations of levothyroxine and liothyronine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03A,THYROID PREPARATIONS,H03AA,Thyroid hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hypothyrosis.,H03AA04,tiratricol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03A,THYROID PREPARATIONS,H03AA,Thyroid hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hypothyrosis.,H03AA05,thyroid gland preparations,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03A,THYROID PREPARATIONS,H03AA,Thyroid hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hypothyrosis.,H03AA51,levothyroxine sodium and iodine compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BA,Thiouracils,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BA01,methylthiouracil,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BA,Thiouracils,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BA02,propylthiouracil,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BA,Thiouracils,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BA03,benzylthiouracil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BB,Sulfur-containing imidazole derivatives,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BB01,carbimazole,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BB,Sulfur-containing imidazole derivatives,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BB02,thiamazole,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BB,Sulfur-containing imidazole derivatives,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BB52,"thiamazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BC,Perchlorates,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BC01,potassium perchlorate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BX,Other antithyroid preparations,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BX01,diiodotyrosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03B,ANTITHYROID PREPARATIONS,H03BX,Other antithyroid preparations,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs are based on the treatment of hyperthyrosis.,H03BX02,dibromotyrosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H03,THYROID THERAPY,H03C,IODINE THERAPY,H03CA,Iodine therapy,NA,H03CA,Iodine therapy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H04,PANCREATIC HORMONES,H04A,GLYCOGENOLYTIC HORMONES,H04AA,Glycogenolytic hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of glucagon is based on single dose treatment of hypoglycemia.,H04AA01,glucagon,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,3,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H04,PANCREATIC HORMONES,H04A,GLYCOGENOLYTIC HORMONES,H04AA,Glycogenolytic hormones,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDD of glucagon is based on single dose treatment of hypoglycemia.,H04AA02,dasiglucagon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05A,PARATHYROID HORMONES AND ANALOGUES,H05AA,Parathyroid hormones and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H05AA01,parathyroid gland extract,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05A,PARATHYROID HORMONES AND ANALOGUES,H05AA,Parathyroid hormones and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H05AA02,teriparatide,NA,20,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05A,PARATHYROID HORMONES AND ANALOGUES,H05AA,Parathyroid hormones and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H05AA03,parathyroid hormone,NA,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05A,PARATHYROID HORMONES AND ANALOGUES,H05AA,Parathyroid hormones and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H05AA04,abaloparatide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05A,PARATHYROID HORMONES AND ANALOGUES,H05AA,Parathyroid hormones and analogues,The DDDs are generally based on the treatment or diagnosis of endocrine disorders.,H05AA05,palopegteriparatide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BA,Calcitonin preparations,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of the calcitonins are based on the treatment of Pagets disease.,H05BA01,calcitonin (salmon synthetic),NA,100,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,200,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BA,Calcitonin preparations,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of the calcitonins are based on the treatment of Pagets disease.,H05BA02,calcitonin (pork natural),NA,100,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BA,Calcitonin preparations,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of the calcitonins are based on the treatment of Pagets disease.,H05BA03,calcitonin (human synthetic),NA,100,NA,NA,NA,NA,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BA,Calcitonin preparations,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs of the calcitonins are based on the treatment of Pagets disease.,H05BA04,elcatonin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BX,Other anti-parathyroid agents,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism.,H05BX01,cinacalcet,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BX,Other anti-parathyroid agents,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism.,H05BX02,paricalcitol,2,2,NA,NA,NA,NA,mcg,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BX,Other anti-parathyroid agents,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism.,H05BX03,doxercalciferol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BX,Other anti-parathyroid agents,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism.,H05BX04,etelcalcetide,NA,2.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BX,Other anti-parathyroid agents,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism.,H05BX05,calcifediol,30,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H,"SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS",H05,CALCIUM HOMEOSTASIS,H05B,ANTI-PARATHYROID AGENTS,H05BX,Other anti-parathyroid agents,The DDDs are generally based on the treatment or diagnosis of endocrine disorders. The DDDs for cinacalcet and evocalcet are based on the treatment of secondary hyperparathyroidism.,H05BX06,evocalcet,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA01,demeclocycline,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA02,doxycycline,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA03,chlortetracycline,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA04,lymecycline,0.6,0.6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA05,metacycline,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA06,oxytetracycline,1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA07,tetracycline,1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA08,minocycline,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA09,rolitetracycline,NA,0.35,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA10,penimepicycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA11,clomocycline,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA12,tigecycline,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA13,eravacycline,NA,0.14,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA14,sarecycline,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA15,omadacycline,0.3,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA20,combinations of tetracyclines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01A,TETRACYCLINES,J01AA,Tetracyclines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The tetracyclines have different DDDs due to kinetic differences.  The use of tetracyclines in long-term, low dose treatment of acne is not taken into account in the assignment of DDDs.",J01AA56,"oxytetracycline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01B,AMPHENICOLS,J01BA,Amphenicols,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01BA01,chloramphenicol,3,3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01B,AMPHENICOLS,J01BA,Amphenicols,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01BA02,thiamphenicol,1.5,1.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01B,AMPHENICOLS,J01BA,Amphenicols,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01BA52,"thiamphenicol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA01,ampicillin,2,6,2,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA02,pivampicillin,1.05,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA03,carbenicillin,NA,12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA04,amoxicillin,1.5,3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA05,carindacillin,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA06,bacampicillin,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA07,epicillin,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA08,pivmecillinam,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA09,azlocillin,NA,12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA10,mezlocillin,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA11,mecillinam,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA12,piperacillin,NA,14,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA13,ticarcillin,NA,15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA14,metampicillin,1.5,1.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA15,talampicillin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA16,sulbenicillin,NA,15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA17,temocillin,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA18,hetacillin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA19,aspoxicillin,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CA,Penicillins with extended spectrum,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The esters, for instance pivampicillin and pivmecillinam, have a higher bioavailability and thus a lower DDD than the corresponding non-ester compounds.The DDDs for some of the compounds, for instance carbenicillin, piperacillin, ticarcillin and sulbenicillin, are based on the dosages used for narrow indications, i.e. life threatening infections.",J01CA51,"ampicillin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE01,benzylpenicillin,NA,3.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE02,phenoxymethylpenicillin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE03,propicillin,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE04,azidocillin,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE05,pheneticillin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE06,penamecillin,1.05,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE07,clometocillin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE08,benzathine benzylpenicillin,NA,3.6,NA,NA,NA,NA,NA,g,NA,NA,NA,Expressed as benzylpenicillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE09,procaine benzylpenicillin,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE10,benzathine phenoxymethylpenicillin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CE,Beta-lactamase sensitive penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Benzylpenicillin and phenoxymethylpenicillin have different DDDs due to differences in indications, route of administration and bioavailability.  The DDDs for the combination of benzylpenicillin and procaine penicillin is based on the treatment of syphilis, see list of DDDs for combination products, www.whocc.no.",J01CE30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CF,Beta-lactamase resistant penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01CF01,dicloxacillin,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CF,Beta-lactamase resistant penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01CF02,cloxacillin,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CF,Beta-lactamase resistant penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01CF03,meticillin,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CF,Beta-lactamase resistant penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01CF04,oxacillin,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CF,Beta-lactamase resistant penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01CF05,flucloxacillin,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CF,Beta-lactamase resistant penicillins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01CF06,nafcillin,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CG,Beta-lactamase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sulbactam is based on its use together with ampicillin, usually in a dose ratio of 1:2 respectively.",J01CG01,sulbactam,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CG,Beta-lactamase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sulbactam is based on its use together with ampicillin, usually in a dose ratio of 1:2 respectively.",J01CG02,tazobactam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CR,"Combinations of penicillins, incl. beta-lactamase inhibitors","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is lower than the corresponding DDD for the ordinary combination due to higher bioavailability.",J01CR01,ampicillin and beta-lactamase inhibitor,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to ampicillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CR,"Combinations of penicillins, incl. beta-lactamase inhibitors","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is lower than the corresponding DDD for the ordinary combination due to higher bioavailability.",J01CR02,amoxicillin and beta-lactamase inhibitor,1.5,3,NA,NA,NA,NA,g,g,NA,NA,NA,Refers to amoxicillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CR,"Combinations of penicillins, incl. beta-lactamase inhibitors","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is lower than the corresponding DDD for the ordinary combination due to higher bioavailability.",J01CR03,ticarcillin and beta-lactamase inhibitor,NA,15,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to ticarcillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CR,"Combinations of penicillins, incl. beta-lactamase inhibitors","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is lower than the corresponding DDD for the ordinary combination due to higher bioavailability.",J01CR04,sultamicillin,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CR,"Combinations of penicillins, incl. beta-lactamase inhibitors","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is lower than the corresponding DDD for the ordinary combination due to higher bioavailability.",J01CR05,piperacillin and beta-lactamase inhibitor,NA,14,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to piperacillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01C,"BETA-LACTAM ANTIBACTERIALS, PENICILLINS",J01CR,"Combinations of penicillins, incl. beta-lactamase inhibitors","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for sultamicillin, a prodrug for sulbactam and ampicillin, is lower than the corresponding DDD for the ordinary combination due to higher bioavailability.",J01CR50,combinations of penicillins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB01,cefalexin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB02,cefaloridine,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB03,cefalotin,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB04,cefazolin,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB05,cefadroxil,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB06,cefazedone,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB07,cefatrizine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB08,cefapirin,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB09,cefradine,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB10,cefacetrile,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB11,cefroxadine,2.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DB,First-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DB12,ceftezole,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC01,cefoxitin,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC02,cefuroxime,0.5,3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC03,cefamandole,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC04,cefaclor,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC05,cefotetan,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC06,cefonicid,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC07,cefotiam,1.2,4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC08,loracarbef,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC09,cefmetazole,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC10,cefprozil,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC11,ceforanide,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC12,cefminox,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC13,cefbuperazone,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC14,flomoxef,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DC,Second-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DC52,cefuroxime and beta-lactamase inhibitor,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to cefuroxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD01,cefotaxime,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD02,ceftazidime,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD03,cefsulodin,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD04,ceftriaxone,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD05,cefmenoxime,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD06,latamoxef,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD07,ceftizoxime,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD08,cefixime,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD09,cefodizime,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD10,cefetamet,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD11,cefpiramide,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD12,cefoperazone,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD13,cefpodoxime,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD14,ceftibuten,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD15,cefdinir,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD16,cefditoren,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD17,cefcapene,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD18,cefteram,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD51,cefotaxime and beta-lactamase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD52,ceftazidime and beta-lactamase inhibitor,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to ceftazidime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD54,"ceftriaxone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD58,cefixime and beta-lactamase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD62,cefoperazone and beta-lactamase inhibitor,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to cefoperazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD63,ceftriaxone and beta-lactamase inhibitor,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to ceftriaxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DD,Third-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DD64,cefpodoxime and beta-lactamase inhibitor,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to cefpodoxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DE,Fourth-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DE01,cefepime,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DE,Fourth-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DE02,cefpirome,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DE,Fourth-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DE03,cefozopran,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DE,Fourth-generation cephalosporins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DE51,cefepime and beta-lactamase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DF,Monobactams,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DF01,aztreonam,NA,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,0.225,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DF,Monobactams,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DF02,carumonam,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH02,meropenem,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH03,ertapenem,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH04,doripenem,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH05,biapenem,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH06,tebipenem pivoxil,0.56,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH51,imipenem and cilastatin,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to imipenem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH52,meropenem and vaborbactam,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to meropenem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH55,panipenem and betamipron,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to panipenem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DH,Carbapenems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections. The DDD for meropenem is based on treatment of severe infections.",J01DH56,"imipenem, cilastatin and relebactam",NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to imipenem,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DI,Other cephalosporins and penems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DI01,ceftobiprole medocaril,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DI,Other cephalosporins and penems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DI02,ceftaroline fosamil,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DI,Other cephalosporins and penems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DI03,faropenem,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DI,Other cephalosporins and penems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DI04,cefiderocol,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01D,OTHER BETA-LACTAM ANTIBACTERIALS,J01DI,Other cephalosporins and penems,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The cephalosporins are used in highly variable dosages for different indications, which should be reflected in the assigned DDDs.  The indications for use of the cephalosporins (i.e. the severity of the infections) vary rather extensively from one country to another.  The assigned DDDs are placed in the upper area of the dose range for moderate to severe infections.",J01DI54,ceftolozane and beta-lactamase inhibitor,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,Refers to ceftolozane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EA,Trimethoprim and derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. The DDDs are based on the treatment of acute urinary-tract infections.",J01EA01,trimethoprim,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EA,Trimethoprim and derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. The DDDs are based on the treatment of acute urinary-tract infections.",J01EA02,brodimoprim,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EA,Trimethoprim and derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. The DDDs are based on the treatment of acute urinary-tract infections.",J01EA03,iclaprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB01,sulfaisodimidine,4,4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB02,sulfamethizole,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB03,sulfadimidine,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB04,sulfapyridine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB05,sulfafurazole,4,4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB06,sulfanilamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB07,sulfathiazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB08,sulfathiourea,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EB,Short-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EB20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EC,Intermediate-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EC01,sulfamethoxazole,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EC,Intermediate-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EC02,sulfadiazine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EC,Intermediate-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EC03,sulfamoxole,1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EC,Intermediate-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01EC20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED01,sulfadimethoxine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED02,sulfalene,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED03,sulfametomidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED04,sulfametoxydiazine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED05,sulfamethoxypyridazine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED06,sulfaperin,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED07,sulfamerazine,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED08,sulfaphenazole,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED09,sulfamazone,1.5,NA,1.5,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01ED,Long-acting sulfonamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting.",J01ED20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE01,sulfamethoxazole and trimethoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE02,sulfadiazine and trimethoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE03,sulfametrole and trimethoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE04,sulfamoxole and trimethoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE05,sulfadimidine and trimethoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE06,sulfadiazine and tetroxoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01E,SULFONAMIDES AND TRIMETHOPRIM,J01EE,"Combinations of sulfonamides and trimethoprim, incl. derivatives","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the sulfonamides are related to the duration of effect, i.e. usually the long-acting sulfonamides will have lower DDDs than the short-acting. When establishing DDDs for combination products, both components are taken into consideration, see list of DDDs for combination products, www.whocc.no.",J01EE07,sulfamerazine and trimethoprim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA01,erythromycin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,erythromycin ethylsuccinate tablets,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA01,erythromycin,1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA02,spiramycin,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA03,midecamycin,1.2,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA05,oleandomycin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA06,roxithromycin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA07,josamycin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA08,troleandomycin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA09,clarithromycin,0.5,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA10,azithromycin,0.3,0.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA11,miocamycin,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA12,rokitamycin,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA13,dirithromycin,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA14,flurithromycin,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA15,telithromycin,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FA,Macrolides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Erythromycin ethylsuccinate tablets have been assigned a higher DDD than other preparations of erythromycin due to a lower bio-availability.  This DDD is mainly based on the dose recommendations.The oral DDD for azithromycin is based on a 5-day regimen.",J01FA16,solithromycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FF,Lincosamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Orally and parenterally administered clindamycin have different DDDs due to different indications, i.e. the intestinal and systemic infections, respectively.",J01FF01,clindamycin,1.2,1.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FF,Lincosamides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Orally and parenterally administered clindamycin have different DDDs due to different indications, i.e. the intestinal and systemic infections, respectively.",J01FF02,lincomycin,1.8,1.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FG,Streptogramins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01FG01,pristinamycin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01F,"MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS",J01FG,Streptogramins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01FG02,quinupristin/dalfopristin,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GA,Streptomycins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01GA01,streptomycin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GA,Streptomycins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01GA02,streptoduocin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB01,tobramycin,NA,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,0.3,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.112,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB03,gentamicin,NA,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB04,kanamycin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB05,neomycin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB06,amikacin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,0.59,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB07,netilmicin,0.35,0.35,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB08,sisomicin,NA,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB09,dibekacin,NA,0.14,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB10,ribostamycin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB11,isepamicin,NA,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB12,arbekacin,NA,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB13,bekanamycin,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01G,AMINOGLYCOSIDE ANTIBACTERIALS,J01GB,Other aminoglycosides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the aminoglycosides are based on use in severe infections.",J01GB14,plazomicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA01,ofloxacin,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA02,ciprofloxacin,1,0.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA03,pefloxacin,0.8,0.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA04,enoxacin,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA05,temafloxacin,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA06,norfloxacin,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA07,lomefloxacin,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA08,fleroxacin,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA09,sparfloxacin,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA10,rufloxacin,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA11,grepafloxacin,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA12,levofloxacin,0.5,0.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,0.24,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA13,trovafloxacin,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA14,moxifloxacin,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA15,gemifloxacin,0.32,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA16,gatifloxacin,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA17,prulifloxacin,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA18,pazufloxacin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA19,garenoxacin,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA21,sitafloxacin,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA22,tosufloxacin,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA23,delafloxacin,0.9,0.6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA24,levonadifloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MA,Fluoroquinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the fluoroquinolones are mainly based on the treatment of respiratory tract infections.The DDDs for pefloxacin, enoxacin and norfloxacin are based on the treatment of complicated urinary tract infections.",J01MA25,lascufloxacin,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB01,rosoxacin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB02,nalidixic acid,4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB03,piromidic acid,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB04,pipemidic acid,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB05,oxolinic acid,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB06,cinoxacin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB07,flumequine,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01M,QUINOLONE ANTIBACTERIALS,J01MB,Other quinolones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.  The DDD for rosoxacin is based on single dose treatment of gonorrhoea.",J01MB08,nemonoxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA01,"penicillins, combinations with other antibacterials",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA02,"sulfonamides, combinations with other antibacterials (excl. trimethoprim)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA03,cefuroxime and metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA04,spiramycin and metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA05,levofloxacin and ornidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA06,cefepime and amikacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA07,"azithromycin, fluconazole and secnidazole",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA08,tetracycline and oleandomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA09,ofloxacin and ornidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA10,ciprofloxacin and metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA11,ciprofloxacin and tinidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA12,ciprofloxacin and ornidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA13,norfloxacin and tinidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA14,norfloxacin and metronidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA15,cefixime and ornidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01R,COMBINATIONS OF ANTIBACTERIALS,J01RA,Combinations of antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01RA16,cefixime and azithromycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XA,Glycopeptide antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XA01,vancomycin,NA,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XA,Glycopeptide antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XA02,teicoplanin,NA,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XA,Glycopeptide antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XA03,telavancin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XA,Glycopeptide antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XA04,dalbavancin,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XA,Glycopeptide antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XA05,oritavancin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XB,Polymyxins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XB01,colistin,NA,9,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,3,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XB,Polymyxins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XB02,polymyxin B,NA,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XC,Steroid antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J01XC01,fusidic acid,1.5,1.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XD,Imidazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the parenteral imidazole formulations are based on the treatment of anaerobic bacteria infections.",J01XD01,metronidazole,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XD,Imidazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the parenteral imidazole formulations are based on the treatment of anaerobic bacteria infections.",J01XD02,tinidazole,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XD,Imidazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for the parenteral imidazole formulations are based on the treatment of anaerobic bacteria infections.",J01XD03,ornidazole,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XE,Nitrofuran derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.",J01XE01,nitrofurantoin,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XE,Nitrofuran derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.",J01XE02,nifurtoinol,0.16,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XE,Nitrofuran derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.",J01XE03,furazidin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XE,Nitrofuran derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are generally based on the treatment of acute urinary tract infections.",J01XE51,"nitrofurantoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX01,fosfomycin,3,8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX02,xibornol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX03,clofoctol,NA,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX04,spectinomycin,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX05,methenamine,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,hippurate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX05,methenamine,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,mandelate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX06,mandelic acid,12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX07,nitroxoline,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX08,linezolid,1.2,1.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX09,daptomycin,NA,0.28,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX10,bacitracin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX11,tedizolid,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J01,ANTIBACTERIALS FOR SYSTEMIC USE,J01X,OTHER ANTIBACTERIALS,J01XX,Other antibacterials,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The parenteral DDD for fosfomycin is based on the use of a single prophylactic dose in connection with surgery, whilst the oral DDD is based on treatment of uncomplicated lower urinary tract infections given as a single dose of fosfomycin trometamol.The DDD for spectinomycin is based on the use of a single dose for treatment of uncomplicated gonorrhea.The DDD for methenamine is based on prophylaxis of urinary tract infections.  The DDDs for mandelic acid and nitroxoline are based on the treatment of acute urinary tract infections.",J01XX12,lefamulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AA,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Lipid formulations (e.g. liposomal, lipid complex) of amphotericin B have been assigned a separate, higher DDD from the conventional formulations due to a considerably higher dosage.",J02AA01,amphotericin B,NA,210,NA,NA,NA,NA,NA,mg,NA,NA,NA,lipid formulations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AA,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Lipid formulations (e.g. liposomal, lipid complex) of amphotericin B have been assigned a separate, higher DDD from the conventional formulations due to a considerably higher dosage.",J02AA01,amphotericin B,NA,35,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AA,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). Lipid formulations (e.g. liposomal, lipid complex) of amphotericin B have been assigned a separate, higher DDD from the conventional formulations due to a considerably higher dosage.",J02AA02,hachimycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AB,Imidazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AB01,miconazole,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AB,Imidazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AB02,ketoconazole,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AC,Triazole and tetrazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.",J02AC01,fluconazole,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AC,Triazole and tetrazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.",J02AC02,itraconazole,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AC,Triazole and tetrazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.",J02AC03,voriconazole,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AC,Triazole and tetrazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.",J02AC04,posaconazole,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AC,Triazole and tetrazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.",J02AC05,isavuconazole,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AC,Triazole and tetrazole derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The oral DDD for posaconazole is based on the recommended dose for gastro-resistant tablets.",J02AC06,oteseconazole,21,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AX,Other antimycotics for systemic use,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AX01,flucytosine,10,10,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AX,Other antimycotics for systemic use,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AX04,caspofungin,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AX,Other antimycotics for systemic use,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AX05,micafungin,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AX,Other antimycotics for systemic use,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AX06,anidulafungin,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AX,Other antimycotics for systemic use,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AX07,ibrexafungerp,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J02,ANTIMYCOTICS FOR SYSTEMIC USE,J02A,ANTIMYCOTICS FOR SYSTEMIC USE,J02AX,Other antimycotics for systemic use,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J02AX08,rezafungin acetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AA,Aminosalicylic acid and derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AA01,4-aminosalicylic acid,12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AA,Aminosalicylic acid and derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AA02,sodium aminosalicylate,14,14,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AA,Aminosalicylic acid and derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AA03,calcium aminosalicylate,15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB01,cycloserine,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB02,rifampicin,0.6,0.6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB03,rifamycin,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB04,rifabutin,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB05,rifapentine,0.11,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB06,enviomycin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AB,Antibiotics,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no. The DDD for rifapentine is based on the first 6 months treatment period, including both the initial phase and the continuous phase.",J04AB30,capreomycin,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AC,Hydrazides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AC01,isoniazid,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AC,Hydrazides,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AC51,"isoniazid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AD,Thiocarbamide derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AD01,protionamide,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AD,Thiocarbamide derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AD02,tiocarlide,7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AD,Thiocarbamide derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AD03,ethionamide,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK01,pyrazinamide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK02,ethambutol,1.2,1.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK03,terizidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK04,morinamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK05,bedaquiline,86,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK06,delamanid,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK07,thioacetazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AK,Other drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AK08,pretomanid,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM01,streptomycin and isoniazid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM02,rifampicin and isoniazid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM03,ethambutol and isoniazid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM04,thioacetazone and isoniazid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM05,"rifampicin, pyrazinamide and isoniazid",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM06,"rifampicin, pyrazinamide, ethambutol and isoniazid",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM07,"rifampicin, ethambutol and isoniazid",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04A,DRUGS FOR TREATMENT OF TUBERCULOSIS,J04AM,Combinations of drugs for treatment of tuberculosis,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in the treatment of tuberculosis. DDDs for combination products see www.whocc.no.",J04AM08,"isoniazid, sulfamethoxazole, trimethoprim and pyridoxine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04B,DRUGS FOR TREATMENT OF LEPRA,J04BA,Drugs for treatment of lepra,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J04BA01,clofazimine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04B,DRUGS FOR TREATMENT OF LEPRA,J04BA,Drugs for treatment of lepra,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J04BA02,dapsone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04B,DRUGS FOR TREATMENT OF LEPRA,J04BA,Drugs for treatment of lepra,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J04BA03,aldesulfone sodium,0.33,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04B,DRUGS FOR TREATMENT OF LEPRA,J04BA,Drugs for treatment of lepra,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J04BA50,dapsone and rifampicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J04,ANTIMYCOBACTERIALS,J04B,DRUGS FOR TREATMENT OF LEPRA,J04BA,Drugs for treatment of lepra,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J04BA51,"dapsone, rifampicin and clofazimine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AA,Thiosemicarbazones,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AA01,metisazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB01,aciclovir,4,4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB02,idoxuridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB03,vidarabine,NA,0.7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB06,ganciclovir,3,0.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB09,famciclovir,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB11,valaciclovir,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB12,cidofovir,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB13,penciclovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB14,valganciclovir,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB15,brivudine,0.125,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB16,remdesivir,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB17,brincidofovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AB,Nucleosides and nucleotides excl. reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.",J05AB18,molnupiravir,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AC,Cyclic amines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AC02,rimantadine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AC,Cyclic amines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AC03,tromantadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AD,Phosphonic acid derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for foscarnet is based on the treatment of CMV-retinitis in AIDS patients.",J05AD01,foscarnet,NA,6.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AD,Phosphonic acid derivatives,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for foscarnet is based on the treatment of CMV-retinitis in AIDS patients.",J05AD02,fosfonet,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE01,saquinavir,1.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE02,indinavir,2.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE03,ritonavir,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE04,nelfinavir,2.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE05,amprenavir,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE07,fosamprenavir,1.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE08,atazanavir,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE09,tipranavir,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE10,darunavir,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE16,ensitrelvir,0.175,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AE,Protease inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.The DDD for saquinavir is based on the dose recommendations for hard capsules.",J05AE30,nirmatrelvir and ritonavir,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,refers to nirmatrelvir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF01,zidovudine,0.6,0.6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF02,didanosine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF03,zalcitabine,2.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF04,stavudine,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF05,lamivudine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF06,abacavir,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF07,tenofovir disoproxil,0.245,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF08,adefovir dipivoxil,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF09,emtricitabine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF10,entecavir,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF11,telbivudine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF12,clevudine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.",J05AF13,tenofovir alafenamide,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AG,Non-nucleoside reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.",J05AG01,nevirapine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AG,Non-nucleoside reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.",J05AG02,delavirdine,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AG,Non-nucleoside reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.",J05AG03,efavirenz,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AG,Non-nucleoside reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.",J05AG04,etravirine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AG,Non-nucleoside reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.",J05AG05,rilpivirine,25,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AG,Non-nucleoside reverse transcriptase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDDs are based on combination therapy in HIV infections.",J05AG06,doravirine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AH,Neuraminidase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for oseltamivir is based on the treatment of influenza.",J05AH01,zanamivir,NA,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AH,Neuraminidase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for oseltamivir is based on the treatment of influenza.",J05AH02,oseltamivir,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AH,Neuraminidase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for oseltamivir is based on the treatment of influenza.",J05AH03,peramivir,NA,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AH,Neuraminidase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The DDD for oseltamivir is based on the treatment of influenza.",J05AH04,laninamivir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.16,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AJ,Integrase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AJ01,raltegravir,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AJ,Integrase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AJ02,elvitegravir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AJ,Integrase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AJ03,dolutegravir,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AJ,Integrase inhibitors,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AJ04,cabotegravir,30,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP01,ribavirin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,6,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP02,telaprevir,2.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP03,boceprevir,2.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP04,faldaprevir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP05,simeprevir,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP06,asunaprevir,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP07,daclatasvir,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP08,sofosbuvir,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP09,dasabuvir,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP10,elbasvir,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP11,grazoprevir,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP12,coblopasvir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP13,ravidasvir,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP51,sofosbuvir and ledipasvir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP52,"dasabuvir, ombitasvir, paritaprevir and ritonavir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP53,"ombitasvir, paritaprevir and ritonavir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP54,elbasvir and grazoprevir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP55,sofosbuvir and velpatasvir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP56,"sofosbuvir, velpatasvir and voxilaprevir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP57,glecaprevir and pibrentasvir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AP,Antivirals for treatment of HCV infections,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.",J05AP58,"daclatasvir, asunaprevir and beclabuvir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR01,zidovudine and lamivudine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR02,lamivudine and abacavir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR03,tenofovir disoproxil and emtricitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR04,"zidovudine, lamivudine and abacavir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR05,"zidovudine, lamivudine and nevirapine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR06,"emtricitabine, tenofovir disoproxil and efavirenz",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR07,"stavudine, lamivudine and nevirapine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR08,"emtricitabine, tenofovir disoproxil and rilpivirine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR09,"emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR10,lopinavir and ritonavir,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to lopinavir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR11,"lamivudine, tenofovir disoproxil and efavirenz",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR12,lamivudine and tenofovir disoproxil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR13,"lamivudine, abacavir and dolutegravir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR14,darunavir and cobicistat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR15,atazanavir and cobicistat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR16,lamivudine and raltegravir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR17,emtricitabine and tenofovir alafenamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR18,"emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR19,"emtricitabine, tenofovir alafenamide and rilpivirine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR20,"emtricitabine, tenofovir alafenamide and bictegravir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR21,dolutegravir and rilpivirine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR22,"emtricitabine, tenofovir alafenamide, darunavir and cobicistat",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR23,atazanavir and ritonavir,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to atazanavir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR24,"lamivudine, tenofovir disoproxil and doravirine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR25,lamivudine and dolutegravir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR26,darunavir and ritonavir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR27,"lamivudine, tenofovir disoproxil and dolutegravir",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AR,"Antivirals for treatment of HIV infections, combinations","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). See list of DDDs for combination products, www.whocc.no.",J05AR28,stavudine and lamivudine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX01,moroxydine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX02,lysozyme,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX05,inosine pranobex,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX06,pleconaril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX07,enfuvirtide,NA,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX09,maraviroc,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX10,maribavir,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX13,umifenovir,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX17,enisamium iodide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX18,letermovir,0.48,0.48,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX19,tilorone,0.125,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX21,pentanedioic acid imidazolyl ethanamide,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX23,ibalizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX24,tecovirimat,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX25,baloxavir marboxil,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX26,amenamevir,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX27,favipiravir,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX28,bulevirtide,NA,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX29,fostemsavir,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J05,ANTIVIRALS FOR SYSTEMIC USE,J05A,DIRECT ACTING ANTIVIRALS,J05AX,Other antivirals,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).",J05AX31,lenacapavir,0.19,5.1,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06A,IMMUNE SERA,J06AA,Immune sera,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06AA01,diphtheria antitoxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06A,IMMUNE SERA,J06AA,Immune sera,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06AA02,tetanus antitoxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06A,IMMUNE SERA,J06AA,Immune sera,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06AA03,snake venom antiserum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06A,IMMUNE SERA,J06AA,Immune sera,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06AA04,botulinum antitoxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06A,IMMUNE SERA,J06AA,Immune sera,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06AA05,gas-gangrene sera,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06A,IMMUNE SERA,J06AA,Immune sera,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06AA06,rabies serum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BA,"Immunoglobulins, normal human","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BA01,"immunoglobulins, normal human, for extravascular adm.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BA,"Immunoglobulins, normal human","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BA02,"immunoglobulins, normal human, for intravascular adm.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB01,anti-D (rh) immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB02,tetanus immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB03,varicella/zoster immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB04,hepatitis B immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB05,rabies immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB06,rubella immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB07,vaccinia immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB08,staphylococcus immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB09,cytomegalovirus immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB10,diphtheria immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB11,hepatitis A immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB12,"encephalitis, tick borne immunoglobulin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB13,pertussis immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB14,measles immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB15,mumps immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB19,anthrax immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BB,Specific immunoglobulins,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BB30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BC,Antibacterial monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BC01,nebacumab,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BC,Antibacterial monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BC02,raxibacumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BC,Antibacterial monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BC03,bezlotoxumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BC,Antibacterial monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BC04,obiltoxaximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD01,palivizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD02,motavizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD03,tixagevimab and cilgavimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD04,ansuvimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD05,sotrovimab,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD06,regdanvimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD07,casirivimab and imdevimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J06,IMMUNE SERA AND IMMUNOGLOBULINS,J06B,IMMUNOGLOBULINS,J06BD,Antiviral monoclonal antibodies,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned, with a few exceptions.",J06BD08,nirsevimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AC,Anthrax vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AC01,anthrax antigen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AD,Brucellosis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AD01,brucella antigen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AE,Cholera vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AE01,"cholera, inactivated, whole cell",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AE,Cholera vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AE02,"cholera, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AE,Cholera vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AE51,"cholera, combinations with typhoid vaccine, inactivated, whole cell",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AF,Diphtheria vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AF01,diphtheria toxoid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AG,Haemophilus influenzae B vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AG01,"haemophilus influenzae B, purified antigen conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AG,Haemophilus influenzae B vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AG51,"haemophilus influenzae B, combinations with toxoids",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AG,Haemophilus influenzae B vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AG52,"haemophilus influenzae B, combinations with pertussis and toxoids",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AG,Haemophilus influenzae B vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AG53,"haemophilus influenzae B, combinations with meningococcus C, conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AG,Haemophilus influenzae B vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AG54,"haemophilus influenza B, combinations with meningococcus C,Y, conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH01,"meningococcus A, purified polysaccharides antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH02,other meningococcal monovalent purified polysaccharides antigen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH03,"meningococcus A,C, bivalent purified polysaccharides antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH04,"meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH05,other meningococcal polyvalent purified polysaccharides antigen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH06,"meningococcus B, outer membrane vesicle vaccine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH07,"meningococcus C, purified polysaccharides antigen conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH08,"meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH09,"meningococcus B, multicomponent vaccine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AH,Meningococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AH10,"meningococcus A, purified polysaccharides antigen conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AJ,Pertussis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AJ01,"pertussis, inactivated, whole cell",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AJ,Pertussis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AJ02,"pertussis, purified antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AJ,Pertussis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AJ51,"pertussis, inactivated, whole cell, combinations with toxoids",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AJ,Pertussis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AJ52,"pertussis, purified antigen, combinations with toxoids",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AK,Plague vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AK01,"plague, inactivated, whole cell",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AL,Pneumococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AL01,"pneumococcus, purified polysaccharides antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AL,Pneumococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AL02,"pneumococcus, purified polysaccharides antigen conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AL,Pneumococcal vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AL52,"pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AM,Tetanus vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AM01,tetanus toxoid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AM,Tetanus vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AM51,"tetanus toxoid, combinations with diphtheria toxoid",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AM,Tetanus vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AM52,"tetanus toxoid, combinations with tetanus immunoglobulin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AN,Tuberculosis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AN01,"tuberculosis, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AP,Typhoid vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AP01,"typhoid, oral, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AP,Typhoid vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AP02,"typhoid, inactivated, whole cell",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AP,Typhoid vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AP03,"typhoid, purified polysaccharide antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AP,Typhoid vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AP10,"typhoid, combinations with paratyphi types",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AR,Typhus (exanthematicus) vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AR01,"typhus exanthematicus, inactivated, whole cell",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07A,BACTERIAL VACCINES,J07AX,Other bacterial vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07AX01,leptospira vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BA,Encephalitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BA01,"encephalitis, tick borne, inactivated, whole virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BA,Encephalitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BA02,"encephalitis, Japanese, inactivated, whole virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BA,Encephalitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BA03,"encephalitis, Japanese, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BB,Influenza vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BB01,"influenza, inactivated, whole virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BB,Influenza vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BB02,"influenza, inactivated, split virus or surface antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BB,Influenza vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BB03,"influenza, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BB,Influenza vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BB04,"influenza, virus like particles",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BC,Hepatitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BC01,"hepatitis B, purified antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BC,Hepatitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BC02,"hepatitis A, inactivated, whole virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BC,Hepatitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BC20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BD,Measles vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BD01,"measles, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BD,Measles vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BD51,"measles, combinations with mumps, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BD,Measles vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BD52,"measles, combinations with mumps and rubella, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BD,Measles vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BD53,"measles, combinations with rubella, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BD,Measles vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BD54,"measles, combinations with mumps, rubella and varicella, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BE,Mumps vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BE01,"mumps, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BF,Poliomyelitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BF01,"poliomyelitis oral, monovalent, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BF,Poliomyelitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BF02,"poliomyelitis oral, trivalent, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BF,Poliomyelitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BF03,"poliomyelitis, trivalent, inactivated, whole virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BF,Poliomyelitis vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BF04,"poliomyelitis oral, bivalent, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BG,Rabies vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BG01,"rabies, inactivated, whole virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BH,Rota virus diarrhea vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BH01,"rota virus, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BH,Rota virus diarrhea vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BH02,"rota virus, pentavalent, live, reassorted",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BJ,Rubella vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BJ01,"rubella, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BJ,Rubella vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BJ51,"rubella, combinations with mumps, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BK,Varicella zoster vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BK01,"varicella, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BK,Varicella zoster vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BK02,"zoster, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BK,Varicella zoster vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BK03,"zoster, purified antigen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BL,Yellow fever vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BL01,"yellow fever, live attenuated",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BM,Papillomavirus vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BM01,"papillomavirus (human types 6, 11, 16, 18)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BM,Papillomavirus vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BM02,"papillomavirus (human types 16, 18)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BM,Papillomavirus vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BM03,"papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BN,Covid-19 vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BN01,"covid-19, RNA-based vaccine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BN,Covid-19 vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BN02,"covid-19, viral vector, non-replicating",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BN,Covid-19 vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BN03,"covid-19, inactivated virus",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BN,Covid-19 vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BN04,"covid-19, protein subunit",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BN,Covid-19 vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BN05,"covid-19, virus-like particles",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BX,Other viral vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BX01,smallpox and monkeypox vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BX,Other viral vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BX02,ebola vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BX,Other viral vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BX04,dengue virus vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BX,Other viral vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BX05,respiratory syncytial virus vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07B,VIRAL VACCINES,J07BX,Other viral vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07BX06,enterovirus 71 vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA01,diphtheria-poliomyelitis-tetanus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA03,diphtheria-rubella-tetanus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA04,haemophilus influenzae B and poliomyelitis,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA05,diphtheria-hepatitis B-pertussis-tetanus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA06,diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA07,diphtheria-hepatitis B-tetanus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA08,haemophilus influenzae B and hepatitis B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA09,diphtheria-haemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA10,typhoid-hepatitis A,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA11,diphtheria-haemophilus influenzae B-pertussis-tetanus-hepatitis B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA12,diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07C,"BACTERIAL AND VIRAL VACCINES, COMBINED",J07CA,"Bacterial and viral vaccines, combined","The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07CA13,diphtheria-haemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A + C,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
J,ANTIINFECTIVES FOR SYSTEMIC USE,J07,VACCINES,J07X,OTHER VACCINES,J07XA,Parasitic vaccines,"The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity.  However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly.  The DDDs assigned are based on daily treatment.  The duration of the treatment periods is not taken into consideration.  For antiinfectives given in a high initially starting dose followed by a lower daily ""maintenance"" dose, the DDDs are based on the ""maintenance"" dose if the total duration of the treat-ment course is more than one week.  If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin). No DDDs have been assigned.",J07XA01,malaria vaccines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA01,cyclophosphamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA02,chlorambucil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA03,melphalan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA05,chlormethine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA06,ifosfamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA07,trofosfamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA08,prednimustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA09,bendamustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA10,melphalan flufenamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AB,Alkyl sulfonates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AB01,busulfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AB,Alkyl sulfonates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AB02,treosulfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AB,Alkyl sulfonates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AB03,mannosulfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AC,Ethylene imines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AC01,thiotepa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AC,Ethylene imines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AC02,triaziquone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AC,Ethylene imines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AC03,carboquone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD01,carmustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD02,lomustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD03,semustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD04,streptozocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD05,fotemustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD06,nimustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD07,ranimustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD08,uramustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AG,Epoxides,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AG01,etoglucid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX01,mitobronitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX02,pipobroman,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX03,temozolomide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX04,dacarbazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA01,methotrexate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA03,raltitrexed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA04,pemetrexed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA05,pralatrexate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB02,mercaptopurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB03,tioguanine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB04,cladribine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB05,fludarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB06,clofarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB07,nelarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC01,cytarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC02,fluorouracil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC03,tegafur,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC04,carmofur,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC05,gemcitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC06,capecitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC07,azacitidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC08,decitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC09,floxuridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC52,"fluorouracil, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC53,"tegafur, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC58,"decitabine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC59,"trifluridine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA01,vinblastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA02,vincristine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA03,vindesine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA04,vinorelbine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA05,vinflunine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA06,vintafolide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CB,Podophyllotoxin derivatives,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CB01,etoposide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CB,Podophyllotoxin derivatives,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CB02,teniposide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CC,Colchicine derivatives,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CC01,demecolcine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD01,paclitaxel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD02,docetaxel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD03,paclitaxel poliglumex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD04,cabazitaxel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD51,paclitaxel and encequidar,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE01,topotecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE02,irinotecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE03,etirinotecan pegol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE04,belotecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CX,Other plant alkaloids and natural products,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CX01,trabectedin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DA,Actinomycines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DA01,dactinomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB01,doxorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB02,daunorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB03,epirubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB04,aclarubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB05,zorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB06,idarubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB07,mitoxantrone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB08,pirarubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB09,valrubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB10,amrubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB11,pixantrone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC01,bleomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC02,plicamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC03,mitomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC04,ixabepilone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA01,imatinib,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA02,dasatinib,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA03,nilotinib,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA04,bosutinib,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA05,ponatinib,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA06,asciminib,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB01,gefitinib,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB02,erlotinib,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB03,afatinib,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB04,osimertinib,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB05,rociletinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB06,olmutinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB07,dacomitinib,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB08,icotinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB09,lazertinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB10,mobocertinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB11,aumolertinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for encorafenib is based on the treatment of melanoma.",L01EC01,vemurafenib,1.92,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for encorafenib is based on the treatment of melanoma.",L01EC02,dabrafenib,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for encorafenib is based on the treatment of melanoma.",L01EC03,encorafenib,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED01,crizotinib,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED02,ceritinib,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED03,alectinib,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED04,brigatinib,0.18,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED05,lorlatinib,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE01,trametinib,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE02,cobimetinib,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE03,binimetinib,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE04,selumetinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EF,Cyclin-dependent kinase (CDK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EF01,palbociclib,94,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EF,Cyclin-dependent kinase (CDK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EF02,ribociclib,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EF,Cyclin-dependent kinase (CDK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EF03,abemaciclib,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG01,temsirolimus,NA,3.57,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG02,everolimus,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG03,ridaforolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG04,sirolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EH,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EH01,lapatinib,1.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EH,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EH02,neratinib,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EH,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EH03,tucatinib,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ01,ruxolitinib,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ02,fedratinib,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ03,pacritinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ04,momelotinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK01,axitinib,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK02,cediranib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK03,tivozanib,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK04,fruquintinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL01,ibrutinib,0.42,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL02,acalabrutinib,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL03,zanubrutinib,0.32,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL04,orelabrutinib,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL05,pirtobrutinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM01,idelalisib,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM02,copanlisib,NA,6.43,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM03,alpelisib,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM04,duvelisib,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM05,parsaclisib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN01,erdafitinib,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN02,pemigatinib,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN03,infigratinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN04,futibatinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX01,sunitinib,33,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX02,sorafenib,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX03,pazopanib,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX04,vandetanib,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX05,regorafenib,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX06,masitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX07,cabozantinib,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX08,lenvatinib,18,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX09,nintedanib,0.38,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX10,midostaurin,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX11,quizartinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX12,larotrectinib,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX13,gilteritinib,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX14,entrectinib,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX15,pexidartinib,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX17,capmatinib,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX18,avapritinib,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX19,ripretinib,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX21,tepotinib,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX22,selpercatinib,0.32,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX23,pralsetinib,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX24,surufatinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX25,umbralisib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX26,sitravatinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX27,capivasertib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FA,CD20 (Clusters of Differentiation 20) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FA01,rituximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FA,CD20 (Clusters of Differentiation 20) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FA02,ofatumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FA,CD20 (Clusters of Differentiation 20) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FA03,obinutuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FB,CD22 (Clusters of Differentiation 22) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FB01,inotuzumab ozogamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FB,CD22 (Clusters of Differentiation 22) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FB02,moxetumomab pasudotox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FC,CD38 (Clusters of Differentiation 38) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FC01,daratumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FC,CD38 (Clusters of Differentiation 38) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FC02,isatuximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD01,trastuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD02,pertuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD03,trastuzumab emtansine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD04,trastuzumab deruxtecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD05,trastuzumab duocarmazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD06,margetuximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FE,EGFR (Epidermal Growth Factor Receptor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FE01,cetuximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FE,EGFR (Epidermal Growth Factor Receptor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FE02,panitumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FE,EGFR (Epidermal Growth Factor Receptor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FE03,necitumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF01,nivolumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF02,pembrolizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF03,durvalumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF04,avelumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF05,atezolizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF06,cemiplimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF07,dostarlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF08,prolgolimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF09,tislelizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF10,retifanlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF11,sugemalimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF12,serplulimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF13,toripalimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FG,VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FG01,bevacizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FG,VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FG02,ramucirumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX01,edrecolomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX02,gemtuzumab ozogamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX03,catumaxomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX04,ipilimumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX05,brentuximab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX06,dinutuximab beta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX07,blinatumomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX08,elotuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX09,mogamulizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX10,olaratumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX11,bermekimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX12,tafasitamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX13,enfortumab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX14,polatuzumab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX15,belantamab mafodotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX16,oportuzumab monatox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX17,sacituzumab govitecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX18,amivantamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX19,sabatolimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX20,tremelimumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX21,naxitamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX22,loncastuximab tesirine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX23,tisotumab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX24,teclistamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX25,mosunetuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX26,mirvetuximab soravtansine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX27,epcoritamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX28,glofitamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX29,talquetamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FY,Combinations of monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FY01,pertuzumab and trastuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FY,Combinations of monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FY02,nivolumab and relatlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FY,Combinations of monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FY03,prolgolimab and nurulimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA01,cisplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA02,carboplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA03,oxaliplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA04,satraplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA05,polyplatillen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XB,Methylhydrazines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XB01,procarbazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD01,porfimer sodium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD03,methyl aminolevulinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD04,aminolevulinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD05,temoporfin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD06,efaproxiral,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD07,padeliporfin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XF,Retinoids for cancer treatment,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XF01,tretinoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XF,Retinoids for cancer treatment,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XF02,alitretinoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XF,Retinoids for cancer treatment,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XF03,bexarotene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XG,Proteasome inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XG01,bortezomib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XG,Proteasome inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XG02,carfilzomib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XG,Proteasome inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XG03,ixazomib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH01,vorinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH02,romidepsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH03,panobinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH04,belinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH05,entinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XJ,Hedgehog pathway inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XJ01,vismodegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XJ,Hedgehog pathway inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XJ02,sonidegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XJ,Hedgehog pathway inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XJ03,glasdegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK01,olaparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK02,niraparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK03,rucaparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK04,talazoparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK05,veliparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK06,pamiparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK52,niraparib and abiraterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL01,sitimagene ceradenovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL02,talimogene laherparepvec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL03,axicabtagene ciloleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL04,tisagenlecleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL05,ciltacabtagene autoleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL06,brexucabtagene autoleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL07,idecabtagene vicleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL08,lisocabtagene maraleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL09,tabelecleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL10,nadofaragene firadenovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL11,lifileucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX01,amsacrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX02,asparaginase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX03,altretamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX05,hydroxycarbamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX07,lonidamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX08,pentostatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX10,masoprocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX11,estramustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX16,mitoguazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX18,tiazofurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX23,mitotane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX24,pegaspargase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX27,arsenic trioxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX29,denileukin diftitox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX33,celecoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX35,anagrelide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX36,oblimersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX40,omacetaxine mepesuccinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX41,eribulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX44,aflibercept,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX52,venetoclax,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX53,vosaroxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX57,plitidepsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX58,epacadostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX59,enasidenib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX62,ivosidenib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX66,selinexor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX67,tagraxofusp,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX69,lurbinectedin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX72,tazemetostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX73,sotorasib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX74,belzutifan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX75,tebentafusp,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX77,adagrasib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX78,navitoclax,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX79,eflornithine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX80,imetelstat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XY,Combinations of antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XY01,cytarabine and daunorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA01,diethylstilbestrol,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA02,polyestradiol phosphate,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA03,ethinylestradiol,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA04,fosfestrol,0.25,0.25,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AB,Progestogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AB01,megestrol,0.16,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AB,Progestogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AB02,medroxyprogesterone,1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AB,Progestogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AB03,gestonorone,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE01,buserelin,NA,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,1.2,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.11,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE02,leuprorelin,NA,0.134,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot inj,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE02,leuprorelin,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,60,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE03,goserelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.129,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE04,triptorelin,NA,0.134,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot inj,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE04,triptorelin,NA,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE05,histrelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.137,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE51,leuprorelin and bicalutamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AX,Other hormones,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA01,tamoxifen,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA02,toremifene,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA03,fulvestrant,NA,8.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA04,elacestrant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB01,flutamide,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB02,nilutamide,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB03,bicalutamide,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB04,enzalutamide,0.16,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB05,apalutamide,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB06,darolutamide,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG01,aminoglutethimide,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG02,formestane,NA,18,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG03,anastrozole,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG04,letrozole,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG05,vorozole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG06,exemestane,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX01,abarelix,NA,3.6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX02,degarelix,NA,2.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX03,abiraterone,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX04,relugolix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX53,abiraterone and prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA02,filgrastim,NA,0.35,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA03,molgramostim,NA,0.35,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA09,sargramostim,NA,0.45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA10,lenograstim,NA,0.35,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA12,ancestim,NA,1.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA13,pegfilgrastim,NA,0.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA14,lipegfilgrastim,NA,0.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA15,balugrastim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA16,empegfilgrastim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA17,pegteograstim,NA,0.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA18,efbemalenograstim alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA19,eflapegrastim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB01,interferon alfa natural,NA,2,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB02,interferon beta natural,NA,33.33,NA,NA,NA,NA,NA,TU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB03,interferon gamma,NA,40,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB04,interferon alfa-2a,NA,2,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB05,interferon alfa-2b,NA,2,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB06,interferon alfa-n1,NA,5,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB07,interferon beta-1a,NA,4.3,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB08,interferon beta-1b,NA,4,NA,NA,NA,NA,NA,MU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB09,interferon alfacon-1,NA,4,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB10,peginterferon alfa-2b,NA,7.5,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB11,peginterferon alfa-2a,NA,26,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB12,albinterferon alfa-2b,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB13,peginterferon beta-1a,NA,8.9,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB14,cepeginterferon alfa-2b,NA,17,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB15,ropeginterferon alfa-2b,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB16,peginterferon alfacon-2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB17,sampeginterferon beta-1a,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB60,"peginterferon alfa-2b, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB61,"peginterferon alfa-2a, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AC,Interleukins,The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per treatment cycle of 33 days.,L03AC01,aldesleukin,NA,0.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AC,Interleukins,The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per treatment cycle of 33 days.,L03AC02,oprelvekin,NA,3.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX01,lentinan,0.3,0.3,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX02,roquinimex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX03,BCG vaccine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.8,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX04,pegademase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX05,pidotimod,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX07,poly I:C,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX08,poly ICLC,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX09,thymopentin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX10,immunocyanin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX11,tasonermin,NA,3.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX12,melanoma vaccine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX13,glatiramer acetate,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX14,histamine dihydrochloride,NA,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX15,mifamurtide,NA,0.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX16,plerixafor,NA,16.8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX17,sipuleucel-T,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX18,cridanimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX19,dasiprotimut-T,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX21,elapegademase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX22,leniolisib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA03,antilymphocyte immunoglobulin (horse),NA,1.05,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA04,antithymocyte immunoglobulin (rabbit),NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA06,mycophenolic acid,2,2,NA,NA,NA,NA,g,g,NA,NA,NA,as mycophenolate mofetil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA15,alefacept,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA19,gusperimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA22,abetimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA24,abatacept,NA,27,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA28,belatacept,NA,12.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA32,apremilast,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA40,cladribine,0.34,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA41,imlifidase,NA,17.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA48,belumosudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA58,efgartigimod alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB01,etanercept,NA,7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB02,infliximab,NA,3.75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB03,afelimomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB04,adalimumab,NA,2.9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB05,certolizumab pegol,NA,14,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB06,golimumab,NA,1.66,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB07,opinercept,NA,7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC01,daclizumab,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC02,basiliximab,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC03,anakinra,NA,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC04,rilonacept,NA,23,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC05,ustekinumab,NA,0.54,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC07,tocilizumab,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC08,canakinumab,NA,2.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC09,briakinumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC10,secukinumab,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC11,siltuximab,NA,37,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC12,brodalumab,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC13,ixekizumab,NA,2.9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC14,sarilumab,NA,14.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC15,sirukumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC16,guselkumab,NA,1.79,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC17,tildrakizumab,NA,1.11,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC18,risankizumab,NA,1.67,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC19,satralizumab,NA,4.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC20,netakimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC21,bimekizumab,NA,5.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC22,spesolimab,NA,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC23,olokizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC24,mirikizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC25,levilimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AD,Calcineurin inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AD01,ciclosporin,0.25,0.25,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AD,Calcineurin inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AD02,tacrolimus,5,5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AD,Calcineurin inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AD03,voclosporin,47.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE01,fingolimod,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE02,ozanimod,0.92,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE03,siponimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE04,ponesimod,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE05,etrasimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF01,tofacitinib,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF02,baricitinib,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF03,upadacitinib,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF04,filgotinib,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF05,itacitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF06,peficitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF07,deucravacitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF08,ritlecitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG01,muromonab-CD3,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG02,efalizumab,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG03,natalizumab,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG04,belimumab,NA,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG05,vedolizumab,NA,5.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG06,alemtuzumab,NA,0.13,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG07,begelomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG08,ocrelizumab,NA,3.29,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG09,emapalumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG10,inebilizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG11,anifrolumab,NA,10.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG12,ofatumumab,NA,0.67,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG13,teprotumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG14,ublituximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG15,divozilimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG16,rozanolixizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AH,Mammalian target of rapamycin (mTOR) kinase inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AH01,sirolimus,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AH,Mammalian target of rapamycin (mTOR) kinase inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AH02,everolimus,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ01,eculizumab,NA,64,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ02,ravulizumab,NA,58.9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ03,pegcetacoplan,NA,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ04,sutimlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ05,avacopan,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ06,zilucoplan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ07,crovalimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ08,iptacopan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ09,danicopan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AK,Dihydroorotate dehydrogenase (DHODH) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for leflunomide is based on the treatment of rheumatoid arthritis.The DDD for teriflunomide is based on the treatment of multiple sclerosis.,L04AK01,leflunomide,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AK,Dihydroorotate dehydrogenase (DHODH) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for leflunomide is based on the treatment of rheumatoid arthritis.The DDD for teriflunomide is based on the treatment of multiple sclerosis.,L04AK02,teriflunomide,14,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX01,azathioprine,0.15,0.15,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX02,thalidomide,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX03,methotrexate,2.5,2.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX04,lenalidomide,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX05,pirfenidone,2.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX06,pomalidomide,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX07,dimethyl fumarate,0.48,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX08,darvadstrocel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX09,diroximel fumarate,0.924,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AA,Butylpyrazolidines,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AA01,phenylbutazone,0.3,0.3,0.3,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AA,Butylpyrazolidines,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AA02,mofebutazone,0.75,0.75,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AA,Butylpyrazolidines,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AA03,oxyphenbutazone,0.3,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AA,Butylpyrazolidines,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AA05,clofezone,0.6,NA,0.6,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AA,Butylpyrazolidines,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AA06,kebuzone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB01,indometacin,0.1,0.1,0.1,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB02,sulindac,0.4,0.4,0.4,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB03,tolmetin,0.7,NA,0.7,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB04,zomepirac,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB05,diclofenac,0.1,0.1,0.1,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB06,alclofenac,1.25,NA,1.25,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB07,bumadizone,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB08,etodolac,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB09,lonazolac,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB10,fentiazac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB11,acemetacin,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB12,difenpiramide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB13,oxametacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB14,proglumetacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB15,ketorolac,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB16,aceclofenac,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB17,bufexamac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB51,"indometacin, combinations",0.1,NA,0.1,NA,NA,NA,g,NA,g,NA,NA,Refers to indometacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AB,Acetic acid derivatives and related substances,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AB55,"diclofenac, combinations",0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to diclofenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AC,Oxicams,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for meloxicam is based on the treatment of osteoarthritis.",M01AC01,piroxicam,20,20,20,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AC,Oxicams,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for meloxicam is based on the treatment of osteoarthritis.",M01AC02,tenoxicam,20,20,20,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AC,Oxicams,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for meloxicam is based on the treatment of osteoarthritis.",M01AC04,droxicam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AC,Oxicams,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for meloxicam is based on the treatment of osteoarthritis.",M01AC05,lornoxicam,12,12,12,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AC,Oxicams,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for meloxicam is based on the treatment of osteoarthritis.",M01AC06,meloxicam,15,15,15,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AC,Oxicams,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for meloxicam is based on the treatment of osteoarthritis.",M01AC56,"meloxicam, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE01,ibuprofen,1.2,1.2,1.2,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE02,naproxen,0.5,NA,0.5,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE03,ketoprofen,0.15,0.15,0.15,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE04,fenoprofen,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE05,fenbufen,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE06,benoxaprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE07,suprofen,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE08,pirprofen,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE09,flurbiprofen,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE10,indoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE11,tiaprofenic acid,0.6,NA,0.6,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE12,oxaprozin,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE13,ibuproxam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE14,dexibuprofen,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE15,flunoxaprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE16,alminoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE17,dexketoprofen,75,75,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE18,naproxcinod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE51,"ibuprofen, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE52,naproxen and esomeprazole,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to naproxen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE53,"ketoprofen, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE56,naproxen and misoprostol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AE,Propionic acid derivatives,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AE57,naproxen and diphenhydramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AG,Fenamates,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AG01,mefenamic acid,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AG,Fenamates,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AG02,tolfenamic acid,0.3,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AG,Fenamates,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AG03,flufenamic acid,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AG,Fenamates,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH).",M01AG04,meclofenamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH01,celecoxib,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH02,rofecoxib,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH03,valdecoxib,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH04,parecoxib,NA,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH05,etoricoxib,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH06,lumiracoxib,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AH,Coxibs,"The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDDs for the coxibs are based on the treatment of osteoarthritis.",M01AH07,polmacoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX01,nabumetone,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX02,niflumic acid,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX04,azapropazone,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX05,glucosamine,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to glucosamine sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX07,benzydamine,0.15,NA,0.15,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX12,glucosaminoglycan polysulfate,NA,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX13,proquazone,0.9,NA,0.9,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX14,orgotein,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX17,nimesulide,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX18,feprazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX21,diacerein,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX22,morniflumate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX23,tenidap,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX24,oxaceprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX25,chondroitin sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX26,"avocado and soyabean oil, unsaponifiables",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01A,"ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS",M01AX,"Other antiinflammatory and antirheumatic agents, non-steroids","The DDDs are based on the treatment of rheumatoid arthritis, except for the coxibs (M01AH). The DDD for glucosamine refers to glucosamine sulfate.",M01AX68,"feprazone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01B,ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION,M01BA,Antiinflammatory/antirheumatic agents in combination with corticosteroids,NA,M01BA01,phenylbutazone and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01B,ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION,M01BA,Antiinflammatory/antirheumatic agents in combination with corticosteroids,NA,M01BA02,dipyrocetyl and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01B,ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION,M01BA,Antiinflammatory/antirheumatic agents in combination with corticosteroids,NA,M01BA03,acetylsalicylic acid and corticosteroids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01B,ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION,M01BX,Other antiinflammatory/antirheumatic agents in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CA,Quinolines,The DDDs are based on the treatment of rheumatoid arthritis.,M01CA03,oxycinchophen,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CB,Gold preparations,The DDDs are based on the treatment of rheumatoid arthritis.,M01CB01,sodium aurothiomalate,NA,2.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CB,Gold preparations,The DDDs are based on the treatment of rheumatoid arthritis.,M01CB02,sodium aurotiosulfate,NA,14,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CB,Gold preparations,The DDDs are based on the treatment of rheumatoid arthritis.,M01CB03,auranofin,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CB,Gold preparations,The DDDs are based on the treatment of rheumatoid arthritis.,M01CB04,aurothioglucose,NA,2.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CB,Gold preparations,The DDDs are based on the treatment of rheumatoid arthritis.,M01CB05,aurotioprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CC,Penicillamine and similar agents,The DDDs are based on the treatment of rheumatoid arthritis.,M01CC01,penicillamine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CC,Penicillamine and similar agents,The DDDs are based on the treatment of rheumatoid arthritis.,M01CC02,bucillamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M01,ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS,M01C,SPECIFIC ANTIRHEUMATIC AGENTS,M01CX,Other specific antirheumatic agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA01,phenylbutazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA02,mofebutazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA03,clofezone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA04,oxyphenbutazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA05,benzydamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA06,etofenamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA07,piroxicam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA08,felbinac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA09,bufexamac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA10,ketoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA11,bendazac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA12,naproxen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA13,ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA14,fentiazac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA15,diclofenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA16,feprazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA17,niflumic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA18,meclofenamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA19,flurbiprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA21,tolmetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA22,suxibuzone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA23,indometacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA24,nifenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA25,aceclofenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA26,nimesulide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA27,dexketoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA28,piketoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA29,esflurbiprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AA,"Antiinflammatory preparations, non-steroids for topical use",No DDDs have been assigned in this group.,M02AA31,loxoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AB,Capsaicin and similar agents,No DDDs have been assigned in this group.,M02AB01,capsaicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AB,Capsaicin and similar agents,No DDDs have been assigned in this group.,M02AB02,zucapsaicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AC,Preparations with salicylic acid derivatives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AX,Other topical products for joint and muscular pain,No DDDs have been assigned in this group.,M02AX02,tolazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AX,Other topical products for joint and muscular pain,No DDDs have been assigned in this group.,M02AX03,dimethyl sulfoxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AX,Other topical products for joint and muscular pain,No DDDs have been assigned in this group.,M02AX05,idrocilamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AX,Other topical products for joint and muscular pain,No DDDs have been assigned in this group.,M02AX06,tolperisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M02,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02A,TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN,M02AX,Other topical products for joint and muscular pain,No DDDs have been assigned in this group.,M02AX10,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AA,Curare alkaloids,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AA01,alcuronium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AA,Curare alkaloids,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AA02,tubocurarine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AA,Curare alkaloids,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AA04,dimethyltubocurarine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AB,Choline derivatives,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AB01,suxamethonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC01,pancuronium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC02,gallamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC03,vecuronium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC04,atracurium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC05,hexafluronium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC06,pipecuronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC07,doxacurium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC08,fazadinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC09,rocuronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC10,mivacurium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AC,Other quaternary ammonium compounds,"As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AC11,cisatracurium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03A,"MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS",M03AX,"Other muscle relaxants, peripherally acting agents","As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.",M03AX01,botulinum toxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA01,phenprobamate,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA02,carisoprodol,1.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA03,methocarbamol,3,3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA04,styramate,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA05,febarbamate,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA51,"phenprobamate, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA52,"carisoprodol, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA53,"methocarbamol, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA71,"phenprobamate, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA72,"carisoprodol, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BA,Carbamic acid esters,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BA73,"methocarbamol, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BB,"Oxazol, thiazine, and triazine derivatives","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BB02,chlormezanone,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BB,"Oxazol, thiazine, and triazine derivatives","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BB03,chlorzoxazone,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BB,"Oxazol, thiazine, and triazine derivatives","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BB52,"chlormezanone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BB,"Oxazol, thiazine, and triazine derivatives","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BB53,"chlorzoxazone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BB,"Oxazol, thiazine, and triazine derivatives","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BB72,"chlormezanone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BB,"Oxazol, thiazine, and triazine derivatives","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BB73,"chlorzoxazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BC,"Ethers, chemically close to antihistamines","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BC01,orphenadrine (citrate),0.12,0.12,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BC,"Ethers, chemically close to antihistamines","These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BC51,"orphenadrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX01,baclofen,50,0.55,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX02,tizanidine,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX03,pridinol,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX04,tolperisone,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX05,thiocolchicoside,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX06,mephenesin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX07,tetrazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX08,cyclobenzaprine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX09,eperisone,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX30,fenyramidol,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX53,"pridinol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03B,"MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS",M03BX,Other centrally acting agents,"These drugs are used in different conditions associated with pain and rigidity in the muscles, joints etc.DDDs for combination products, see list on the website www.whocc.no.",M03BX55,"thiocolchicoside, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M03,MUSCLE RELAXANTS,M03C,"MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS",M03CA,Dantrolene and derivatives,The DDD of dantrolene is based on the treatment of spasticity after spinal injury.,M03CA01,dantrolene,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AA,Preparations inhibiting uric acid production,The DDDs are based on prophylaxis.,M04AA01,allopurinol,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AA,Preparations inhibiting uric acid production,The DDDs are based on prophylaxis.,M04AA02,tisopurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AA,Preparations inhibiting uric acid production,The DDDs are based on prophylaxis.,M04AA03,febuxostat,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AA,Preparations inhibiting uric acid production,The DDDs are based on prophylaxis.,M04AA51,"allopurinol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AB,Preparations increasing uric acid excretion,The DDDs are based on prophylaxis.,M04AB01,probenecid,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AB,Preparations increasing uric acid excretion,The DDDs are based on prophylaxis.,M04AB02,sulfinpyrazone,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AB,Preparations increasing uric acid excretion,The DDDs are based on prophylaxis.,M04AB03,benzbromarone,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AB,Preparations increasing uric acid excretion,The DDDs are based on prophylaxis.,M04AB04,isobromindione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AB,Preparations increasing uric acid excretion,The DDDs are based on prophylaxis.,M04AB05,lesinurad,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AC,Preparations with no effect on uric acid metabolism,The DDDs are based on prophylaxis.,M04AC01,colchicine,1,1,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AC,Preparations with no effect on uric acid metabolism,The DDDs are based on prophylaxis.,M04AC02,cinchophen,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AC,Preparations with no effect on uric acid metabolism,The DDDs are based on prophylaxis.,M04AC51,colchicine and probenecid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AX,Other antigout preparations,The DDDs are based on prophylaxis.,M04AX01,urate oxidase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M04,ANTIGOUT PREPARATIONS,M04A,ANTIGOUT PREPARATIONS,M04AX,Other antigout preparations,The DDDs are based on prophylaxis.,M04AX02,pegloticase,NA,0.57,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA01,etidronic acid,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA01,etidronic acid,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA02,clodronic acid,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA02,clodronic acid,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA03,pamidronic acid,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA04,alendronic acid,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA05,tiludronic acid,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA06,ibandronic acid,NA,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA06,ibandronic acid,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA07,risedronic acid,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BA,Bisphosphonates,"The DDDs for the bisphosphonates are based on the treatment of osteoporosis if this is an approved indication.The DDDs for clodronic acid, pamidronic acid, zoledronic acid, parenteral etidronic acid and parenteral ibandronic acid are based on tumor induced hypercalcemia. The oral DDD for ibandronic acid is based on osteoporosis.  Since the duration of the intravenous treatment courses with the bisphosphonates are varying, from 1-5 days, the DDDs for these parenteral formulations are assigned according to the total course dose.  The DDDs for the oral formulations, which are mainly used for maintenance therapy, are assigned according to daily dosages.The DDD for tiludronic acid is based on the treatment of Pagets disease.",M05BA08,zoledronic acid,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,course dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB01,"etidronic acid and calcium, sequential",0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to etidronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB02,"risedronic acid and calcium, sequential",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB03,alendronic acid and colecalciferol,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to alendronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB04,"risedronic acid, calcium and colecalciferol, sequential",5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to risedronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB05,"alendronic acid, calcium and colecalciferol, sequential",10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to alendronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB06,"alendronic acid and alfacalcidol, sequential",10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to alendronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB07,risedronic acid and colecalciferol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB08,"zoledronic acid, calcium and colecalciferol, sequential",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BB,"Bisphosphonates, combinations",NA,M05BB09,ibandronic acid and colecalciferol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BC,Bone morphogenetic proteins,NA,M05BC01,dibotermin alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BC,Bone morphogenetic proteins,NA,M05BC02,eptotermin alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX01,ipriflavone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX02,aluminium chlorohydrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX03,strontium ranelate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX04,denosumab,NA,0.33,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX05,burosumab,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX06,romosozumab,NA,7,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX07,vosoritide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX08,menatetrenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M05,DRUGS FOR TREATMENT OF BONE DISEASES,M05B,DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION,M05BX,Other drugs affecting bone structure and mineralization,The DDD for denosumab is based on the treatment of osteoporosis.,M05BX53,strontium ranelate and colecalciferol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AA,Quinine and derivatives,NA,M09AA01,hydroquinine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AA,Quinine and derivatives,NA,M09AA72,"quinine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AB,Enzymes,NA,M09AB01,chymopapain,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AB,Enzymes,NA,M09AB02,collagenase clostridium histolyticum,NA,0.9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AB,Enzymes,NA,M09AB03,bromelains,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AB,Enzymes,NA,M09AB52,"trypsin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX01,hyaluronic acid,NA,3.6,NA,NA,NA,NA,NA,mg,NA,NA,NA,intraarticular,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX02,"chondrocytes, autologous",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX03,ataluren,2.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX04,drisapersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX05,aceneuramic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX06,eteplirsen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX07,nusinersen,NA,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX08,golodirsen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX09,onasemnogene abeparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX10,risdiplam,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX11,palovarotene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX12,viltolarsen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX13,casimersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX14,givinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
M,MUSCULO-SKELETAL SYSTEM,M09,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09A,OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM,M09AX,Other drugs for disorders of the musculo-skeletal system,The DDD for hyaluronic acid is based on intraarticular treatment of arthritis.  The DDD is assigned according to daily dose even if the product is given as weekly injections.,M09AX15,delandistrogene moxeparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AA,Ethers,No DDDs have been established in this group because the doses used vary substantially.,N01AA01,diethyl ether,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AA,Ethers,No DDDs have been established in this group because the doses used vary substantially.,N01AA02,vinyl ether,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB01,halothane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB02,chloroform,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB04,enflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB05,trichloroethylene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB06,isoflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB07,desflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AB,Halogenated hydrocarbons,No DDDs have been established in this group because the doses used vary substantially.,N01AB08,sevoflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AF,"Barbiturates, plain",No DDDs have been established in this group because the doses used vary substantially.,N01AF01,methohexital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AF,"Barbiturates, plain",No DDDs have been established in this group because the doses used vary substantially.,N01AF02,hexobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AF,"Barbiturates, plain",No DDDs have been established in this group because the doses used vary substantially.,N01AF03,thiopental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AG,Barbiturates in combination with other drugs,No DDDs have been established in this group because the doses used vary substantially.,N01AG01,narcobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH01,fentanyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH02,alfentanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH03,sufentanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH04,phenoperidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH05,anileridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH06,remifentanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AH,Opioid anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AH51,"fentanyl, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX03,ketamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX04,propanidid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX05,alfaxalone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX07,etomidate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX10,propofol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX11,sodium oxybate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX13,nitrous oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX14,esketamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX15,xenon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01A,"ANESTHETICS, GENERAL",N01AX,Other general anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01AX63,"nitrous oxide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA01,metabutethamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA02,procaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA03,tetracaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA04,chloroprocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA05,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA52,"procaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BA,Esters of aminobenzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BA53,"tetracaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB01,bupivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB02,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB03,mepivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB04,prilocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB05,butanilicaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB06,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB07,etidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB08,articaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB09,ropivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB10,levobupivacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB51,"bupivacaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB52,"lidocaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB53,"mepivacaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB54,"prilocaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB57,"etidocaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB58,"articaine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BB,Amides,No DDDs have been established in this group because the doses used vary substantially.,N01BB59,bupivacaine and meloxicam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BC,Esters of benzoic acid,No DDDs have been established in this group because the doses used vary substantially.,N01BC01,cocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX01,ethyl chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX02,dyclonine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX03,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N01,ANESTHETICS,N01B,"ANESTHETICS, LOCAL",N01BX,Other local anesthetics,No DDDs have been established in this group because the doses used vary substantially.,N01BX04,capsaicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA01,morphine,0.1,30,30,NA,NA,NA,g,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA02,opium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA03,hydromorphone,20,4,4,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA04,nicomorphine,30,30,30,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA05,oxycodone,75,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA08,dihydrocodeine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA10,papaveretum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA11,oxymorphone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA51,"morphine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA53,hydromorphone and naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA55,oxycodone and naloxone,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to oxycodone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA56,oxycodone and naltrexone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA58,"dihydrocodeine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA59,"codeine, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AA,Natural opium alkaloids,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AA79,"codeine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB01,ketobemidone,50,50,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB02,pethidine,0.4,0.4,0.4,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB03,fentanyl,NA,NA,NA,0.6,1.2,NA,NA,NA,NA,mg,mg,NA,NA,0.6,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB52,"pethidine, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AB,Phenylpiperidine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The transdermal DDD for fentanyl is based on the amount delivered per 24 hours.,N02AB72,"pethidine, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC01,dextromoramide,20,20,40,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC03,piritramide,NA,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC04,dextropropoxyphene,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC04,dextropropoxyphene,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,napsylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC05,bezitramide,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC52,"methadone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC54,"dextropropoxyphene, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AC,Diphenylpropylamine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. Different DDDs are assigned for different dextropropoxyphene salts based on their different solubility.,N02AC74,"dextropropoxyphene, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AD,Benzomorphan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AD01,pentazocine,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AD,Benzomorphan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AD02,phenazocine,NA,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AD,Benzomorphan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AD51,pentazocine and naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AE,Oripavine derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AE01,buprenorphine,NA,1.2,NA,1.2,1.2,NA,NA,mg,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AF,Morphinan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AF01,butorphanol,NA,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AF,Morphinan derivatives,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AF02,nalbuphine,NA,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG01,morphine and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG02,ketobemidone and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG03,pethidine and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AG,Opioids in combination with antispasmodics,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs in this group are as far as possible equipotent to the DDD for parenteral morphine.,N02AG04,hydromorphone and antispasmodics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ01,dihydrocodeine and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ02,dihydrocodeine and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ03,dihydrocodeine and other non-opioid analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ06,codeine and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ07,codeine and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ08,codeine and ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ09,codeine and other non-opioid analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ13,tramadol and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ14,tramadol and dexketoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ15,tramadol and other non-opioid analgesics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ16,tramadol and celecoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ17,oxycodone and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ18,oxycodone and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ19,oxycodone and ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ22,hydrocodone and paracetamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AJ,Opioids in combination with non-opioid analgesics,"The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability. The DDDs are based on approved dose recommendations.When establishing DDDs for combination products all analgesic components are taken into consideration.The DDD, expressed in UD, should normally not exceed the approved dose recommendations for any of the components.See list of DDDs for combination products, www.whocc.no.",N02AJ23,hydrocodone and ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX01,tilidine,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX02,tramadol,0.3,0.3,0.3,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX03,dezocine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX05,meptazinol,1.2,1.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX06,tapentadol,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX07,oliceridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02A,OPIOIDS,N02AX,Other opioids,The DDDs in this group are based on the treatment of pain.The DDD for oral morphine is higher than the parenteral DDD because of lower bioavailability.,N02AX51,tilidine and naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA01,acetylsalicylic acid,NA,1,NA,NA,NA,NA,NA,g,NA,NA,NA,Expressed as lysine acetylsalisylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA01,acetylsalicylic acid,3,NA,3,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA02,aloxiprin,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA03,choline salicylate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA04,sodium salicylate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA05,salicylamide,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA06,salsalate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA07,ethenzamide,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA08,morpholine salicylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA09,dipyrocetyl,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA10,benorilate,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA11,diflunisal,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA12,potassium salicylate,7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA14,guacetisal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA15,carbasalate calcium,3.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA16,imidazole salicylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA51,"acetylsalicylic acid, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA55,"salicylamide, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA57,"ethenzamide, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA59,"dipyrocetyl, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA65,carbasalate calcium combinations excl. psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA67,"magnesium salicylate, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA71,"acetylsalicylic acid, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA75,"salicylamide, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA77,"ethenzamide, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BA,Salicylic acid and derivatives,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDDs are based on the treatment of pain and not on use in rheumatic diseases.DDDs for combined preparations, see N02B.",N02BA79,"dipyrocetyl, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB01,phenazone,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB02,metamizole sodium,3,3,3,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB03,aminophenazone,NA,NA,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB04,propyphenazone,NA,NA,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB05,nifenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB51,"phenazone, combinations excl. psycholeptics",3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to phenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB52,"metamizole sodium, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB53,"aminophenazone, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB54,"propyphenazone, combinations excl. psycholeptics",3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to propyphenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB71,"phenazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB72,"metamizole sodium, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB73,"aminophenazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BB,Pyrazolones,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BB74,"propyphenazone, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE01,paracetamol,3,3,3,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE03,phenacetin,1.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE04,bucetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE05,propacetamol,NA,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE51,"paracetamol, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE53,"phenacetin, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE54,"bucetin, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE71,"paracetamol, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE73,"phenacetin, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BE,Anilides,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BE74,"bucetin, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BF,Gabapentinoids,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BF01,gabapentin,1.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BF,Gabapentinoids,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BF02,pregabalin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BF,Gabapentinoids,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no.",N02BF03,mirogabalin,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG02,rimazolium,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG03,glafenine,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG04,floctafenine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG05,viminol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG06,nefopam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG07,flupirtine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG08,ziconotide,NA,12,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG09,methoxyflurane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG10,cannabinoids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02B,OTHER ANALGESICS AND ANTIPYRETICS,N02BG,Other analgesics and antipyretics,"The DDDs are based on approved dose recommendations.When establishing DDDs for combination products in the 50-series, all analgesic components are taken into consideration.The DDD expressed in UD, should normally not exceed the approved dose recommendations for any of the components. See list of DDDs for combinations products, www.whocc.no. The DDD for ziconotide is based on intrathecal administration.DDDs established for products classified in N02BG10 - cannabinoids are available on the list of DDDs for combinations on the website www.whocc.no.",N02BG12,tanezumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA01,dihydroergotamine,4,4,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,1,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA02,ergotamine,4,4,4,4,NA,NA,mg,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,NA,NA,mg,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA04,methysergide,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA07,lisuride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA51,"dihydroergotamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA52,"ergotamine, combinations excl. psycholeptics",4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to ergotamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CA,Ergot alkaloids,"The DDD for ergotamine is based on the treatment of acute migraine attacks, whereas the DDDs for dihydroergotamine and methysergide are based on prophylaxis.The DDD for dihydroergotamine nasal spray is based on the treatment of acute migraine attacks.",N02CA72,"ergotamine, combinations with psycholeptics",4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to ergotamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CB,Corticosteroid derivatives,The DDDs for corticosteroid derivatives are based on prophylaxis of migraine.,N02CB01,flumedroxone,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC01,sumatriptan,50,6,25,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,20,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC02,naratriptan,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC03,zolmitriptan,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,2.5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC04,rizatriptan,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC05,almotriptan,12.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC06,eletriptan,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC07,frovatriptan,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC08,lasmiditan,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CC,Selective serotonin (5HT1) agonists,The DDDs for the selective serotonin (5HT1) agonists are based on the recommended initial dose in acute attacks of migraine.,N02CC51,sumatriptan and naproxen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD01,erenumab,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD02,galcanezumab,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD03,fremanezumab,NA,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD04,ubrogepant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD05,eptinezumab,NA,1.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD06,rimegepant,37.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CD,Calcitonin gene-related peptide (CGRP) antagonists,The DDDs for the CGRP antagonists are based on the prophylaxis of migraine.,N02CD07,atogepant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX01,pizotifen,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX02,clonidine,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX03,iprazochrome,24,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX05,dimetotiazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N02,ANALGESICS,N02C,ANTIMIGRAINE PREPARATIONS,N02CX,Other antimigraine preparations,The DDDs for the substances in this group are based on the prophylaxis of migraine.,N02CX06,oxetorone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA01,methylphenobarbital,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA02,phenobarbital,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA03,primidone,1.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA04,barbexaclone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AA,Barbiturates and derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AA30,metharbital,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB01,ethotoin,2.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB02,phenytoin,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB03,amino(diphenylhydantoin) valeric acid,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB04,mephenytoin,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB05,fosphenytoin,NA,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB52,"phenytoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AB,Hydantoin derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AB54,"mephenytoin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AC,Oxazolidine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AC01,paramethadione,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AC,Oxazolidine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AC02,trimethadione,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AC,Oxazolidine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AC03,ethadione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD01,ethosuximide,1.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD02,phensuximide,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD03,mesuximide,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AD,Succinimide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AD51,"ethosuximide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AE,Benzodiazepine derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AE01,clonazepam,8,8,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF01,carbamazepine,1,NA,1,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF02,oxcarbazepine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF03,rufinamide,1.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AF,Carboxamide derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AF04,eslicarbazepine,0.8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG01,valproic acid,1.5,1.5,1.5,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG02,valpromide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG03,aminobutyric acid,1,1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG04,vigabatrin,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG05,progabide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AG,Fatty acid derivatives,The DDDs for the antiepileptics are based on combination therapy.,N03AG06,tiagabine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX03,sultiame,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX07,phenacemide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX09,lamotrigine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX10,felbamate,2.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX11,topiramate,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX13,pheneturide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX14,levetiracetam,1.5,1.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX15,zonisamide,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX17,stiripentol,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX18,lacosamide,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX19,carisbamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX21,retigabine,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX22,perampanel,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX23,brivaracetam,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX24,cannabidiol,0.7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX25,cenobamate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX26,fenfluramine,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX27,ganaxolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N03,ANTIEPILEPTICS,N03A,ANTIEPILEPTICS,N03AX,Other antiepileptics,The DDDs for the antiepileptics are based on combination therapy. The DDDs for stiripentol and fenfluramine are based on the treatment of children with a bodyweight of 20 kg.,N03AX30,beclamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA01,trihexyphenidyl,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA02,biperiden,10,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA03,metixene,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA04,procyclidine,25,25,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA05,profenamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA08,dexetimide,0.5,0.125,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA09,phenglutarimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA10,mazaticol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA11,bornaprine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AA,Tertiary amines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AA12,tropatepine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AB,Ethers chemically close to antihistamines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AB01,etanautine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AB,Ethers chemically close to antihistamines,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AB02,orphenadrine (chloride),0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AC,Ethers of tropine or tropine derivatives,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AC01,benzatropine,2,2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04A,ANTICHOLINERGIC AGENTS,N04AC,Ethers of tropine or tropine derivatives,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04AC30,etybenzatropine,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA01,levodopa,3.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA02,levodopa and decarboxylase inhibitor,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to levodopa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA03,"levodopa, decarboxylase inhibitor and COMT inhibitor",0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to levodopa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA04,melevodopa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA05,melevodopa and decarboxylase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA06,etilevodopa and decarboxylase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BA,Dopa and dopa derivatives,"The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations. The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.",N04BA07,foslevodopa and decarboxylase inhibitor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BB,Adamantane derivatives,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BB01,amantadine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC01,bromocriptine,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC02,pergolide,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC03,dihydroergocryptine mesylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC04,ropinirole,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC05,pramipexole,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,hydrochloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC06,cabergoline,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC07,apomorphine,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC08,piribedil,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BC,Dopamine agonists,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BC09,rotigotine,NA,NA,NA,NA,6,NA,NA,NA,NA,NA,mg,patch,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BD,Monoamine oxidase B inhibitors,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BD01,selegiline,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BD,Monoamine oxidase B inhibitors,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BD02,rasagiline,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BD,Monoamine oxidase B inhibitors,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BD03,safinamide,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX01,tolcapone,0.45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX02,entacapone,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX03,budipine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04B,DOPAMINERGIC AGENTS,N04BX,Other dopaminergic agents,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04BX04,opicapone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N04,ANTI-PARKINSON DRUGS,N04C,OTHER ANTIPARKINSON DRUGS,N04CX,Other antiparkinson drugs,The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.No separate DDDs are established for oral depot formulations.,N04CX01,istradefylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA01,chlorpromazine,0.3,0.1,0.3,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA02,levomepromazine,0.3,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA03,promazine,0.3,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA04,acepromazine,0.1,50,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA05,triflupromazine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA06,cyamemazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AA,Phenothiazines with aliphatic side-chain,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AA07,chlorproethazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB01,dixyrazine,50,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB02,fluphenazine,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB02,fluphenazine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB03,perphenazine,NA,7,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB03,perphenazine,30,10,16,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB04,prochlorperazine,0.1,50,0.1,NA,NA,NA,g,mg,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB05,thiopropazate,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB06,trifluoperazine,20,8,20,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB07,acetophenazine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB08,thioproperazine,75,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB09,butaperazine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AB,Phenothiazines with piperazine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AB10,perazine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC01,periciazine,50,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC02,thioridazine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC03,mesoridazine,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC04,pipotiazine,NA,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AC,Phenothiazines with piperidine structure,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AC04,pipotiazine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD01,haloperidol,NA,3.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD01,haloperidol,8,8,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD02,trifluperidol,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD03,melperone,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD04,moperone,20,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD05,pipamperone,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD06,bromperidol,NA,3.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD06,bromperidol,10,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD07,benperidol,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD08,droperidol,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD09,fluanisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AD,Butyrophenone derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD for parenteral droperidol is based on treatment of post-operative nausea and vomiting.",N05AD10,lumateperone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE01,oxypertine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE02,molindone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE03,sertindole,16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE04,ziprasidone,80,40,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AE,Indole derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AE05,lurasidone,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,as hydrochloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF01,flupentixol,NA,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF01,flupentixol,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF02,clopenthixol,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF03,chlorprothixene,0.3,50,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF04,tiotixene,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF05,zuclopenthixol,NA,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AF,Thioxanthene derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AF05,zuclopenthixol,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AG,Diphenylbutylpiperidine derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AG01,fluspirilene,NA,0.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AG,Diphenylbutylpiperidine derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AG02,pimozide,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AG,Diphenylbutylpiperidine derivatives,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AG03,penfluridol,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH01,loxapine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,delivered dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9.1,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH01,loxapine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH02,clozapine,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH03,olanzapine,NA,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH03,olanzapine,10,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH04,quetiapine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH05,asenapine,NA,NA,NA,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH06,clotiapine,80,80,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AH,"Diazepines, oxazepines, thiazepines and oxepines","The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AH53,olanzapine and samidorphan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL01,sulpiride,0.8,0.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL02,sultopride,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL03,tiapride,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL04,remoxipride,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL05,amisulpride,0.4,7.5,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL06,veralipride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AL,Benzamides,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AL07,levosulpiride,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AN,Lithium,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval. The DDD is based on the prophylaxis of mania or depression.",N05AN01,lithium,24,NA,NA,NA,NA,NA,mmol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX07,prothipendyl,0.24,0.24,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX08,risperidone,NA,2.7,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX08,risperidone,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX10,mosapramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX11,zotepine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX12,aripiprazole,NA,13.3,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX12,aripiprazole,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX13,paliperidone,NA,2.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,depot    Expressed as paliperidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX13,paliperidone,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX14,iloperidone,18,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX15,cariprazine,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX16,brexpiprazole,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05A,ANTIPSYCHOTICS,N05AX,Other antipsychotics,"The DDDs are based on the treatment of psychosis.  The substances in this group are sometimes used for other indications in much lower doses.For depot injections, the DDDs are based on the average recommended doses divided by the dosing interval.",N05AX17,pimavanserin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA01,diazepam,10,10,10,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA02,chlordiazepoxide,30,50,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA03,medazepam,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA04,oxazepam,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA05,potassium clorazepate,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA06,lorazepam,2.5,2.5,NA,2.5,NA,NA,mg,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA07,adinazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA08,bromazepam,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA09,clobazam,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA10,ketazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA11,prazepam,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA12,alprazolam,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA13,halazepam,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA14,pinazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA15,camazepam,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA16,nordazepam,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA17,fludiazepam,0.75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA18,ethyl loflazepate,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA19,etizolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA21,clotiazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA22,cloxazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA23,tofisopam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA24,bentazepam,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA25,mexazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BA,Benzodiazepine derivatives,The DDDs are based on the treatment of anxiety. The parenteral DDD for chlordiazepoxide is higher than the oral DDD due to lower bioavailability for intramuscular injections.,N05BA56,"lorazepam, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BB,Diphenylmethane derivatives,The DDDs are based on the treatment of anxiety.,N05BB01,hydroxyzine,75,75,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BB,Diphenylmethane derivatives,The DDDs are based on the treatment of anxiety.,N05BB02,captodiame,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BB,Diphenylmethane derivatives,The DDDs are based on the treatment of anxiety.,N05BB51,"hydroxyzine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC01,meprobamate,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC03,emylcamate,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC04,mebutamate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BC,Carbamates,The DDDs are based on the treatment of anxiety.,N05BC51,"meprobamate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BD,Dibenzo-bicyclo-octadiene derivatives,The DDDs are based on the treatment of anxiety.,N05BD01,benzoctamine,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BE,Azaspirodecanedione derivatives,The DDDs are based on the treatment of anxiety.,N05BE01,buspirone,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX01,mephenoxalone,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX02,gedocarnil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX03,etifoxine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX04,fabomotizole,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05B,ANXIOLYTICS,N05BX,Other anxiolytics,The DDDs are based on the treatment of anxiety.,N05BX05,Lavandulae aetheroleum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA01,pentobarbital,0.1,0.1,0.1,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA02,amobarbital,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA03,butobarbital,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA04,barbital,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA05,aprobarbital,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA06,secobarbital,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA07,talbutal,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA08,vinylbital,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA09,vinbarbital,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA10,cyclobarbital,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA11,heptabarbital,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA12,reposal,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA15,methohexital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA16,hexobarbital,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA19,thiopental,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA20,etallobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA21,allobarbital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CA,"Barbiturates, plain",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CA22,proxibarbal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CB,"Barbiturates, combinations",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CB01,combinations of barbiturates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CB,"Barbiturates, combinations",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CB02,barbiturates in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC01,chloral hydrate,1,NA,1,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC02,chloralodol,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC03,acetylglycinamide chloral hydrate,1.7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC04,dichloralphenazone,1.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CC,Aldehydes and derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CC05,paraldehyde,5,5,5,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD01,flurazepam,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD02,nitrazepam,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD03,flunitrazepam,1,1,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD04,estazolam,3,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD05,triazolam,0.25,NA,NA,0.2,NA,NA,mg,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD06,lormetazepam,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD07,temazepam,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD08,midazolam,15,15,NA,10,NA,NA,mg,mg,NA,mg,NA,NA,NA,5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD09,brotizolam,0.25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD10,quazepam,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD11,loprazolam,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD12,doxefazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD13,cinolazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD14,remimazolam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CD,Benzodiazepine derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDDs for nasal and sublingual formulations (oromucosal administration) of midazolam are based on acute treatment of seizures in patients with epilepsy.,N05CD15,nimetazepam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CE,Piperidinedione derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CE01,glutethimide,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CE,Piperidinedione derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CE02,methyprylon,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CE,Piperidinedione derivatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CE03,pyrithyldione,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF01,zopiclone,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF02,zolpidem,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF03,zaleplon,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CF,Benzodiazepine related drugs,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CF04,eszopiclone,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CH,Melatonin receptor agonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDD for melatonin is based on dose recommendations for the 2  mg depot tablet approved in Europe.,N05CH01,melatonin,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CH,Melatonin receptor agonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDD for melatonin is based on dose recommendations for the 2  mg depot tablet approved in Europe.,N05CH02,ramelteon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CH,Melatonin receptor agonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet. The DDD for melatonin is based on dose recommendations for the 2  mg depot tablet approved in Europe.,N05CH03,tasimelteon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CJ,Orexin receptor antagonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CJ01,suvorexant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CJ,Orexin receptor antagonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CJ02,lemborexant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CJ,Orexin receptor antagonists,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CJ03,daridorexant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM01,methaqualone,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM02,clomethiazole,1.5,1.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM03,bromisoval,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM04,carbromal,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM05,scopolamine,0.9,0.9,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM06,propiomazine,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM07,triclofos,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM08,ethchlorvynol,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM09,Valerianae radix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM10,hexapropymate,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM11,bromides,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM12,apronal,0.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM13,valnoctamide,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM15,methylpentynol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM16,niaprazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CM,Other hypnotics and sedatives,The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CM18,dexmedetomidine,NA,1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX01,"meprobamate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX02,"methaqualone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX03,"methylpentynol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX04,"clomethiazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX05,"emepronium, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N05,PSYCHOLEPTICS,N05C,HYPNOTICS AND SEDATIVES,N05CX,"Hypnotics and sedatives in combination, excl. barbiturates",The DDDs are based on use of the drugs as hypnotics.The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.,N05CX06,"dipiperonylaminoethanol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA01,desipramine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA02,imipramine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA03,imipramine oxide,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA04,clomipramine,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA05,opipramol,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA06,trimipramine,0.15,0.15,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA07,lofepramine,0.105,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA08,dibenzepin,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA09,amitriptyline,75,75,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA10,nortriptyline,75,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA11,protriptyline,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA12,doxepin,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA13,iprindole,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA14,melitracen,75,75,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA15,butriptyline,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA16,dosulepin,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA17,amoxapine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA18,dimetacrine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA19,amineptine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA21,maprotiline,0.1,0.1,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AA,Non-selective monoamine reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AA23,quinupramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB02,zimeldine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB03,fluoxetine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB04,citalopram,20,20,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB05,paroxetine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB06,sertraline,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB07,alaproclate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB08,fluvoxamine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB09,etoperidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AB,Selective serotonin reuptake inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AB10,escitalopram,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF01,isocarboxazid,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF02,nialamide,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF03,phenelzine,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF04,tranylcypromine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF05,iproniazide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AF,"Monoamine oxidase inhibitors, non-selective",The DDDs are based on treatment of moderately severe depressions.,N06AF06,iproclozide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AG,Monoamine oxidase A inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AG02,moclobemide,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AG,Monoamine oxidase A inhibitors,The DDDs are based on treatment of moderately severe depressions.,N06AG03,toloxatone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX01,oxitriptan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX02,tryptophan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX03,mianserin,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX04,nomifensine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX05,trazodone,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX06,nefazodone,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX07,minaprine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX08,bifemelane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX09,viloxazine,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX10,oxaflozane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX11,mirtazapine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX12,bupropion,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX13,medifoxamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX14,tianeptine,37.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX15,pivagabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX16,venlafaxine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX17,milnacipran,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX18,reboxetine,8,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX19,gepirone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX21,duloxetine,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX22,agomelatine,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX23,desvenlafaxine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX24,vilazodone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX25,Hyperici herba,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX26,vortioxetine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX27,esketamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX28,levomilnacipran,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX29,brexanolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06A,ANTIDEPRESSANTS,N06AX,Other antidepressants,The DDDs are based on treatment of moderately severe depressions.,N06AX62,bupropion and dextromethorphan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA01,amfetamine,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA02,dexamfetamine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA03,metamfetamine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA04,methylphenidate,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA05,pemoline,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA06,fencamfamin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA07,modafinil,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA08,fenozolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA09,atomoxetine,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA10,fenetylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA11,dexmethylphenidate,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA12,lisdexamfetamine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA13,armodafinil,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA14,solriamfetol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BA,Centrally acting sympathomimetics,NA,N06BA15,dexmethylphenidate and serdexmethylphenidate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BC,Xanthine derivatives,NA,N06BC01,caffeine,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BC,Xanthine derivatives,NA,N06BC02,propentofylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX01,meclofenoxate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX02,pyritinol,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX03,piracetam,2.4,6,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX04,deanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX05,fipexide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX06,citicoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX07,oxiracetam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX08,pirisudanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX09,linopirdine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX10,nizofenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX11,aniracetam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX12,acetylcarnitine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX13,idebenone,0.9,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX14,prolintane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX15,pipradrol,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX16,pramiracetam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX17,adrafinil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX18,vinpocetine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX21,temgicoluril,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06B,"PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS",N06BX,Other psychostimulants and nootropics,The DDD for idebenone is based on treatment of Lebers hereditary optic neuropathy.,N06BX22,phenibut,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CA,Antidepressants in combination with psycholeptics,NA,N06CA01,amitriptyline and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CA,Antidepressants in combination with psycholeptics,NA,N06CA02,melitracen and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CA,Antidepressants in combination with psycholeptics,NA,N06CA03,fluoxetine and psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06C,PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION,N06CB,Psychostimulants in combination with psycholeptics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA01,tacrine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA02,donepezil,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA03,rivastigmine,NA,NA,NA,NA,9.5,NA,NA,NA,NA,NA,mg,delivered dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA03,rivastigmine,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA04,galantamine,16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA05,ipidacrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA52,donepezil and memantine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DA,Anticholinesterases,NA,N06DA53,"donepezil, memantine and Ginkgo folium",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX01,memantine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX02,Ginkgo folium,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX03,aducanumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX04,lecanemab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX05,donanemab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N06,PSYCHOANALEPTICS,N06D,ANTI-DEMENTIA DRUGS,N06DX,Other anti-dementia drugs,NA,N06DX30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA01,neostigmine,60,2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA02,pyridostigmine,0.18,10,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA03,distigmine,5,0.25,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA30,ambenonium,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AA,Anticholinesterases,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AA51,"neostigmine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AB,Choline esters,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AB01,carbachol,6,0.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AB,Choline esters,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AB02,bethanechol,45,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AX,Other parasympathomimetics,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AX01,pilocarpine,15,10,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AX,Other parasympathomimetics,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AX02,choline alfoscerate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07A,PARASYMPATHOMIMETICS,N07AX,Other parasympathomimetics,This group includes various drugs used for different indications.  The DDDs are therefore established individually for each ATC 5th level.,N07AX03,cevimeline,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BA,Drugs used in nicotine dependence,The DDD for chewing gum and lozenges is identical.,N07BA01,nicotine,NA,NA,NA,30,14,NA,NA,NA,NA,mg,mg,NA,NA,30,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,60,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BA,Drugs used in nicotine dependence,The DDD for chewing gum and lozenges is identical.,N07BA03,varenicline,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BA,Drugs used in nicotine dependence,The DDD for chewing gum and lozenges is identical.,N07BA04,cytisinicline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB01,disulfiram,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB02,calcium carbimide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB03,acamprosate,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB04,naltrexone,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BB,Drugs used in alcohol dependence,The DDD for nalmefene is based on the recommended dose on treatment days.,N07BB05,nalmefene,18,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC01,buprenorphine,NA,2.1,NA,8,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.6,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC02,methadone,25,25,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC03,levacetylmethadol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC04,lofexidine,1.4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC05,levomethadone,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC06,diamorphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07B,DRUGS USED IN ADDICTIVE DISORDERS,N07BC,Drugs used in opioid dependence,NA,N07BC51,"buprenorphine, combinations",NA,NA,NA,8,NA,NA,NA,NA,NA,mg,NA,Refers to buprenorphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA01,betahistine,24,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA02,cinnarizine,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA03,flunarizine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA04,acetylleucine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07C,ANTIVERTIGO PREPARATIONS,N07CA,Antivertigo preparations,The DDDs are based on treatment of vestibular symptoms. The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.,N07CA52,"cinnarizine, combinations",90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to cinnarizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XA,Gangliosides and ganglioside derivatives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX01,tirilazad,NA,0.42,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX02,riluzole,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX03,xaliproden,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX04,sodium oxybate,7.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX05,amifampridine,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX06,tetrabenazine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX07,fampridine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX08,tafamidis,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX10,laquinimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX11,pitolisant,18,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX12,patisiran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX13,valbenazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX14,edaravone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX15,inotersen,NA,41,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX16,deutetrabenazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX17,arimoclomol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX18,vutrisiran,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX19,sodium phenylbutyrate and ursodoxicoltaurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX21,eplontersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX22,tofersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX23,troriluzole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
N,NERVOUS SYSTEM,N07,OTHER NERVOUS SYSTEM DRUGS,N07X,OTHER NERVOUS SYSTEM DRUGS,N07XX,Other nervous system drugs,The DDD for tafamidis is based on treatment of nerve damage caused by transthyretin amyloidosis.,N07XX59,"dextromethorphan, combinations",40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Refers to dextromethorphan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AA,Hydroxyquinoline derivatives,NA,P01AA01,broxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AA,Hydroxyquinoline derivatives,NA,P01AA02,clioquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AA,Hydroxyquinoline derivatives,NA,P01AA04,chlorquinaldol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AA,Hydroxyquinoline derivatives,NA,P01AA05,tilbroquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AA,Hydroxyquinoline derivatives,NA,P01AA30,tilbroquinol and tiliquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AA,Hydroxyquinoline derivatives,NA,P01AA52,"clioquinol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB01,metronidazole,2,NA,2,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB02,tinidazole,2,NA,2,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB03,ornidazole,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB04,azanidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB05,propenidazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB06,nimorazole,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB07,secnidazole,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB51,metronidazole and furazolidone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AB,Nitroimidazole derivatives,"The DDDs are based on the treatment of amoebiasis, giardiasis and trichomoniasis.  The duration of the treatment periods is not taken into consideration.",P01AB52,metronidazole and diloxanide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AC,Dichloroacetamide derivatives,The DDDs in this group are based on treatment of luminal amoebiasis.,P01AC01,diloxanide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AC,Dichloroacetamide derivatives,The DDDs in this group are based on treatment of luminal amoebiasis.,P01AC02,clefamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AC,Dichloroacetamide derivatives,The DDDs in this group are based on treatment of luminal amoebiasis.,P01AC03,etofamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AC,Dichloroacetamide derivatives,The DDDs in this group are based on treatment of luminal amoebiasis.,P01AC04,teclozan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AR,Arsenic compounds,NA,P01AR01,arsthinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AR,Arsenic compounds,NA,P01AR02,difetarsone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AR,Arsenic compounds,NA,P01AR03,glycobiarsol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AR,Arsenic compounds,NA,P01AR53,"glycobiarsol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX01,chiniofon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX02,emetine,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX04,phanquinone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX05,mepacrine,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX06,atovaquone,2.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX07,trimetrexate,NA,85,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX08,tenonitrozole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX09,dehydroemetine,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX10,fumagillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX11,nitazoxanide,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01A,AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES,P01AX,Other agents against amoebiasis and other protozoal diseases,NA,P01AX52,"emetine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BA,Aminoquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDDs are based on the average daily dose for the treatment period.",P01BA01,chloroquine,0.5,0.5,NA,NA,NA,NA,g,g,NA,NA,NA,base,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BA,Aminoquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDDs are based on the average daily dose for the treatment period.",P01BA02,hydroxychloroquine,0.516,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,base,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BA,Aminoquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDDs are based on the average daily dose for the treatment period.",P01BA03,primaquine,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,base,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BA,Aminoquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDDs are based on the average daily dose for the treatment period.",P01BA06,amodiaquine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BA,Aminoquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDDs are based on the average daily dose for the treatment period.",P01BA07,tafenoquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BB,Biguanides,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for proguanil is based on the daily dose given for prophylaxis of malaria.  The DDD for the fixed combination of proguanil and atovaquone is based on the treatment of acute malaria, while the DDD for the fixed combination of proguanil and chloroquine is based on prophylaxis of malaria, see list of DDDs for combination products www.whocc.no.",P01BB01,proguanil,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,"hydrochloride, (prophylactic daily dose)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BB,Biguanides,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for proguanil is based on the daily dose given for prophylaxis of malaria.  The DDD for the fixed combination of proguanil and atovaquone is based on the treatment of acute malaria, while the DDD for the fixed combination of proguanil and chloroquine is based on prophylaxis of malaria, see list of DDDs for combination products www.whocc.no.",P01BB02,cycloguanil embonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BB,Biguanides,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for proguanil is based on the daily dose given for prophylaxis of malaria.  The DDD for the fixed combination of proguanil and atovaquone is based on the treatment of acute malaria, while the DDD for the fixed combination of proguanil and chloroquine is based on prophylaxis of malaria, see list of DDDs for combination products www.whocc.no.",P01BB51,proguanil and atovaquone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BB,Biguanides,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for proguanil is based on the daily dose given for prophylaxis of malaria.  The DDD for the fixed combination of proguanil and atovaquone is based on the treatment of acute malaria, while the DDD for the fixed combination of proguanil and chloroquine is based on prophylaxis of malaria, see list of DDDs for combination products www.whocc.no.",P01BB52,chloroquine and proguanil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BC,Methanolquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BC01,quinine,1.5,1.5,NA,NA,NA,NA,g,g,NA,NA,NA,base,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BC,Methanolquinolines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BC02,mefloquine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,base,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BD,Diaminopyrimidines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for pyrimethamine is based on combination therapy with a sulphonamide for the treatment of malaria.",P01BD01,pyrimethamine,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BD,Diaminopyrimidines,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for pyrimethamine is based on combination therapy with a sulphonamide for the treatment of malaria.",P01BD51,"pyrimethamine, combinations",75,75,NA,NA,NA,NA,mg,mg,NA,NA,NA,Refers to pyrimethamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BE,"Artemisinin and derivatives, plain","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The parenteral DDD for arthemether is based on monotherapy.The DDDs for artemisinin derivatives are based on combination therapy with other antimalarials.",P01BE01,artemisinin,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BE,"Artemisinin and derivatives, plain","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The parenteral DDD for arthemether is based on monotherapy.The DDDs for artemisinin derivatives are based on combination therapy with other antimalarials.",P01BE02,artemether,0.28,0.12,0.28,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BE,"Artemisinin and derivatives, plain","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The parenteral DDD for arthemether is based on monotherapy.The DDDs for artemisinin derivatives are based on combination therapy with other antimalarials.",P01BE03,artesunate,0.28,0.28,0.28,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BE,"Artemisinin and derivatives, plain","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The parenteral DDD for arthemether is based on monotherapy.The DDDs for artemisinin derivatives are based on combination therapy with other antimalarials.",P01BE04,artemotil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BE,"Artemisinin and derivatives, plain","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The parenteral DDD for arthemether is based on monotherapy.The DDDs for artemisinin derivatives are based on combination therapy with other antimalarials.",P01BE05,artenimol,0.28,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF01,artemether and lumefantrine,0.28,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to artemether,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF02,artesunate and mefloquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF03,artesunate and amodiaquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF04,"artesunate, sulfalene and pyrimethamine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF05,artenimol and piperaquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF06,artesunate and pyronaridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF07,artemisinin and piperaquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF08,artemisinin and naphthoquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BF,"Artemisinin and derivatives, combinations","The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index.",P01BF09,"artesunate, sulfadoxine and pyrimethamine",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BX,Other antimalarials,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for halofantrine is based on a one-day (12h) treatment.",P01BX01,halofantrine,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01B,ANTIMALARIALS,P01BX,Other antimalarials,"The DDDs are based on the treatment of malaria, except for proguanil, which is used for prophylaxis only.  For some substances the DDDs are expressed as amount of base.  These are indicated in the ATC index. The DDD for halofantrine is based on a one-day (12h) treatment.",P01BX02,arterolane and piperaquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CA,Nitroimidazole derivatives,The DDD for benznidazole is based on the treatment of trypanosomiasis.The DDD for fexinidazole is based on the average daily dose for the total 10 days course.,P01CA02,benznidazole,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CA,Nitroimidazole derivatives,The DDD for benznidazole is based on the treatment of trypanosomiasis.The DDD for fexinidazole is based on the average daily dose for the total 10 days course.,P01CA03,fexinidazole,1.44,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CB,Antimony compounds,The DDDs are expressed as pentavalent antimony (Sb5+) used in the treatment of visceral leishmaniasis.,P01CB01,meglumine antimonate,NA,0.85,NA,NA,NA,NA,NA,g,NA,NA,NA,Sb5+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CB,Antimony compounds,The DDDs are expressed as pentavalent antimony (Sb5+) used in the treatment of visceral leishmaniasis.,P01CB02,sodium stibogluconate,NA,0.85,NA,NA,NA,NA,NA,g,NA,NA,NA,Sb5+,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CC,Nitrofuran derivatives,The DDDs are based on the treatment of trypanosomiasis.,P01CC01,nifurtimox,0.7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CC,Nitrofuran derivatives,The DDDs are based on the treatment of trypanosomiasis.,P01CC02,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CD,Arsenic compounds,The DDDs are based on the treatment of trypanosomiasis.,P01CD01,melarsoprol,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CD,Arsenic compounds,The DDDs are based on the treatment of trypanosomiasis.,P01CD02,acetarsol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CX,Other agents against leishmaniasis and trypanosomiasis,The DDD for pentamidine isethionate is based on amount given per injection.  The DDD for suramin sodium is based on the average daily dose for the treatment period.,P01CX01,pentamidine isethionate,NA,0.28,NA,NA,NA,NA,NA,g,NA,NA,NA,per injection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CX,Other agents against leishmaniasis and trypanosomiasis,The DDD for pentamidine isethionate is based on amount given per injection.  The DDD for suramin sodium is based on the average daily dose for the treatment period.,P01CX02,suramin sodium,NA,0.27,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CX,Other agents against leishmaniasis and trypanosomiasis,The DDD for pentamidine isethionate is based on amount given per injection.  The DDD for suramin sodium is based on the average daily dose for the treatment period.,P01CX03,eflornithine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P01,ANTIPROTOZOALS,P01C,AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS,P01CX,Other agents against leishmaniasis and trypanosomiasis,The DDD for pentamidine isethionate is based on amount given per injection.  The DDD for suramin sodium is based on the average daily dose for the treatment period.,P01CX04,miltefosine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BA,Quinoline derivatives and related substances,The DDDs are based on the treatment of schistosomiasis.,P02BA01,praziquantel,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BA,Quinoline derivatives and related substances,The DDDs are based on the treatment of schistosomiasis.,P02BA02,oxamniquine,1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BA,Quinoline derivatives and related substances,The DDDs are based on the treatment of schistosomiasis.,P02BA03,arpraziquantel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BB,Organophosphorous compounds,The DDDs are based on the treatment of schistosomiasis. Metrifonate is administered every second week.  The DDD is the dose divided by the dosing interval.,P02BB01,metrifonate,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BX,Other antitrematodal agents,The DDDs are based on the treatment of schistosomiasis.,P02BX01,bithionol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BX,Other antitrematodal agents,The DDDs are based on the treatment of schistosomiasis.,P02BX02,niridazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BX,Other antitrematodal agents,The DDDs are based on the treatment of schistosomiasis.,P02BX03,stibophen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02B,ANTITREMATODALS,P02BX,Other antitrematodal agents,The DDDs are based on the treatment of schistosomiasis.,P02BX04,triclabendazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA01,mebendazole,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA02,tiabendazole,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA03,albendazole,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA04,ciclobendazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA05,flubendazole,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA06,fenbendazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CA,Benzimidazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CA51,"mebendazole, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CB,Piperazine and derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections. The DDD for diethylcarbamazine is based on the treatment of lymphatic filiariasis.,P02CB01,piperazine,3.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,as hydrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CB,Piperazine and derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections. The DDD for diethylcarbamazine is based on the treatment of lymphatic filiariasis.,P02CB02,diethylcarbamazine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CC,Tetrahydropyrimidine derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CC01,pyrantel,0.75,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CC,Tetrahydropyrimidine derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CC02,oxantel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CE,Imidazothiazole derivatives,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CE01,levamisole,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CF,Avermectines,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CF01,ivermectin,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CX,Other antinematodals,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CX01,pyrvinium,0.35,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CX,Other antinematodals,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CX02,bephenium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02C,ANTINEMATODAL AGENTS,P02CX,Other antinematodals,The DDDs are based on the treatment of different nematode infections e.g. ascariasis (roundworm) and hookworm infections.,P02CX03,moxidectin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02D,ANTICESTODALS,P02DA,Salicylic acid derivatives,The DDDs are based on the treatment of cestode (tapeworm) infections.,P02DA01,niclosamide,2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02D,ANTICESTODALS,P02DX,Other anticestodals,The DDDs are based on the treatment of cestode (tapeworm) infections.,P02DX01,desaspidin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P02,ANTHELMINTICS,P02D,ANTICESTODALS,P02DX,Other anticestodals,The DDDs are based on the treatment of cestode (tapeworm) infections.,P02DX02,dichlorophen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AA,Sulfur containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AA01,dixanthogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AA,Sulfur containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AA02,potassium polysulfide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AA,Sulfur containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AA03,mesulfen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AA,Sulfur containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AA04,disulfiram,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AA,Sulfur containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AA05,thiram,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AA,Sulfur containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AA54,"disulfiram, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AB,Chlorine containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AB01,clofenotane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AB,Chlorine containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AB02,lindane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AB,Chlorine containing products,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AB51,"clofenotane, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC01,pyrethrum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC02,bioallethrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC03,phenothrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC04,permethrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC51,"pyrethrum, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC52,"bioallethrin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC53,"phenothrin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AC,"Pyrethrines, incl. synthetic compounds",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AC54,"permethrin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX01,benzyl benzoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX02,copper oleinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX03,malathion,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX04,quassia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX05,dimeticone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX06,benzyl alcohol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03A,"ECTOPARASITICIDES, INCL. SCABICIDES",P03AX,"Other ectoparasiticides, incl. scabicides",No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03AX07,abametapir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BA,Pyrethrines,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BA01,cyfluthrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BA,Pyrethrines,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BA02,cypermethrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BA,Pyrethrines,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BA03,decamethrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BA,Pyrethrines,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BA04,tetramethrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BX,Other insecticides and repellents,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BX01,diethyltoluamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BX,Other insecticides and repellents,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BX02,dimethylphthalate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BX,Other insecticides and repellents,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BX03,dibutylphthalate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BX,Other insecticides and repellents,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BX04,dibutylsuccinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BX,Other insecticides and repellents,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BX05,dimethylcarbate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P,"ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS",P03,"ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS",P03B,INSECTICIDES AND REPELLENTS,P03BX,Other insecticides and repellents,No DDDs are assigned in this group.  Substances classified in this group are for topical use and the consumption figures for these preparations could be expressed in e.g. grams of preparations regardless of strength.,P03BX06,etohexadiol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA02,cyclopentamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA03,ephedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA04,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA05,oxymetazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA06,tetryzoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.8,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA07,xylometazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.8,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA08,naphazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA09,tramazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA10,metizoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA11,tuaminoheptane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA12,fenoxazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA13,tymazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA14,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AA,"Sympathomimetics, plain",The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of acute rhinitis.,R01AA15,indanazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB01,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB02,naphazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB03,tetryzoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB05,ephedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB06,xylometazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB07,oxymetazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AB,"Sympathomimetics, combinations excl. corticosteroids","The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.  DDDs are given in volume (i.e. ml).  Most of the products classified in this group are combinations with antihistamines.  So far, all these products are given a fixed DDD of 0.8 ml.",R01AB08,tuaminoheptane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC01,cromoglicic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC02,levocabastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC03,azelastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.56,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC04,antazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC05,spaglumic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC06,thonzylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC07,nedocromil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10.4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC08,olopatadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AC,"Antiallergic agents, excl. corticosteroids",The DDDs are based on treatment of both nostrils. The DDD of cromoglicic acid is based on the prophylaxis of rhinitis.  The DDDs of the antihistamines are based on the maintenance treatment of rhinitis.,R01AC51,"cromoglicic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD01,beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD02,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD03,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD04,flunisolide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.15,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD05,budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD06,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD07,tixocortol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD08,fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD09,mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD11,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.22,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD12,fluticasone furoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.11,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD13,ciclesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.2,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD52,"prednisolone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD53,"dexamethasone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD57,"tixocortol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD58,"fluticasone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD59,"mometasone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AD,Corticosteroids,The DDDs are based on treatment of both nostrils. The DDDs are mainly based on the starting dose in the treatment of rhinitis.,R01AD60,"hydrocortisone, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX01,calcium hexamine thiocyanate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX02,retinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,800,NA,U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX03,ipratropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.24,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX05,ritiometan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX06,mupirocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX07,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX08,framycetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX09,hyaluronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX10,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01A,DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE,R01AX,Other nasal preparations,The DDDs are based on treatment of both nostrils. The DDDs are based on the treatment of rhinitis.,R01AX30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA01,phenylpropanolamine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA02,pseudoephedrine,0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA03,phenylephrine,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA51,"phenylpropanolamine, combinations",0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to phenylpropanolamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA52,"pseudoephedrine, combinations",0.24,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Refers to pseudoephedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R01,NASAL PREPARATIONS,R01B,NASAL DECONGESTANTS FOR SYSTEMIC USE,R01BA,Sympathomimetics,The DDDs are based on the treatment of rhinitis.,R01BA53,"phenylephrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA01,ambazone,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA02,dequalinium,1.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA03,dichlorobenzyl alcohol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA05,chlorhexidine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA06,cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA09,benzethonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA10,myristyl-benzalkonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA11,chlorquinaldol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA12,hexylresorcinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA13,acriflavinium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA14,oxyquinoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA15,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA16,benzalkonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA17,cetrimonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA18,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA19,phenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA20,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AA,Antiseptics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AA21,octenidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB01,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB02,tyrothricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB03,fusafungine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB04,bacitracin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AB,Antibiotics,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AB30,gramicidin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD01,benzocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD02,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD03,cocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD04,dyclonine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AD,"Anesthetics, local","The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets).",R02AD05,ambroxol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AX,Other throat preparations,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets). The DDD for flurbiprofen is based on lozenges and mouth spray which have equivalent dose recommendations.",R02AX01,flurbiprofen,44,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AX,Other throat preparations,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets). The DDD for flurbiprofen is based on lozenges and mouth spray which have equivalent dose recommendations.",R02AX02,ibuprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R02,THROAT PREPARATIONS,R02A,THROAT PREPARATIONS,R02AX,Other throat preparations,"The DDDs are based on the treatment of common minor infections of mouth and throat.  For combination products, DDDs are given as fixed doses of 6 UD (6 tablets). The DDD for flurbiprofen is based on lozenges and mouth spray which have equivalent dose recommendations.",R02AX03,benzydamine,9,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AA,Alpha- and beta-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are based on the treatment of asthma.",R03AA01,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.24,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AB,Non-selective beta-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are based on the treatment of asthma.",R03AB02,isoprenaline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.64,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AB,Non-selective beta-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are based on the treatment of asthma.",R03AB03,orciprenaline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC02,salbutamol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.8,mg,NA,NA,NA,NA,NA,NA,0.8,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC03,terbutaline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,mg,NA,NA,NA,NA,NA,NA,2,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC04,fenoterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,mg,NA,NA,NA,NA,NA,NA,0.6,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC05,rimiterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.6,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC06,hexoprenaline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.5,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC07,isoetarine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC08,pirbuterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.2,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC09,tretoquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC10,carbuterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC11,tulobuterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.6,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC12,salmeterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.1,mg,NA,NA,NA,NA,NA,NA,0.1,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC13,formoterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,mcg,NA,NA,NA,NA,NA,NA,24,NA,NA,mcg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC14,clenbuterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC15,reproterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC16,procaterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,60,NA,NA,mcg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC17,bitolterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC18,indacaterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.15,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AC,Selective beta-2-adrenoreceptor agonists,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs are mainly based on the treatment of asthma.The DDDs for formoterol and salmeterol inhalation powders are based on metered dose, even though products containing these substances could be declared as delivered dose.The DDD for indacaterol is based on the treatment of COPD (Chronic Obstructive Pulmonary Disease).",R03AC19,olodaterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AH,Combinations of adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK01,epinephrine and other drugs for obstructive airway diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK02,isoprenaline and other drugs for obstructive airway diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK04,salbutamol and sodium cromoglicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK05,reproterol and sodium cromoglicate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK06,salmeterol and fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK07,formoterol and budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK08,formoterol and beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK09,formoterol and mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK10,vilanterol and fluticasone furoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK11,formoterol and fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK12,salmeterol and budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK13,salbutamol and beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK14,indacaterol and mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AK,"Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics","It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma. The DDDs for combination products are based on the maintenance treatment of severe asthma or COPD (Chronic Obstructive Pulmonary Disease).  The assigned DDDs cannot always be compared with the DDDs assigned for plain preparations.  See list of DDDs for combination products; www.whocc.no.",R03AK15,salbutamol and budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL01,fenoterol and ipratropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL02,salbutamol and ipratropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL03,vilanterol and umeclidinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL04,indacaterol and glycopyrronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL05,formoterol and aclidinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL06,olodaterol and tiotropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL07,formoterol and glycopyrronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL08,"vilanterol, umeclidinium bromide and fluticasone furoate",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL09,"formoterol, glycopyrronium bromide and beclometasone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL10,formoterol and tiotropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL11,"formoterol, glycopyrronium bromide and budesonide",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03A,"ADRENERGICS, INHALANTS",R03AL,Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids,"It is complicated to decide DDDs for the different dosage forms and even the different inhalation devices of the same dosage form. It has been shown that certain inhalation devices give a better deposition of the active ingredient in the lungs.  This gives a better clinical effect, and therefore the active ingredients can be used in lower dosages.  It has been decided not to take this aspect into consideration when assigning DDDs in this group, since the picture is very complex and satisfactory comparative documentation is not always available.  Accordingly, only one DDD is assigned for one dosage form of a substance (e.g. powder inhalation).For some substances, the labelling of the strength of identical inhalation products may differ between countries.  In some countries, metered dose (measured as the amount of substance released from the inhaler with the mouthpiece removed) is used while in other countries delivered dose (measured as the amount of substance released from the inhaler with the mouthpiece in place) is used in the labelling.  Delivered dose will usually be lower than metered dose.  This is important to take into considerations when linking DDD information to the products in the different countries.The DDDs for inhalation aerosol and inhalation powder of the same substance are in most cases given the same DDD value.  The DDDs for inhalation solutions are, however, different from these and much higher, partly because less amount of the active ingredient will reach the target organ, and partly because this dosage form often is used in more severe asthma.",R03AL12,"indacaterol, glycopyrronium bromide and mometasone",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA01,beclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.8,mg,NA,NA,NA,NA,NA,NA,0.8,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA02,budesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.8,mg,NA,NA,NA,NA,NA,NA,0.8,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA03,flunisolide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA04,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA05,fluticasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,mg,NA,NA,NA,NA,NA,NA,0.6,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA06,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA07,mometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.4,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA08,ciclesonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.16,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BA,Glucocorticoids,See comment under R03A. The DDDs are based on the starting dose in moderate to severe asthma.,R03BA09,fluticasone furoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB01,ipratropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.3,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.12,mg,NA,NA,NA,NA,NA,NA,0.12,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB02,oxitropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.6,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB03,stramoni preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB04,tiotropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Expressed as tiotropium, delivered dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB04,tiotropium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB05,aclidinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Expressed as aclidinium, delivered dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.644,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB06,glycopyrronium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Expressed as glycopyrronium, delivered dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB07,umeclidinium bromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Expressed as umeclidinium, delivered dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB08,revefenacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BB,Anticholinergics,"See comment under R03A. The DDDs are based on the maintenance treatment of asthma.The DDDs for tiotropium bromide and umeclidinium bromide are based on treatment of COPD (Chronic Obstructive Pulmonary Disease).The DDD for tiotropium bromide inhalation powder is based on tiotropium, delivered dose.The DDD for aclidinium bromide inhalation powder is based on aclidinium, delivered dose.The DDD for glycopyrronium bromide inhalation powder is based on glycopyrronium, delivered dose.The DDD for umeclidinium bromide inhalation powder is based on umeclidinium, delivered dose.",R03BB54,"tiotropium bromide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BC,"Antiallergic agents, excl. corticosteroids","See comment under R03A. The DDDs are based on the prophylaxis of asthma.DDD for inhalation aerosol and inhalation powder differ in this group, due to differences in dosage recommendations for these dosage forms.",R03BC01,cromoglicic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,mg,NA,NA,NA,NA,NA,NA,40,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BC,"Antiallergic agents, excl. corticosteroids","See comment under R03A. The DDDs are based on the prophylaxis of asthma.DDD for inhalation aerosol and inhalation powder differ in this group, due to differences in dosage recommendations for these dosage forms.",R03BC03,nedocromil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,NA,NA,mg,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03B,"OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS",R03BX,"Other drugs for obstructive airway diseases, inhalants",See comment under R03A.,R03BX01,fenspiride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CA,Alpha- and beta-adrenoreceptor agonists,NA,R03CA02,ephedrine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB01,isoprenaline,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB02,methoxyphenamine,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB03,orciprenaline,60,60,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB51,"isoprenaline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CB,Non-selective beta-adrenoreceptor agonists,NA,R03CB53,"orciprenaline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC02,salbutamol,12,12,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC03,terbutaline,15,15,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC04,fenoterol,10,NA,10,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC05,hexoprenaline,1.5,1.5,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC06,isoetarine,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC07,pirbuterol,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC08,procaterol,0.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC09,tretoquinol,9,0.2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC10,carbuterol,6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC11,tulobuterol,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC12,bambuterol,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC13,clenbuterol,40,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC14,reproterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC15,formoterol,0.16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC53,"terbutaline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CC,Selective beta-2-adrenoreceptor agonists,NA,R03CC63,clenbuterol and ambroxol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03C,ADRENERGICS FOR SYSTEMIC USE,R03CK,Adrenergics and other drugs for obstructive airway diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA01,diprophylline,1,1,1,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA02,choline theophyllinate,0.6,NA,0.6,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA03,proxyphylline,1.2,1.2,1.2,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA04,theophylline,0.4,0.4,0.4,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA05,aminophylline,0.6,0.6,0.6,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA06,etamiphylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA07,theobromine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA08,bamifylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA09,acefylline piperazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA10,bufylline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA11,doxofylline,0.8,0.8,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA12,mepyramine theophyllinacetate,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA20,combinations of xanthines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA51,"diprophylline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA54,"theophylline, combinations excl. psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA55,"aminophylline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA57,"theobromine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DA,Xanthines,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DA74,"theophylline, combinations with psycholeptics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB01,diprophylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB02,choline theophyllinate and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB03,proxyphylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB04,theophylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB05,aminophylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DB,Xanthines and adrenergics,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DB06,etamiphylline and adrenergics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC01,zafirlukast,40,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC02,pranlukast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC03,montelukast,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC04,ibudilast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DC,Leukotriene receptor antagonists,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DC53,"montelukast, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX01,amlexanox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX02,eprozinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX03,fenspiride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX05,omalizumab,NA,16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX06,seratrodast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX07,roflumilast,0.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX08,reslizumab,NA,7.1,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX09,mepolizumab,NA,3.6,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX10,benralizumab,NA,0.54,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R03,DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03D,OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,R03DX,Other systemic drugs for obstructive airway diseases,This group comprises mainly the xanthines.  The DDDs for these substances are based on treatment of obstructive lung diseases.,R03DX11,tezepelumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA01,tyloxapol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA02,potassium iodide,1.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA03,guaifenesin,0.9,0.9,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA04,ipecacuanha,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,emetine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA05,altheae radix,1.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,root,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA06,senega,3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,root,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA07,antimony pentasulfide,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA08,creosote,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA09,guaiacolsulfonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA11,levoverbenone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA12,Hederae helicis folium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CA,Expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05CA13,cineole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB01,acetylcysteine,0.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,1.6,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB02,bromhexine,24,24,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB03,carbocisteine,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB04,eprazinone,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB05,mesna,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.2,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB06,ambroxol,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB07,sobrerol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB08,domiodol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB09,letosteine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB11,stepronin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB13,dornase alfa (desoxyribonuclease),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.5,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB14,neltenexine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB15,erdosteine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05C,"EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS",R05CB,Mucolytics,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered. For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.",R05CB16,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.8,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA01,ethylmorphine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA03,hydrocodone,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA04,codeine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA05,opium alkaloids with morphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA06,normethadone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA07,noscapine,0.125,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA08,pholcodine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA09,dextromethorphan,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA10,thebacon,15,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA11,dimemorfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA12,acetyldihydrocodeine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DA,Opium alkaloids and derivatives,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DA20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB01,benzonatate,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB02,benproperine,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB03,clobutinol,0.12,0.12,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB04,isoaminile,0.11,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB05,pentoxyverine,0.1,NA,0.1,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB07,oxolamine,0.6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB09,oxeladin,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB10,clofedanol,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB11,pipazetate,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB12,bibenzonium bromide,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB13,butamirate,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB14,fedrilate,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB15,zipeprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB16,dibunate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB17,droxypropine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB18,prenoxdiazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB19,dropropizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB20,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB21,cloperastine,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,Expressed as cloperastine hydrochloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB22,meprotixol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB23,piperidione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB24,tipepidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB25,morclofone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB26,nepinalone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB27,levodropropizine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB28,dimethoxanate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05D,"COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS",R05DB,Other cough suppressants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05DB29,gefapixant,90,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FA,Opium derivatives and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FA01,opium derivatives and mucolytics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FA,Opium derivatives and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FA02,opium derivatives and expectorants,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FB,Other cough suppressants and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FB01,cough suppressants and mucolytics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05F,"COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS",R05FB,Other cough suppressants and expectorants,"Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.",R05FB02,cough suppressants and expectorants,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R05,COUGH AND COLD PREPARATIONS,R05X,OTHER COLD PREPARATIONS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA01,bromazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA02,diphenhydramine,0.2,NA,0.2,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA04,clemastine,2,2,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA06,chlorphenoxamine,80,80,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA07,diphenylpyraline,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA08,carbinoxamine,16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA09,doxylamine,25,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA10,trimethobenzamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA11,dimenhydrinate,0.3,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA52,"diphenhydramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA54,"clemastine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA56,"chlorphenoxamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA57,"diphenylpyraline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA59,"doxylamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AA,Aminoalkyl ethers,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability. The DDD of doxylamine is based on the treatment of insomnia.",R06AA61,"dimenhydrinate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB01,brompheniramine,24,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB02,dexchlorpheniramine,6,6,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB03,dimetindene,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB04,chlorphenamine,12,12,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB05,pheniramine,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB06,dexbrompheniramine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB07,talastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB51,"brompheniramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB52,"dexchlorpheniramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB54,"chlorphenamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AB,Substituted alkylamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AB56,"dexbrompheniramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC01,mepyramine,0.2,0.2,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC02,histapyrrodine,80,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC03,chloropyramine,0.15,20,NA,NA,NA,NA,g,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC04,tripelennamine,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC05,methapyrilene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC06,thonzylamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC52,"histapyrrodine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AC,Substituted ethylene diamines,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AC53,"chloropyramine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD01,alimemazine,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD02,promethazine,25,25,25,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD03,thiethylperazine,13,13,13,NA,NA,NA,mg,mg,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD04,methdilazine,16,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD05,hydroxyethylpromethazine,75,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD06,thiazinam,0.9,NA,0.3,NA,NA,NA,g,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD07,mequitazine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD08,oxomemazine,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD09,isothipendyl,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD52,"promethazine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AD,Phenothiazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AD55,"hydroxyethylpromethazine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE01,buclizine,50,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE03,cyclizine,0.1,0.1,0.3,NA,NA,NA,g,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE04,chlorcyclizine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE05,meclozine,50,NA,50,NA,NA,NA,mg,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE06,oxatomide,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE07,cetirizine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE09,levocetirizine,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE51,"buclizine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE53,"cyclizine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AE,Piperazine derivatives,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AE55,"meclozine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AK,Combinations of antihistamines,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX01,bamipine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX02,cyproheptadine,12,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX03,thenalidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX04,phenindamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX05,antazoline,0.3,0.3,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX07,triprolidine,7.5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX08,pyrrobutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX09,azatadine,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX11,astemizole,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX12,terfenadine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX13,loratadine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX15,mebhydrolin,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX16,deptropine,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX17,ketotifen,2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX18,acrivastine,24,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX19,azelastine,4,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX21,tritoqualine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX22,ebastine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX23,pimethixene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX24,epinastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX25,mizolastine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX26,fexofenadine,0.12,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX27,desloratadine,5,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX28,rupatadine,10,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX29,bilastine,20,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX31,quifenadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX32,sequifenadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX53,"thenalidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R06,ANTIHISTAMINES FOR SYSTEMIC USE,R06A,ANTIHISTAMINES FOR SYSTEMIC USE,R06AX,Other antihistamines for systemic use,"For some of the substances, different dosage forms are given different DDDs, due to differences in bioavailability.",R06AX58,"pyrrobutamine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AA,Lung surfactants,"The DDDs of colfosceril palmitate and natural phospholipids are based on the treatment of respiratory distress syndrome in neonates, and correspond to the treatment of children weighing 1.6 kg.",R07AA01,colfosceril palmitate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.108,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AA,Lung surfactants,"The DDDs of colfosceril palmitate and natural phospholipids are based on the treatment of respiratory distress syndrome in neonates, and correspond to the treatment of children weighing 1.6 kg.",R07AA02,natural phospholipids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.16,g,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AA,Lung surfactants,"The DDDs of colfosceril palmitate and natural phospholipids are based on the treatment of respiratory distress syndrome in neonates, and correspond to the treatment of children weighing 1.6 kg.",R07AA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB01,doxapram,NA,0.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB02,nikethamide,0.5,0.5,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB03,pentetrazol,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB04,etamivan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB05,bemegride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB06,prethcamide,0.4,0.4,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB07,almitrine,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB08,dimefline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB09,mepixanox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB52,"nikethamide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AB,Respiratory stimulants,This group includes various drugs used on different indications. The DDDs are therefore established individually for each ATC 5th level.,R07AB53,"pentetrazol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX01,nitric oxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX02,ivacaftor,0.3,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX30,ivacaftor and lumacaftor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX31,ivacaftor and tezacaftor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R,RESPIRATORY SYSTEM,R07,OTHER RESPIRATORY SYSTEM PRODUCTS,R07A,OTHER RESPIRATORY SYSTEM PRODUCTS,R07AX,Other respiratory system products,NA,R07AX32,"ivacaftor, tezacaftor and elexacaftor",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA01,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA02,chlortetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA03,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA04,oxytetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA05,tyrothricin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA07,framycetin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA09,tetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA10,natamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA11,gentamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA12,tobramycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA13,fusidic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA14,benzylpenicillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA15,dihydrostreptomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA16,rifamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA17,erythromycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA18,polymyxin B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA19,ampicillin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA20,antibiotics in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA21,amikacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA22,micronomicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA23,netilmicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA24,kanamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA25,azidamfenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA26,azithromycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA27,cefuroxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA28,vancomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA29,dibekacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA30,combinations of different antibiotics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA31,cefmenoxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AA,Antibiotics,DDDs have been assigned for antiglaucoma preparations only.,S01AA32,bacitracin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AB,Sulfonamides,DDDs have been assigned for antiglaucoma preparations only.,S01AB01,sulfamethizole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AB,Sulfonamides,DDDs have been assigned for antiglaucoma preparations only.,S01AB02,sulfafurazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AB,Sulfonamides,DDDs have been assigned for antiglaucoma preparations only.,S01AB03,sulfadicramide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AB,Sulfonamides,DDDs have been assigned for antiglaucoma preparations only.,S01AB04,sulfacetamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AB,Sulfonamides,DDDs have been assigned for antiglaucoma preparations only.,S01AB05,sulfafenazol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD01,idoxuridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD02,trifluridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD03,aciclovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD05,interferon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD06,vidarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD07,famciclovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD08,fomivirsen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AD,Antivirals,DDDs have been assigned for antiglaucoma preparations only.,S01AD09,ganciclovir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE01,ofloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE02,norfloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE03,ciprofloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE04,lomefloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE05,levofloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE06,gatifloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE07,moxifloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE08,besifloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AE,Fluoroquinolones,DDDs have been assigned for antiglaucoma preparations only.,S01AE09,tosufloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX01,mercury compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX02,silver compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX03,zinc compounds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX04,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX05,bibrocathol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX06,resorcinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX07,sodium borate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX08,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX09,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX10,sodium propionate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX14,dibrompropamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX15,propamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX16,picloxydine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX18,povidone-iodine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01A,ANTIINFECTIVES,S01AX,Other antiinfectives,DDDs have been assigned for antiglaucoma preparations only.,S01AX24,polihexanide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA01,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA02,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA03,cortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA04,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA05,triamcinolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA06,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA07,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA08,medrysone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA09,clobetasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA10,alclometasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA11,desonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA12,formocortal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA13,rimexolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA14,loteprednol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA15,fluocinolone acetonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BA,"Corticosteroids, plain",DDDs have been assigned for antiglaucoma preparations only.,S01BA16,difluprednate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BB,Corticosteroids and mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01BB01,hydrocortisone and mydriatics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BB,Corticosteroids and mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01BB02,prednisolone and mydriatics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BB,Corticosteroids and mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01BB03,fluorometholone and mydriatics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BB,Corticosteroids and mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01BB04,betamethasone and mydriatics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC01,indometacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC02,oxyphenbutazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC03,diclofenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC04,flurbiprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC05,ketorolac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC06,piroxicam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC07,bendazac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC08,salicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC09,pranoprofen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC10,nepafenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01B,ANTIINFLAMMATORY AGENTS,S01BC,"Antiinflammatory agents, non-steroids",DDDs have been assigned for antiglaucoma preparations only.,S01BC11,bromfenac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA01,dexamethasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA02,prednisolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA03,hydrocortisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA04,fluocortolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA05,betamethasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA06,fludrocortisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA07,fluorometholone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA08,methylprednisolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA09,chloroprednisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA10,fluocinolone acetonide and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA11,clobetasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CA,Corticosteroids and antiinfectives in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CA12,loteprednol and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CB,Corticosteroids/antiinfectives/mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CB01,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CB,Corticosteroids/antiinfectives/mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CB02,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CB,Corticosteroids/antiinfectives/mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CB03,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CB,Corticosteroids/antiinfectives/mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CB04,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CB,Corticosteroids/antiinfectives/mydriatics in combination,DDDs have been assigned for antiglaucoma preparations only.,S01CB05,fluorometholone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CC,"Antiinflammatory agents, non-steroids and antiinfectives in combination",DDDs have been assigned for antiglaucoma preparations only.,S01CC01,diclofenac and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01C,ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION,S01CC,"Antiinflammatory agents, non-steroids and antiinfectives in combination",DDDs have been assigned for antiglaucoma preparations only.,S01CC02,indometacin and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EA,Sympathomimetics in glaucoma therapy,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EA01,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EA,Sympathomimetics in glaucoma therapy,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EA02,dipivefrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EA,Sympathomimetics in glaucoma therapy,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EA03,apraclonidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EA,Sympathomimetics in glaucoma therapy,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EA04,clonidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EA,Sympathomimetics in glaucoma therapy,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EA05,brimonidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EA,Sympathomimetics in glaucoma therapy,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EA51,"epinephrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB01,pilocarpine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0.285,40,NA,mg
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB02,carbachol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB03,ecothiopate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB04,demecarium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB05,physostigmine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB06,neostigmine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,NA,mg
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB07,fluostigmine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB08,aceclidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB09,acetylcholine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB10,paraoxon,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB51,"pilocarpine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EB,Parasympathomimetics,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDD for pilocarpine lamellas has been obtained by dividing two lamellas by seven days (the recommended dose is 1 lamella/eye/week).",S01EB58,"aceclidine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EC,Carbonic anhydrase inhibitors,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDDs are based on the average recommended doses in the treatment of chronic glaucoma.",S01EC01,acetazolamide,0.75,0.75,NA,NA,NA,NA,g,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EC,Carbonic anhydrase inhibitors,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDDs are based on the average recommended doses in the treatment of chronic glaucoma.",S01EC02,diclofenamide,0.1,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EC,Carbonic anhydrase inhibitors,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDDs are based on the average recommended doses in the treatment of chronic glaucoma.",S01EC03,dorzolamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EC,Carbonic anhydrase inhibitors,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDDs are based on the average recommended doses in the treatment of chronic glaucoma.",S01EC04,brinzolamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EC,Carbonic anhydrase inhibitors,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDDs are based on the average recommended doses in the treatment of chronic glaucoma.",S01EC05,methazolamide,0.2,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EC,Carbonic anhydrase inhibitors,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes. The DDDs are based on the average recommended doses in the treatment of chronic glaucoma.",S01EC54,"brinzolamide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED01,timolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED02,betaxolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED03,levobunolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED04,metipranolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED05,carteolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED06,befunolol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED51,"timolol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED52,"betaxolol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED54,"metipranolol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01ED,Beta blocking agents,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01ED55,"carteolol, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE01,latanoprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE02,unoprostone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE03,bimatoprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE04,travoprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE05,tafluprost,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE06,latanoprostene bunod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EE,Prostaglandin analogues,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EE51,latanoprost and netarsudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EX,Other antiglaucoma preparations,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EX01,guanethidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EX,Other antiglaucoma preparations,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EX02,dapiprazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EX,Other antiglaucoma preparations,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EX05,netarsudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EX,Other antiglaucoma preparations,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EX06,omidenepag,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01E,ANTIGLAUCOMA PREPARATIONS AND MIOTICS,S01EX,Other antiglaucoma preparations,"DDDs have been assigned for antiglaucoma preparations only. The DDDs are based on single dose (or single package) and administration frequencies.  A single dose is defined as two eye drops (one in each eye) corresponding to 0.1 ml.  For eye drops administered once daily the DDD is 0.1 ml, for eye drops administered twice daily the DDD is 0.2 ml, etc. For single use packages one dose is the volume of one package.  This also applies for combinations.  In eye ointments one dose corresponds to about 10 mm (20 mg) per eye thus corresponding to 40 mg for both eyes.",S01EX07,ripasudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA01,atropine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA02,scopolamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA03,methylscopolamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA04,cyclopentolate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA05,homatropine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA06,tropicamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA54,"cyclopentolate, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FA,Anticholinergics,DDDs have been assigned for antiglaucoma preparations only.,S01FA56,"tropicamide, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FB,Sympathomimetics excl. antiglaucoma preparations,DDDs have been assigned for antiglaucoma preparations only.,S01FB01,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FB,Sympathomimetics excl. antiglaucoma preparations,DDDs have been assigned for antiglaucoma preparations only.,S01FB02,ephedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FB,Sympathomimetics excl. antiglaucoma preparations,DDDs have been assigned for antiglaucoma preparations only.,S01FB03,ibopamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01F,MYDRIATICS AND CYCLOPLEGICS,S01FB,Sympathomimetics excl. antiglaucoma preparations,DDDs have been assigned for antiglaucoma preparations only.,S01FB51,phenylephrine and ketorolac,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA01,naphazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA02,tetryzoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA03,xylometazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA04,oxymetazoline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA05,phenylephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA06,oxedrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA07,brimonidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA51,"naphazoline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA52,"tetryzoline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA53,"xylometazoline, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA55,"phenylephrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GA,Sympathomimetics used as decongestants,DDDs have been assigned for antiglaucoma preparations only.,S01GA56,"oxedrine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX01,cromoglicic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX02,levocabastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX03,spaglumic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX04,nedocromil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX05,lodoxamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX06,emedastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX07,azelastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX08,ketotifen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX09,olopatadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX10,epinastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX11,alcaftadine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX12,cetirizine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX13,bilastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01G,DECONGESTANTS AND ANTIALLERGICS,S01GX,Other antiallergics,DDDs have been assigned for antiglaucoma preparations only.,S01GX51,"cromoglicic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA01,cocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA02,oxybuprocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA03,tetracaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA04,proxymetacaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA05,procaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA06,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA07,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA08,chloroprocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01H,LOCAL ANESTHETICS,S01HA,Local anesthetics,DDDs have been assigned for antiglaucoma preparations only.,S01HA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01J,DIAGNOSTIC AGENTS,S01JA,Colouring agents,DDDs have been assigned for antiglaucoma preparations only.,S01JA01,fluorescein,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01J,DIAGNOSTIC AGENTS,S01JA,Colouring agents,DDDs have been assigned for antiglaucoma preparations only.,S01JA02,rose bengal sodium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01J,DIAGNOSTIC AGENTS,S01JA,Colouring agents,DDDs have been assigned for antiglaucoma preparations only.,S01JA51,"fluorescein, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01J,DIAGNOSTIC AGENTS,S01JX,Other ophthalmological diagnostic agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01K,SURGICAL AIDS,S01KA,Viscoelastic substances,DDDs have been assigned for antiglaucoma preparations only.,S01KA01,hyaluronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01K,SURGICAL AIDS,S01KA,Viscoelastic substances,DDDs have been assigned for antiglaucoma preparations only.,S01KA02,hypromellose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01K,SURGICAL AIDS,S01KA,Viscoelastic substances,DDDs have been assigned for antiglaucoma preparations only.,S01KA51,"hyaluronic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01K,SURGICAL AIDS,S01KX,Other surgical aids,DDDs have been assigned for antiglaucoma preparations only.,S01KX01,chymotrypsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01K,SURGICAL AIDS,S01KX,Other surgical aids,DDDs have been assigned for antiglaucoma preparations only.,S01KX02,trypan blue,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA01,verteporfin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA02,anecortave,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA03,pegaptanib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA04,ranibizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA05,aflibercept,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA06,brolucizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA07,abicipar pegol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA08,bevacizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01L,OCULAR VASCULAR DISORDER AGENTS,S01LA,Antineovascularisation agents,DDDs have been assigned for antiglaucoma preparations only.,S01LA09,faricimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA01,guaiazulen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA02,retinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA03,"sodium chloride, hypertonic",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA04,potassium iodide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA05,sodium edetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA06,ethylmorphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA07,alum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA08,acetylcysteine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA09,iodoheparinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA10,inosine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA11,nandrolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA12,dexpanthenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA13,alteplase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA14,heparin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA15,ascorbic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA18,ciclosporin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA19,"limbal stem cells, autologous",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA20,artificial tears and other indifferent preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA21,mercaptamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA22,ocriplasmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA23,sirolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA24,cenegermin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA25,lifitegrast,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA26,riboflavin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA27,voretigene neparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA28,varenicline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA29,sepofarsen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S01,OPHTHALMOLOGICALS,S01X,OTHER OPHTHALMOLOGICALS,S01XA,Other ophthalmologicals,DDDs have been assigned for antiglaucoma preparations only.,S01XA31,pegcetacoplan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA01,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA02,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA03,boric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA04,aluminium acetotartrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA05,clioquinol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA06,hydrogen peroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA07,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA08,tetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA09,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA10,acetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA11,polymyxin B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA12,rifamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA13,miconazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA14,gentamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA15,ciprofloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA16,ofloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA17,fosfomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA18,cefmenoxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02A,ANTIINFECTIVES,S02AA,Antiinfectives,No DDDs are assigned in this group.,S02AA30,"antiinfectives, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02B,CORTICOSTEROIDS,S02BA,Corticosteroids,No DDDs are assigned in this group.,S02BA01,hydrocortisone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02B,CORTICOSTEROIDS,S02BA,Corticosteroids,No DDDs are assigned in this group.,S02BA03,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02B,CORTICOSTEROIDS,S02BA,Corticosteroids,No DDDs are assigned in this group.,S02BA06,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02B,CORTICOSTEROIDS,S02BA,Corticosteroids,No DDDs are assigned in this group.,S02BA07,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02B,CORTICOSTEROIDS,S02BA,Corticosteroids,No DDDs are assigned in this group.,S02BA08,fluocinolone acetonide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA01,prednisolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA02,flumetasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA03,hydrocortisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA04,triamcinolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA05,fluocinolone acetonide and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA06,dexamethasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S02CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S02CA07,fludrocortisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02D,OTHER OTOLOGICALS,S02DA,Analgesics and anesthetics,No DDDs are assigned in this group.,S02DA01,lidocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02D,OTHER OTOLOGICALS,S02DA,Analgesics and anesthetics,No DDDs are assigned in this group.,S02DA02,cocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02D,OTHER OTOLOGICALS,S02DA,Analgesics and anesthetics,No DDDs are assigned in this group.,S02DA03,phenazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02D,OTHER OTOLOGICALS,S02DA,Analgesics and anesthetics,No DDDs are assigned in this group.,S02DA04,cinchocaine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02D,OTHER OTOLOGICALS,S02DA,Analgesics and anesthetics,No DDDs are assigned in this group.,S02DA30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S02,OTOLOGICALS,S02D,OTHER OTOLOGICALS,S02DC,Indifferent preparations,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA01,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA02,tetracycline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA03,polymyxin B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA04,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA05,hexamidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA06,gentamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA07,ciprofloxacin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA08,chloramphenicol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03A,ANTIINFECTIVES,S03AA,Antiinfectives,No DDDs are assigned in this group.,S03AA30,"antiinfectives, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03B,CORTICOSTEROIDS,S03BA,Corticosteroids,No DDDs are assigned in this group.,S03BA01,dexamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03B,CORTICOSTEROIDS,S03BA,Corticosteroids,No DDDs are assigned in this group.,S03BA02,prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03B,CORTICOSTEROIDS,S03BA,Corticosteroids,No DDDs are assigned in this group.,S03BA03,betamethasone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S03CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S03CA01,dexamethasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S03CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S03CA02,prednisolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S03CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S03CA04,hydrocortisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S03CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S03CA05,fludrocortisone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S03CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S03CA06,betamethasone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03C,CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION,S03CA,Corticosteroids and antiinfectives in combination,No DDDs are assigned in this group.,S03CA07,methylprednisolone and antiinfectives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S,SENSORY ORGANS,S03,OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,S03D,OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA01,feather,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA02,grass pollen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA03,house dust mites,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA04,mould fungus and yeast fungus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA05,tree pollen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA07,insects,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA08,food,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA09,textiles,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA10,flowers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA11,animals,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V01,ALLERGENS,V01A,ALLERGENS,V01AA,Allergen extracts,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V01AA20,various,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB01,ipecacuanha,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB02,nalorphine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB03,edetates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB04,pralidoxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB05,prednisolone and promethazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB06,thiosulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB08,sodium nitrite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB09,dimercaprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB13,obidoxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB14,protamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB15,naloxone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB16,ethanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB17,methylthioninium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB18,potassium permanganate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB19,physostigmine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB20,copper sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB21,potassium iodide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB22,amyl nitrite,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB23,acetylcysteine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB24,digitalis antitoxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB25,flumazenil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB26,methionine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB27,4-dimethylaminophenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB29,cholinesterase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB31,prussian blue,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB32,glutathione,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB33,hydroxocobalamin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB34,fomepizole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB35,sugammadex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB36,phentolamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB37,idarucizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB38,andexanet alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AB,Antidotes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AB54,pralidoxime and atropine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AC,Iron chelating agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AC01,deferoxamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AC,Iron chelating agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AC02,deferiprone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AC,Iron chelating agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AC03,deferasirox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE01,polystyrene sulfonate,45,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE02,sevelamer,6.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE03,lanthanum carbonate,2.25,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,Expressed as lanthanum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE04,calcium acetate and magnesium carbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE05,sucroferric oxyhydroxide,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE06,colestilan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE07,calcium acetate,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE08,ferric citrate,6,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE09,patiromer calcium,8.4,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDD for lanthanum carbonate is expressed as lanthanum and is equivalent to 4.3 g lanthanum carbonate.The DDD for ferric citrate is based on the recommended dose for chronic kidney disease patients not on dialysis.The DDD for patiromer calcium is based on the recommended starting dose.",V03AE10,sodium zirconium cyclosilicate,7.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF01,mesna,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF02,dexrazoxane,NA,1.5,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF03,calcium folinate,60,60,NA,NA,NA,NA,mg,mg,NA,NA,NA,Expressed as folinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF04,calcium levofolinate,30,30,NA,NA,NA,NA,mg,mg,NA,NA,NA,Expressed as levofolinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF05,amifostine,NA,1.7,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF06,sodium folinate,NA,60,NA,NA,NA,NA,NA,mg,NA,NA,NA,Expressed as folinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF07,rasburicase,NA,14,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF08,palifermin,NA,4.2,NA,NA,NA,NA,NA,mg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF09,glucarpidase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF10,sodium levofolinate,NA,30,NA,NA,NA,NA,NA,mg,NA,NA,NA,Expressed as levofolinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF11,arginine and lysine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AF,Detoxifying agents for antineoplastic treatment,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. The DDDs for calcium folinate, calcium levofolinate, sodium folinate and sodium levofolinate are based on the combined treatment with high doses of methotrexate.The DDD for amifostine is based on the use as an adjunct in antineoplastic therapy.",V03AF12,trilaciclib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AG,Drugs for treatment of hypercalcemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AG01,sodium cellulose phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AG,Drugs for treatment of hypercalcemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AG05,sodium phosphate,8,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AH,Drugs for treatment of hypoglycemia,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AH01,diazoxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AK,Tissue adhesives,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AM,Drugs for embolisation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AN,Medical gases,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AN01,oxygen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AN,Medical gases,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AN02,carbon dioxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AN,Medical gases,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AN03,helium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AN,Medical gases,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AN04,nitrogen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AN,Medical gases,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AN05,medical air,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AX,Other therapeutic products,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AX02,nalfurafine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AX,Other therapeutic products,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AX03,cobicistat,0.15,NA,NA,NA,NA,NA,g,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AX,Other therapeutic products,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AX04,difelikefalin,NA,15,NA,NA,NA,NA,NA,mcg,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V03,ALL OTHER THERAPEUTIC PRODUCTS,V03A,ALL OTHER THERAPEUTIC PRODUCTS,V03AZ,Nerve depressants,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V03AZ01,ethanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04B,URINE TESTS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CA,Tests for diabetes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CA01,tolbutamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CA,Tests for diabetes,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CA02,glucose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CB,Tests for fat absorption,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CB01,vitamin A concentrates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CC,Tests for bile duct patency,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CC01,sorbitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CC,Tests for bile duct patency,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CC02,magnesium sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CC,Tests for bile duct patency,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CC03,sincalide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CC,Tests for bile duct patency,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CC04,ceruletide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CD,Tests for pituitary function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CD01,metyrapone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CD,Tests for pituitary function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CD03,sermorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CD,Tests for pituitary function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CD04,corticorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CD,Tests for pituitary function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CD05,somatorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CD,Tests for pituitary function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CD06,macimorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CE,Tests for liver functional capacity,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CE01,galactose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CE,Tests for liver functional capacity,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CE02,sulfobromophthalein,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CE,Tests for liver functional capacity,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CE03,methacetin (13C),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CF,Tuberculosis diagnostics,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CF01,tuberculin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CG,Tests for gastric secretion,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CG01,cation exchange resins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CG,Tests for gastric secretion,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CG02,betazole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CG,Tests for gastric secretion,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CG03,histamine phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CG,Tests for gastric secretion,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CG04,pentagastrin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CG,Tests for gastric secretion,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CG05,methylthioninium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CG,Tests for gastric secretion,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CG30,caffeine and sodium benzoate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CH,Tests for renal function and ureteral injuries,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CH01,inulin and other polyfructosans,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CH,Tests for renal function and ureteral injuries,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CH02,indigo carmine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CH,Tests for renal function and ureteral injuries,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CH03,phenolsulfonphthalein,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CH,Tests for renal function and ureteral injuries,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CH04,alsactide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CH,Tests for renal function and ureteral injuries,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CH30,aminohippuric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CJ,Tests for thyreoidea function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CJ01,thyrotropin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CJ,Tests for thyreoidea function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CJ02,protirelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CK,Tests for pancreatic function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CK01,secretin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CK,Tests for pancreatic function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CK02,pancreozymin (cholecystokinin),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CK,Tests for pancreatic function,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CK03,bentiromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CL,Tests for allergic diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CM,Tests for fertility disturbances,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CM01,gonadorelin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX01,indocyanine green,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX02,folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX03,methacholine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX04,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX05,13C-urea,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX06,hexaminolevulinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX07,edrophonium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX08,carbon monoxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX09,patent blue,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX10,pafolacianine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V04,DIAGNOSTIC AGENTS,V04C,OTHER DIAGNOSTIC AGENTS,V04CX,Other diagnostic agents,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V04CX11,lithium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06A,DIET FORMULATIONS FOR TREATMENT OF OBESITY,V06AA,Low-energy diets,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06B,PROTEIN SUPPLEMENTS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06C,INFANT FORMULAS,V06CA,Nutrients without phenylalanine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DA,"Carbohydrates/proteins/minerals/vitamins, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DB,"Fat/carbohydrates/proteins/minerals/vitamins, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DC,Carbohydrates,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V06DC01,glucose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DC,Carbohydrates,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V06DC02,fructose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DD,"Amino acids, incl. combinations with polypeptides",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DE,"Amino acids/carbohydrates/minerals/vitamins, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DF,Milk substitutes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V06,GENERAL NUTRIENTS,V06D,OTHER NUTRIENTS,V06DX,Other combinations of nutrients,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AA,Plasters,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AB,"Solvents and diluting agents, incl. irrigating solutions",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AC,"Blood transfusion, auxiliary products",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AD,"Blood tests, auxiliary products",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AN,Incontinence equipment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AR,"Sensitivity tests, discs and tablets",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AS,Stomi equipment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AT,Cosmetics,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AV,Technical disinfectants,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AX,Washing agents etc.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AY,Other non-therapeutic auxiliary products,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V07,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07A,ALL OTHER NON-THERAPEUTIC PRODUCTS,V07AZ,Chemicals and reagents for analysis,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA01,diatrizoic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA02,metrizoic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA03,iodamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA04,iotalamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA05,ioxitalamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA06,ioglicic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA07,acetrizoic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA08,iocarmic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA09,methiodal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AA,"Watersoluble, nephrotropic, high osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AA10,diodone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB01,metrizamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB02,iohexol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB03,ioxaglic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB04,iopamidol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB05,iopromide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB06,iotrolan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB07,ioversol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB08,iopentol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB09,iodixanol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB10,iomeprol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB11,iobitridol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AB,"Watersoluble, nephrotropic, low osmolar X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AB12,ioxilan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC01,iodoxamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC02,iotroxic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC03,ioglycamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC04,adipiodone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC05,iobenzamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC06,iopanoic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC07,iocetamic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC08,sodium iopodate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC09,tyropanoic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AC,"Watersoluble, hepatotropic X-ray contrast media","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AC10,calcium iopodate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AD,Non-watersoluble X-ray contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AD01,ethyl esters of iodised fatty acids,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AD,Non-watersoluble X-ray contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AD02,iopydol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AD,Non-watersoluble X-ray contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AD03,propyliodone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08A,"X-RAY CONTRAST MEDIA, IODINATED",V08AD,Non-watersoluble X-ray contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08AD04,iofendylate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08B,"X-RAY CONTRAST MEDIA, NON-IODINATED",V08BA,Barium sulfate containing X-ray contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08BA01,barium sulfate with suspending agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08B,"X-RAY CONTRAST MEDIA, NON-IODINATED",V08BA,Barium sulfate containing X-ray contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08BA02,barium sulfate without suspending agents,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA01,gadopentetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA02,gadoteric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA03,gadodiamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA04,gadoteridol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA05,mangafodipir,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA06,gadoversetamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA07,ferric ammonium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA08,gadobenic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA09,gadobutrol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA10,gadoxetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA11,gadofosveset,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CA,Paramagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CA12,gadopiclenol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CB,Superparamagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CB01,ferumoxsil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CB,Superparamagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CB02,ferristene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CB,Superparamagnetic contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CB03,"iron oxide, nanoparticles",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08C,MAGNETIC RESONANCE IMAGING CONTRAST MEDIA,V08CX,Other magnetic resonance imaging contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08CX01,perflubron,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08D,ULTRASOUND CONTRAST MEDIA,V08DA,Ultrasound contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08DA01,"perflutren, human albumin microspheres",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08D,ULTRASOUND CONTRAST MEDIA,V08DA,Ultrasound contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08DA02,microparticles of galactose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08D,ULTRASOUND CONTRAST MEDIA,V08DA,Ultrasound contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08DA03,perflenapent,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08D,ULTRASOUND CONTRAST MEDIA,V08DA,Ultrasound contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08DA04,"perflutren, phospholipid microspheres",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08D,ULTRASOUND CONTRAST MEDIA,V08DA,Ultrasound contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08DA05,"sulfur hexafluoride, phospholipid microspheres",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V08,CONTRAST MEDIA,V08D,ULTRASOUND CONTRAST MEDIA,V08DA,Ultrasound contrast media,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V08DA06,"perflubutane, phospholipid microspheres",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AA01,technetium (99mTc) exametazime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AA02,technetium (99mTc) bicisate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AB,Iodine (123I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AB01,iodine iofetamine (123I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AB,Iodine (123I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AB02,iodine iolopride (123I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AB,Iodine (123I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AB03,iodine ioflupane (123I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AX,Other central nervous system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AX01,indium (111In) pentetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AX,Other central nervous system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AX03,iodine (124I) 2beta-carbomethoxy-3beta-(4 iodophenyl)-tropane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AX,Other central nervous system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AX04,flutemetamol (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AX,Other central nervous system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AX05,florbetapir (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AX,Other central nervous system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AX06,florbetaben (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09A,CENTRAL NERVOUS SYSTEM,V09AX,Other central nervous system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09AX07,flortaucipir (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09B,SKELETON,V09BA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09BA01,technetium (99mTc) oxidronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09B,SKELETON,V09BA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09BA02,technetium (99mTc) medronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09B,SKELETON,V09BA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09BA03,technetium (99mTc) pyrophosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09B,SKELETON,V09BA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09BA04,technetium (99mTc) butedronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CA01,technetium (99mTc) pentetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CA02,technetium (99mTc) succimer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CA03,technetium (99mTc) mertiatide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CA04,technetium (99mTc) gluceptate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CA05,technetium (99mTc) gluconate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CA06,technetium (99mTc) ethylenedicysteine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CX,Other renal system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CX01,sodium iodohippurate (123I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CX,Other renal system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CX02,sodium iodohippurate (131I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CX,Other renal system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CX03,sodium iothalamate (125I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09C,RENAL SYSTEM,V09CX,Other renal system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09CX04,chromium (51Cr) edetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DA01,technetium (99mTc) disofenin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DA02,technetium (99mTc) etifenin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DA03,technetium (99mTc) lidofenin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DA04,technetium (99mTc) mebrofenin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DA05,technetium (99mTc) galtifenin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB01,technetium (99mTc) nanocolloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB02,technetium (99mTc) microcolloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB03,technetium (99mTc) millimicrospheres,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB04,technetium (99mTc) tin colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB05,technetium (99mTc) sulfur colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB06,technetium (99mTc) rheniumsulfide colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DB,"Technetium (99mTc), particles and colloids","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DB07,technetium (99mTc) phytate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09D,HEPATIC AND RETICULO ENDOTHELIAL SYSTEM,V09DX,Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09DX01,selenium (75Se) tauroselcholic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EA,"Technetium (99mTc), inhalants","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EA01,technetium (99mTc) pentetic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EA,"Technetium (99mTc), inhalants","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EA02,technetium (99mTc) technegas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EA,"Technetium (99mTc), inhalants","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EA03,technetium (99mTc) nanocolloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EB,"Technetium (99mTc), particles for injection","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EB01,technetium (99mTc) macrosalb,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EB,"Technetium (99mTc), particles for injection","This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EB02,technetium (99mTc) microspheres,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EX,Other respiratory system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EX01,krypton (81mKr) gas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EX,Other respiratory system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EX02,xenon (127Xe) gas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09E,RESPIRATORY SYSTEM,V09EX,Other respiratory system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09EX03,xenon (133Xe) gas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09F,THYROID,V09FX,Various thyroid diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09FX01,technetium (99mTc) pertechnetate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09F,THYROID,V09FX,Various thyroid diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09FX02,sodium iodide (123I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09F,THYROID,V09FX,Various thyroid diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09FX03,sodium iodide (131I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09F,THYROID,V09FX,Various thyroid diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09FX04,sodium iodide (124I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA01,technetium (99mTc) sestamibi,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA02,technetium (99mTc) tetrofosmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA03,technetium (99mTc) teboroxime,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA04,technetium (99mTc) human albumin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA05,technetium (99mTc) furifosmin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA06,technetium (99mTc) stannous agent labelled cells,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GA07,technetium (99mTc) apcitide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GB,Iodine (125I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GB01,fibrinogen (125I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GB,Iodine (125I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GB02,iodine (125I) human albumin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GX,Other cardiovascular system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GX01,thallium (201Tl) chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GX,Other cardiovascular system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GX02,indium (111In) imciromab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GX,Other cardiovascular system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GX03,chromium (51Cr) chromate labelled cells,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GX,Other cardiovascular system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GX04,rubidium (82Rb) chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09G,CARDIOVASCULAR SYSTEM,V09GX,Other cardiovascular system diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09GX05,ammonia (13N),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HA01,technetium (99mTc) human immunoglobulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HA02,technetium (99mTc) exametazime labelled cells,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HA03,technetium (99mTc) antigranulocyte antibody,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HA04,technetium (99mTc) sulesomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HB,Indium (111In) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HB01,indium (111In) oxinate labelled cells,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HB,Indium (111In) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HB02,indium (111In) tropolonate labelled cells,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09H,INFLAMMATION AND INFECTION DETECTION,V09HX,Other diagnostic radiopharmaceuticals for inflammation and infection detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09HX01,gallium (67Ga) citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA01,technetium (99mTc) antiCarcinoEmbryonicAntigen antibody,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA02,technetium (99mTc) antimelanoma antibody,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA03,technetium (99mTc) pentavalent succimer,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA04,technetium (99mTc) votumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA05,technetium (99mTc) depreotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA06,technetium (99mTc) arcitumomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA07,technetium (99mTc) hynic-octreotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA08,technetium (99mTc) etarfolatide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA09,technetium (99mTc) tilmanocept,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IA,Technetium (99mTc) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IA10,technetium (99mTc)trofolastat chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IB,Indium (111In) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IB01,indium (111In) pentetreotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IB,Indium (111In) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IB02,indium (111In) satumomab pendetide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IB,Indium (111In) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IB03,indium (111In) antiovariumcarcinoma antibody,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IB,Indium (111In) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IB04,indium (111In) capromab pendetide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX01,iobenguane (123I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX02,iobenguane (131I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX03,iodine (125I) CC49-monoclonal antibody,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX04,fludeoxyglucose (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX05,fluorodopa (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX06,sodium fluoride (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX07,fluorocholine (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX08,fluoroethylcholine (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX09,gallium (68Ga) edotreotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX10,fluoroethyl-L-tyrosine (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX11,fluoroestradiol (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX12,fluciclovine (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX13,methionine (11C),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX14,gallium (68Ga) gozetotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX15,copper (64Cu) dotatate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX16,piflufolastat (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09I,TUMOUR DETECTION,V09IX,Other diagnostic radiopharmaceuticals for tumour detection,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09IX17,PSMA-1007 (18F),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XA01,iodine (131I) norcholesterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XA02,iodocholesterol (131I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XA03,iodine (131I) human albumin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XX,Various diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XX01,cobalt (57Co) cyanocobalamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XX,Various diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XX02,cobalt (58Co) cyanocobalamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XX,Various diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XX03,selenium (75Se) norcholesterol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V09,DIAGNOSTIC RADIOPHARMACEUTICALS,V09X,OTHER DIAGNOSTIC RADIOPHARMACEUTICALS,V09XX,Various diagnostic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group. No DDDs have been assigned for radiopharmaceuticals.",V09XX04,ferric (59Fe) citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AA,Yttrium (90Y) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AA01,yttrium (90Y) citrate colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AA,Yttrium (90Y) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AA02,yttrium (90Y) ferrihydroxide colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AA,Yttrium (90Y) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AA03,yttrium (90Y) silicate colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AX,Other antiinflammatory therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AX01,phosphorous (32P) chromicphosphate colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AX,Other antiinflammatory therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AX02,samarium (153Sm) hydroxyapatite colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AX,Other antiinflammatory therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AX03,dysprosium (165Dy) colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AX,Other antiinflammatory therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AX04,erbium (169Er) citrate colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AX,Other antiinflammatory therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AX05,rhenium (186Re) sulfide colloid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10A,ANTIINFLAMMATORY AGENTS,V10AX,Other antiinflammatory therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10AX06,gold (198Au) colloidal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10B,PAIN PALLIATION (BONE SEEKING AGENTS),V10BX,Various pain palliation radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10BX01,strontium (89Sr) chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10B,PAIN PALLIATION (BONE SEEKING AGENTS),V10BX,Various pain palliation radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10BX02,samarium (153Sm) lexidronam,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10B,PAIN PALLIATION (BONE SEEKING AGENTS),V10BX,Various pain palliation radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10BX03,rhenium (186Re) etidronic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XA01,sodium iodide (131I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XA02,iobenguane (131I),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XA03,iodine (131I) omburtamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XA,Iodine (131I) compounds,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XA53,tositumomab/iodine (131I) tositumomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XX,Various therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XX01,sodium phosphate (32P),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XX,Various therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XX02,ibritumomab tiuxetan (90Y),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XX,Various therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XX03,radium (223Ra) dichloride,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XX,Various therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XX04,lutetium (177Lu) oxodotreotide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
V,VARIOUS,V10,THERAPEUTIC RADIOPHARMACEUTICALS,V10X,OTHER THERAPEUTIC RADIOPHARMACEUTICALS,V10XX,Various therapeutic radiopharmaceuticals,"This group comprises many different types of drugs, and assigning DDDs are difficult.  Very few DDDs are assigned in this group.",V10XX05,lutetium (177Lu) vipivotide tetraxetan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
